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The heavens declare the glory of God; 
the skies declare the work of his hands. 
Day after day they pour forth speech; 
night after night they display knowledge. 
There is no speech nor language 
where their voice is not heard. 
Their voice goes out to all the earth, 





In an attempt to elucidate the transcriptional mechanisms 
that regulate the expression of the human a2(I) procollagen 
gene, cis-acting DNA-elements within the proximal promoter 
were identified and their corresponding trans-acting factors 
characterised. The fibroblast cell lines used in this study 
had previously been transformed with either simian virus 40 
(SVWI-38) or by l-radiation (CT-1). The SVWI-38 fibroblasts 
do not produce any a2 (I) collagen chains, whereas the CT-1 
cell line produces normal type I collagen. 
Previous studies suggested that trans-acting factor(s) may be 
responsible for the inactivation of the a2 (I) procollagen 
gene in SVWI-38 fibroblasts (Parker et. al. (1989) J. Biol. 
Chem 264, 7147-7152; Parker et. al. (1992} Nucleic Acids Res. 
20, 5825-5830). In this study, the SVWI-38 proximal promoter 
(-350 to +54) was sequenced and shown to be normal, thereby 
ruling out any possibility that mutations within this region 
was responsible for inactivation of the gene. 
DNA-protein complexes between the proximal promoter fragment 
and SVWI-38 and CT-1 nuclear extracts were identified using 
the electrophoretic mobility shift assay. Nuclear extracts 
from CT-1 fibroblasts or the parental WI-38 cell line formed 
two DNA-protein complexes (complexes I and III) with the -110 
to -4 6 promoter fragment. SVWI-38 nuclear extracts on the 
other hand, formed an additional complex, complex II, which 
was also present in a transformed mouse macrophage cell line, 
P388D1 . SVWI-38 fibroblasts produced much lower levels of 
complex III compared to CT-1 cells, while P388D1 cells had no 
detectable levels of this complex. It is therefore tempting 
to speculate that the relative ratios of complexes II and III 
may modulate the levels of a2(I) procollagen gene expression. 
Competition and methylation interference assays identified 
two distinct but overlapping DNA-recognition elements within 
this 60 bp region of the human a2 (I) procollagen promoter. 
Com~lex I formation involved a 21 bp element, 
5 'GcCCTCCCATTGGTGGAGGcc3 ', extending from nucleotides -92 to 
-72. This element, the GGAGG/CCAAT box element {G/CBE), 
contains a downstream GGAGG box, and an upstream inverted 
xii 
GGAGG box separated by seven nucleotides containing an 
inverted CCAAT box. The second cis-element, 
5 'GGAGGCCCTTTT3 ', extends from nucleotides -78 to -67 and 
contains the downstream GGAGG box, which also forms part of 
the G/CBE, and 3'-flanking sequences. CT-1 nuclear extracts 
formed one complex with this novel element (complex III), 
whereas SVWI-38 extracts formed two different complexes (II 
and III) . This 12 bp element has been named the collagen 
modulating element {CME) because complex II comprises a 
candidate repressor protein(s). 
Further characterisation of the G/CBE suggested that the 
inverted upstream GGAGG and CCAAT boxes were more important 
motifs for G/CBF {GGAGG/CCAAT binding factor) (complex I 
proteins) binding. Deletion of a single cytosine which 
separates these two motifs abolished or drastically reduced 
the formation of complex I. Deletion and mutagenesis assays 
also suggested that the downstream GGAGG box is only weakly 
involved in DNA-protein contacts and loosely forms part of 
the G/CBE. Physico-chemical analysis of G/CBF suggested that 
this factor is identical or related to the previously 
characterised hetero-multimeric CCAAT-binding factors, NF-Y, 
CBF, a-CPl and others. Under non-denaturing conditions, 
G/CBF had a Stokes radius of 5.22 nm, a sedimentation 
coefficient of 4.9 s, a calculated native molecular weight of 
105 KDa and a frictional ratio of 1.66. UV-crosslinking and 
denaturing gel filtration data suggested that this factor, 
like the other hetero-multimeric CCAAT-binding factors, is a 
multicomponent CCAAT box binding protein. 
Mutations of the downstream GGAGG box and the cytosine 
dinucleotides at positions -72 and -73 resulted in a drastic 
reduction of complex II and III formation. Other DNA-binding 
data suggested that the upstream GGAGG and CCAAT boxes were 
involved in weak DNA-protein contacts with complex II and III 
proteins. The CME binding proteins ( complexes II and III) 
had Stokes radii of 4. 12 and 3 .15 nm, sedimentation 
coefficients of 3.9 and 3.2 s, native molecular weights of 66 
and 41 KDa and frictional ratios of 1. 54 and 1. 38 
respectively. The Stokes radii of both these factors did not 
change during fractionation on gel filtration columns in the 
presence of o. 8 M KCl. The non-denaturing gel filtration, 
xiii 
Southwestern blotting, and UV-crosslinking data suggested 
that complex II consists of a stable multimeric protein 
complex. The physico-chemical analysis suggested that 
complex III, on the other hand, is monomeric. 
Competition binding assays demonstrated that complex I, II 
and III proteins bound to their respective sites in a 
mutually exclusive manner. These results indicated that 
G/CBF and complex III proteins probably fine-tune regulate 
the expression of the human a2(I) procollagen gene in type I 
collagen producing cells. Complex II proteins, on the other 
hand, could repress the expression of this gene via 





The collagens are a large heterogeneous family of structural 
proteins which form the major constituents of the 
extracellular matrix. The structure and function of the 
different collagen types have been extensively reviewed (for 
example Bornstein and Sage, 1980; Mayne and Burgeson, 1987; 
Burgeson, 1988; van der Rest and Garrone, 1991). The 
collagens are important components of tendon, bone and cornea 
(types I, III and V), hyaline cartilage (types II and XI) , 
basement membrane (type IV) and the anchoring fibril network 
(type VII). Other collagens, such as types IX, XII and XIV, 
associate with the surface of collagenous fibrils where they 
probably function by establishing and stabilising the spatial 
arrangement of the fibrils. 
To date, 13 distinct collagen types, types I to XII and XIV, 
have been characterised at both the protein and nucleic acid 
levels. Al though these 13 collagen types are structurally 
and functionally different, they are all trimers consisting 
of three polypeptide subunits with continuous or interrupted 
rod-like triple-helical domains. The triple helix consists 
of repeating Gly-X-Y tripeptides, where X and Y are often 
pro line and hydroxyproline residues respectively. Some of 
these collagen molecules, such as types II and III, are 
homotrimers, while the majority are heterotrimers consisting 
of two (eg type I) or even three (eg type XI) different types 
of a-chains. A summary of the a-chain composition of the 
known collagen types is given in table 1. 1. All collagens 
also contain two or more globular or non-collagenous domains 
ranging in size from a few to several hundred residues. The 
non-collagenous domains generally accounts for the major part 
of the protein. There are exceptions, such as the 
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Table 1.1 Classification, chain composition and tissue 
distribution of the different collagen types. The name, 
chromosomal localisation and the size of the 31 distinct 
collagen genes and the number of exons are tabulated. 
TYPE CONSTITUENT CHAIN GENE 
LOCUS 
CHROMOSOMAL GENE NUMBER 
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Ubiquitous, but mainly bone, skin, 
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Hyaline cartilage 
Blood vessels, Lung and skin 
Widely distributed in many tissues 
Hyaline cartilage 
Vascular, corneal endothellial 
cells and other tissues 
Hypertrophic hyaline cartilage 
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Hyaline cartilage and other 
32b tissues 
52 
Resenbles that of type I 
Resenbles that of type I 
Basement membranes 
a Some evidence for its existence (Fessler et. al., 1985; Fessler and Fessler, 1987) 
b For the chicken gene 
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Table 1.1 continued 
TYPE CONSTITUENT CHAIN GENE CHROMOSOMAL GENE NUMBER TISSUE DISTRIBUTION 
CHAINS COMPOSITION LOCUS LOCALIZATION SIZE EXONS 
(Kb) 
VI a1(VI) a1(VI)a2(VI)cr3(VI) COL6A1 21q22.3 Wide variety of tissues 
a2(VI) COL6A2 21q22.3 36 30 
cr3(VI) COL6A3 2q37 
VII a1(VII) [a1(VI I >l3 COL7A1 3p21.1-21.3 32 118 Basement membrane of 
stratified squamous 
epithelia 
CC) PREDICTED COLLAGENS 
XIII a1(XIII) unknown COL13A1 10q11-qter 
xv a1(XV) unknown COL15A1 9q34-35 Resembling that of type I 
XVI I a1CXVII) unknown COL17A1 10q23.4 
non-collagenous domains of type VI collagen which comprises 
about 80% of the protein (Saitta et. al., 1992). The 
existence of five additional putative collagen types, types 
XIII (Pihlajaniemi and Tamminen, 1990), XV (Myers et. al., 
1992) , XVI (Pan et. al., 1992) , Y (Yoshioka et. al., 1992) 
and XVII (Li et. al., 1993), has been predicted from deduced 
amino acid sequences of complementary and/or genomic clones. 
Each collagen type has a characteristic cell-type or tissue-
specific distribution. Type II collagen is the major 
collagenous protein of hyaline cartilage and is almost 
entirely limited to this tissue (van der Rest and Garrone, 
1991) . Type VII collagen also has a limited anatomical 
distribution (Parente et. al., .1991) , whereas, type I 
collagen is ubiquitous, with high levels in bone, skin, 
tendons and ligaments (van der Rest and Garrone, 1991). 
Types XII, XIV and XV collagens also have a tissue 
distribution pattern which resembles that of type I collagen 
(Shaw and Olsen, 1991; Myers et. al., 1992). Type III 
collagen is usually co-expressed with type I but at 
different ratios in different organs and tissues (Fessler 
and Fessler, 1978; Kuhn, 1981). 
4 
Collagen levels differ during embryogenesis, development and 
in the adult organism (reviewed by Bornstein and Sage, 1989). 
During murine embryogenesis, for example, inactivation of the 
al (I) procollagen gene is lethal (Schnieke et. al., 1983; 
Hartung et. al., 1986). Finally, the shift from the 
synthesis of type I collagen to type II collagen during the 
differentiation of mesenchymal cells into chondrocytes is an 
example of altered collagen gene expression during 
differentiation (reviewed by von der Mark, 1980; Linsenmayer, 
1981) . 
The steady state levels of the different a-chains making up 
the heterotrimeric collagens are co-ordinately regulated. In 
the case of type I collagen, the steady state mRNA levels has 
a stoichometry of 2:1 which is identical to the ratio of the 
al (I) and a2 (I) chains in the triple helix (Vuust et. al., 
1985). Furthermore, collagen levels are altered during 
pathological processes such as wound healing, inflammatory 
conditions, arthritis and fibrosis (reviewed by Bornstein and 
Sage, 1980). The expression of the various procollagen 
genes, therefore, has to be tightly and co-ordinately 
regulated in specific cell and tissue types during the normal 
development of an organism. Numerous studies have been 
initiated to characterise the cis-acting DNA elements and 
trans-acting factors that modulate the spatial and/or 
temporal patterns of collagen gene expression under normal or 
pathological conditions (section 1.3). 
1.2 THE COLLAGEN GENES 
The 18 collagen types are encoded by at least 31 distinct 
genes, which are dispersed throughout the genome (Table 1.1). 
To date, the collagen genes have been mapped to 11 different 
human autosomes. The COL4A5 gene is the only known X-linked 
collagen gene (Hostikka et. al., 1990) • At least eight 
chromosomes contain two or more distinct collagen genes. 
Five collagen genes have been mapped to chromosome 6, of 
which three, the COL9Al, COL12Al and COLYAl encode FACIT or 
FACIT-like collagens and may form a cluster on the long arm 
of this chromosome ( section 1. 1. 3) . In support of this 
hypothesis, two of these genes, the COL9Al and COLYAl genes, 
have both been mapped to 6ql2-14 (Kimura et. al., 1989a; 
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Yoshioka et. al., 1992). The regional localisation of 
COL12Al on chromosome 6 has not been determined {Oh et. al., 
1992). Four and five genes have been mapped to human 
chromosomes 1 and 2 respectively. There are only a few other 
cases where two genes have been mapped to the same locus, 
namely the COL3Al and COL5A2 to 2q24.3-31 {Cutting et. al., 
1990), COL4Al and COL4A2 to 13q34 {Soininen et. al., 1988) 
and COL6Al and COL6A2 to 21q22.3 (Francomano et. al., 1991). 
More recently, COL15Al has been mapped to the same region on 
chromosome 9 as COLSAl {Huebner et. al., 1992). Finally, at 
least three collagen genes, the C0~4A3, the COL4A4 and 
possibly the COL6A3 genes, could form a second cluster on 
chromosome 2 (Mariyama et. al., 1992a; for review see Vuorio 
and de Crombrugghe, 1990). 
The genes that encode the heterotrimeric collagen types are 
often situated on different chromosomes. For example, the 
COLlAl and COL1A2 are located on the long arms of chromosomes 
17 and 7 respectively (Huerre et. al., 1982), while at least 
two of the genes for the heterotrimeric type IX collagen have 
been mapped to two different chromosomes (Kimura et. al . , 
1989a; Perala et. al., 1993). In some cases such as collagen 
types IV (Emanuel et. al., 1986; Griffin et. al., 1987) and 
VI (Francomano et. al., 1991) , however, two co-ordinately 
expressed genes are located on the same locus. 
These phenomena pose interesting questions about the 
co-ordinated regulation of collagen genes (section 1.3). The 
isolation of genomic and/or cDNA clones from human and other 
species, has made it possible to determine the structure of 
the different collagen genes. 
1.2.1 STRUCTURE OF THE FIBRILLAR COLLAGEN GENES 
The five structurally related fibrillar collagen types all 
consist of three domains, a long triple helical domain of 
about 1000 amino acid residues and two short terminal 
globular domains. once the procollagen helix has been 
assembled and secreted, specific extracellular N- and 
C-proteases remove the globular propeptides, leaving short 
telopeptides attached to each end of the triple helix. Based 
on their abundance in collagenous tissues, the fibrillar 
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collagens can be divided into the major {types I, II and III} 
and the minor fibrillar collagens {types- V and XI}. 
The heterotrimeric type I, and the 
homotrimeric type III collagens, (al{III}] 3 , are widely 
distributed in many tissues and are the major collagenous 
constituents of fibres and fibrils in the extracellular 
matrix. Type II collagen, a homotrimer consisting of three 
al{II} chains, is the major collagenous component of hyaline 
cartilage (reviewed by van der Rest and Garrone, 1991}. 
Type V collagen is widely distributed ·in many tissues where 
it is a minor component of the extracellular matrix (reviewed 
by Fessler and Fessler, 1987}. Type V collagen can either 
occur as a homotrimer, (al (V}] 3 , or as two heterotrimeric 
species (al(V}J 2a2(V} and al(V}a2(V}a3(V} (Woodbury et. 
al., 
1989 and references therein}. Although the genetic identity 
of a fourth type V chain, al'(V}, remains unresolved, there 
is some evidence for the existence of an al'(V} chain 
(Fessler et. al., 1985; Fessler and Fessler, 1987). Type XI 
collagen is a minor collagenous component of hyaline 
cartilage and is composed of three distinct a-chains (Morris 
and Bachinger, 1987}. Since types I and V collagens are 
co-expressed in non-cartilagenous tissues and types II and XI 
are co-expressed in cartilage, it has been postulated that 
types V and XI collagens may play a role in regulating the 
diameter of collagen fibrils (Birk et. al., 1988}. 
Nine distinct but structurally related genes encode . the ten 
a-chains making up the fibrillar procollagen types. Except 
for the a3(XI} and the al(II} chains which are probably both 
produced from the COL2Al gene, the remaining seven a-chains 
are synthesised from separate genes. The four major human 
f ibrillar collagen genes, al (I} , a2 (I} , al (II} and al (III} , 
have been isolated and characterised in detail and shown to 
be located as single copies on different chromosomes 
(Table 1.1} (for review see Vuorio and de Crombrugghe, 1990). 
The 18 Kb human al (I} procollagen gene was the first human 
fibrillar collagen gene to be isolated in its entirety (Chu 
et. al., 1984; Westerhausen et. al., 1991} and is located on 
chromosome 17q21.3-22 (Huerre et. al., 1982; Retief et. al., 
1985). Subsequently, the entire human a2(I} (de Wet et. al., 
1987}, al(II} (Sangiorgi et. al., 1985} and al(III} (Chu 
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et. al., 1985; Benson-Chanda et. al., 1989) genes have been 
isolated and characterised. The COL1A2 gene is located on 
chromosome 7q21.3-22 (Junien et. al., 1982; Retief et. al., 
1985), while the COL2Al and COL3Al genes have been mapped to 
12ql4.3 (Law et. al., 1986) and 2q24.3-31 (Cutting et. al., 
1990) respectively. The genomic and/or cDNA clones for these 
genes have also been isolated from a variety of species. 
Genomic and/or cDNA clones of most of the human minor 
fibrillar collagen genes have been characterised (Myers 
et. al. , 1985; Weil et. al., 1987; Bernard et. al., 1988; 
Kimura et. al., 1989b; Woodbury et. al., 1989; Greenspan 
et. al., 1991a; Takahara et. al., 1991). The chromosomal 
localisation of these genes have also been mapped (reviewed 
in Vuorio and de Crombrugghe, 1990; Caridi et. al., 1992). 
All the vertebrate fibrillar collagen genes isolated to date 
contain 51 to 54 short exons with gene sizes ranging from 16 
to 44 Kb. Despite some important differences, comparison 
between the different gene types and between the different 
species have shown that there is considerable structural 
conservation. Not only the number, but the size and 
distribution of the exons are almost identical in the 
fibrillar collagen genes. The exons are separated by large 
introns ranging in length from about 100 to 3000 bp. 
Variations in the sizes of the introns account for the large 
differences in the sizes of these genes (reviewed by Ramirez 
et. al., 1990; Vuorio and de Crombrugghe, 1990). 
In all these genes, 42 short exons of varying sizes encode 
the triple helical domain. The sizes of exons 7 to 48 in the 
fibrillar genes are all multiples of 9 bp where 23 exons are 
54 bp, 8 exons are 108 bp, 1 exon is 162 bp and 5 each are 45 
and 99 bp long. The 9 bp subunit codes for the basic Gly-X-Y 
triplet, so that each exon always starts with a complete Gly 
codon and ends with a codon for an amino acid in the y 
position. With the exception of three cases, the pattern of 
exon sizes of all the fibrillar genes are the same (reviewed 
by Ramirez et. al., 1990; Vuorio and de Crombrugghe, 1990). 
The globular C-propeptide (243 to 247 amino acids), the 
carboxyl telopeptide (11 to 27 amino acids) and the end of 
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the triple helical domain are coded for by 4 exons (exons 49 
to 52) . Exons 51 and 52 of all the f ibrillar genes are 
identical in size, both between the different types and 
different species. There is also a high degree of sequence 
identity between exons 51 (Yamada et. al., 1983) . Small 
variations in the sizes of exons 48 and 49 are responsible 
for the variations in the lengths of the C-propeptide 
domains. Exon 49, the c-joining exon, encodes for the 
c-terminal end of the triple helix (ranging from 45 to 
63 bp), the c-telopeptide and beginning of the c-propeptide. 
The joining exon of the a2{XI) procollagen gene contains only 
18 bp of triple helical sequences (two Gly-X-Y repeats). The 
sizes of exons 48 and 49 in the COL11A2 gene are also much 
smaller than the equivalent exons of the other fibrillar 
collagen genes (Kimura et. al., 1989b) . The slight 
variations in the lengths of the various triple-helical 
domains (1014 to 1029 amino acids) is caused by differences 
in the number of Gly-X-Y repeats in the c- and N-joining 
exons (reviewed by Ramirez et. al., 
de crombrugghe, 1990). 
1990; Vuorio and 
The size, number and organisation of the various exons 
encoding the N-propeptide domain of the a-chains differ 
substantially between the genes and between species. The 
N-propeptide domains can be subdivided into at least four 
regions, namely the signal peptide, cys-rich globular region, 
the short triple-helical region and the N-telopeptide. The 
signal peptides are coded for by exon 1, while exon 2 in the 
al{I), al{II) and al(III) procollagen genes code for the 67 
to 71 amino acid cys-rich globular subdomains. Since this 
subdomain is only found in a fraction of the al{II) 
procollagen mRNA, it is probably removed by alternative 
splicing. Two short exons (2 and 3) of 11 and 15 bp, 
respectively, code for a globular subdomain in the a2 (I) 
chain. The exons that code for the short triple helical 
subdomain of 39 to 79 amino acids, differ in size and number. 
This region is coded for by two exons within the a2{I) (exons 
4 and 5) and al{III) (exons 3 and 4/5) gene. Exons (3, 4 and 
5) and exons (3, 4A, 4B, SA and SB) code for this region in 
the al{I) and al{II) procollagen genes respectively. Exon 6 
is the N-joining exon and codes for the N-telopeptide and the 
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beginning of the triple helix (reviewed by Ramirez et. al., 
1990; Vuorio and de Crombrugghe, 1990). 
The fibrillar collagen genes also contain several 
polyadenylation sites which gives rise to different mRNA 
species (reviewed by Vuorio and de Crombrugghe, 1990). 
1.2.2 SHORT CHAIN COLLAGEN GENES 
The two short chain collagens, types VIII and X, are encoded 
by three genetically distinct genes,· namely, the COL8Al, 
COL8A2 and COLlOAl. This subclass has been named short chain 
collagens due to the relatively small size of the triple 
helical domain which is about half as long as in f ibrillar 
collagens (Yamaguchi et. al., 1991). The short chain 
collagens contain a short triple helical domain of about 450 
to 460 amino acids flanked by N- and C-globular domains 
consisting of 40 to 120 and about 170 residues respectively. 
Although it is conceivable that each of the type VIII 
collagen chains may form homotrimers, it is probably a 
heterotrimer with a chain composition [al(VIII)] 2a2(VIII) 
(Mann et. al., 1990). This collagen is produced by vascular 
and corneal endothelial cells where it is a component of a 
specialised basement membrane known as the Descemet's 
membrane. There is also a much wider tissue distribution of 
type VIII collagen (Yamaguchi et. al., 1989, 1991 and 
references therein) . The transiently and developmentally 
regulated type X collagen, on the other hand, is produced by 
chondrocytes in hypertrophic hyaline cartilage and is a 
homotrimer made up three al(X) chains (Schmid and 
Linsenmayer, 1983). 
The entire human COLlOAl gene has been cloned and shown to 
contain only two exons of 169 bp and approximately 2940 bp, 
separated by an intron of about 3200 bp. Exon 1 encodes the 
5'-untranslated region (15 bp), the signal peptide (54 bp) 
and 100 bp of the N-terminal globular domain. The second 
exon encodes for the rest of the N-globular domain (14 bp), 
the entire triple helical domain of 463 amino acids, the 161 
amino acid long c-terminal globular domain and the 
3 '-untranslated region (1054 bp) (Thomas et. al., 1991; 
Reichenberger et. al., 1992) . The cloning and 
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characterisation of the entire chicken (Lu val le et. al., 
1988) and mouse (Apte et. al., 1992; Apte and Olsen, 1993) 
al{X) collagen genes have shown that they, on the other hand, 
contain three exons. Exon 3 is about 2100 bp and is the 
largest exon in both of these genes. Like the human al (X) 
gene, the human al(VIII) gene contains two exons. Exon 1 is 
331 bp long and the larger exon 2 is about 1907 bp in size 
(Muragaki et. al., 1991b). Interestingly, the 5.3 Kb rabbit 
gene consists of four exons of 69, 120, 331 and 2278 bp 
(Yamagachi et. al., 1991). Although the number and sizes of 
the exons in the human a2(VIII) gene ±snot known, the gene 
has been cloned and shown to be structurally related to the 
other short chain collagen genes (Muragaki et. al., 1991a). 
The three short chain genes have a number of unique 
characteristics (Muragaki et. al., 1991a, 1991b; Thomas 
et. al., 1991) . The entire triple-helical and c-terminal 
globular domains are encoded by a single large exon (Ninomiya 
et. al., 1986; Yamaguchi et. al., 1989, 1991; Thomas et. al., 
1991). This is in direct contrast to the fibrillar collagen 
genes which contain multiple short exons. The rest of the 
molecule is encoded by one or more short exons. 
the carboxyl three-quarters of the c-terminal 
Secondly, 
globular 
domains have a very high degree of sequence conservation. 
Like most of the non-fibrillar collagen genes, the triple 
helical domain of the short chain collagen genes contain 
short imperfections in the Gly-X-Y tripeptides. The short 
chain collagen genes have the same number (usually eight) of 
Gly-X and/or X-Y imperfections. The relative locations of 
these imperfections are also constant. The COL8Al, COL8A2 
and COLlOAl genes have been mapped to chromosomes 3q12-13.1 
(Muragaki et. al., 1991b), lp32.3-34.3 (Muragaki et. al., 
1991a) and 6q21-22 (Apte et. al., 1991; Thomas et. al., 1991) 
respectively. 
1. 2. 3 FIBRIL-ASSOCIATED COLLAGENS WITH INTERRUPTED TRIPLE-
HELICES (FACIT) AND FACIT-LIKE GENES 
Type IX collagen, a heterotrimer of genetically distinct 
al(IX), a2(IX) and a3(IX) chains, was the first member of the 
FACIT subgroup to be identified (Noro et. al., 1983). 
Subsequently, the structurally and functionally related 
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homotrimeric types XII (Gordon et. al., 1987) and XIV (Dublet 
and van der Rest, 1991) collagens have also been classified 
as FACITS. Types XVI (Pan et. al., 1992) and Y (Yoshioka 
et. al., 1992) collagens, discovered by cDNA cloning and 
sequencing, are also probably members of the FACIT group . 
The fibril-associated collagens with interrupted triple-
helices have a number of common unique characteristics. 
Firstly, they do not undergo proteolytic processing like the 
fibrillar collagens and are therefore not secreted as 
procollagen molecules. Secondly, they do not form fibrils, 
instead they are associated with collagenous fibrils or 
fibres. In hyaline cartilage, for example, type IX collagen 
associates with and becomes covalently crosslinked to the 
surface of type-II-containing collagenous fibrils (Eyre 
et. al., 1987; van der Rest et. al., 1988; Vaughan et. al., 
1988) . 
The FACIT molecules contain more than · one triple helical 
domain separated by short non-triple helical domains. Each 
of the three type IX collagen chains contains three triple 
helical domains, designated COLl, containing either 115 (al 
and a2) or 112 (a3) amino acids, COL2 and COL3, consist of 
339 and 137 amino acids respectively, and four non-triple 
helical domains (NCl to NC4) (Ninomiya et. al., 1990; Har-El 
et. al., 1992) . Type XII collagen, on the other hand, 
contains only two helical domains of 105 {COLl) and 152 
(COL2) amino acids and three non-helical domains (NCl to NC3) 
(Gordon et. al., 1989) . The structure and function of the 
FACITS have been extensively reviewed by Shaw and Olsen 
(1991) and van der Rest and Garrone (1991). 
The entire chicken al(IX) and a2(IX) collagen genes have been 
isolated and characterised (Lozano et. al., 1985; 
van der Rest and Mayne, 1987). The a2(IX) gene is 10 Kb long 
and contains 32 exons, while the al{IX) gene is much larger, 
approximately 100 Kb (reviewed by Vuorio and de Crombrugghe, 
1990) . Since the a2 (IX) chain and gene has been the most 
extensively studied, it serves as a prototype molecule for 
the FACITS. More recently, the full length cDNA for the 
chicken a3(IX) chain has been cloned and characterised 
(Brewton et. al., 1992; Har-El et. al. , 1993) . The human 
full length al(IX) (Kimura et. al., 1989a) and a2(IX) (Perala 
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et. al., 1993) cDNA clones have also been isolated and used 
to map these genes to 6q12-14 (Kimura · et. al., 1989a) and 
chromosome 1 (Perala et. al., 1993), respectively. 
A full length chicken al (XII) cDNA has been isolated and 
characterised while only a portion of a genomic clone 
corresponding to exons 1 to 7, has been sequenced ( Gordon 
et. al., 1989). A portion of the mouse al(XII) gene has been 
cloned (Oh et. al., 1992) and used to isolate a human 
al (XII) -like gene which contains 3 exons that encode the 
carboxyl-end of the NC3 domain and the NC3/COL2 junction. 
The human gene has been mapped to chromosome 6 (Oh et. ·al., 
1992). A partial cDNA bovine type XIV clone has been shown 
to contain the COLl, NC2 and part of the COL2 domains (Dublet 
and van der Rest, 1991). 
Comparisons between the various FACIT genes have shown that 
they are very heterogeneous in size and that considerable 
sequence variations also exist. Never the less the FACIT 
genes do have a number of common characteristics. The 
exon/intron organisation of the al(IX) and a2(IX) genes are 
similar (Lozano et. al., 1985; van der Rest, 1987). There is 
also homology in the exon/intron organisation of the partial 
chicken al(XII) gene, encoding the NCl, COLl and NC2 domains, 
with the corresponding regions of the type IX genes (Gordon 
et. al., 1987). Most of the exons, encoding the triple 
helical domains, in these genes adhere to the 9 bp rule. As 
with the fibrillar collagen genes, a significant portion of 
these exons are 54 bp long. The al(IX) and a2(IX) collagen 
genes contain imperfections in their Gly-X-Y tripeptide 
repeats, where either a X, Y or Gly residue is deleted 
(Ninomiya et. al., 1989). 
A full length human cDNA clone of the putative al(XVI) chain, 
contains 10 collagenous domains alternating with 11 
non-collagenous domains, has been isolated and characterised 
recently (Pan et. al., 1992) . This gene is located on 
chromosome lp34-35 (Pan et. al., 1992). A homologue of the 
al(XII) collagen gene, COLYAl (D6S228E) has been isolated and 
mapped to chromosome 6q12-14 (Yoshioka et. al., 1992). In 
addition to this gene, four collagen genes, COL9Al, COLlOAl, 
COL11A2 and COL12Al, have all been mapped to chromosome 6. 
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The chicken (Nishimura et. al., 1989) · and human {Muragaki 
et. al., 1990) al{IX) genes contain two promoters which are 
preferentially utilised in different tissues to give rise to 
proteins with different N-terminal {NC4) domains 
(section 1.3.6.7). The chicken al{IX) gene also contains a 
number of polyadenylation sites (Lozano et. al., 1985; 
Ninomiya et. al., 1989; Nishimura et. al., 1989). 
1.2.4 EXTRACELLULAR MATRIX NETWORKS 
Al though several isoforms of type IV collagen exist in the 
basement membranes, the most common one has the composition 
(al{IV) 2a2{IV)]. Both the al{IV) and a2{IV) chains are 
present in basement membranes. The minor trimeric isoforms 
consist of combinations of the al(IV) chain, the a2{IV) chain 
and three other chains, designated a3(IV), a4(IV) and a5(IV) 
chains, but with restricted tissue distribution. The type IV 
molecule consists of a large c-terminal globular domain 
{NCl), a long triple helical domain of about 1400 amino acid 
residues and a short cysteine-rich non-collagenous N-terminal 
domain (NC2) (reviewed by Schittny and Yurcherico, 1989). 
The loci of the human al{IV) and a2(IV) genes have both been 
mapped to 13q34 (Emanuel et. al., 1986; Griffin et. al., 
1987). In contrast to the other collagen genes and other 
genes of complex organisms, the human al{IV) and a2(IV) genes 
occur in a head-to-head orientation so that they . share a 
common bidirectional promoter (section 1.3.6.4) {Soininen 
et. al., 1988). The COL4A5 gene, to date the only collagen 
gene known to be situated on a sex chromosome, has been 
mapped to Xq21 {Hostikka et. al., 1990) . The COL4A3 and 
COL4A4 genes have both been mapped to chromosome 2q35-37 
(Mariyama et. al., 1992a; Turner et. al., 1992). 
The complete primary structures of the human a2(IV) (Hostikka 
and Tryggvason, 1988) and a5(IV) (Pihlajaniemi et. al., 1990; 
Zhou et. al., 1992) genes have been determined from 
nucleotide sequence analysis. Only partial cDNA clones of 
the human a3(IV) (Morrison et. al., 1991; Turner et. al., 
1992) and the bovine a4(IV) (Mariyama et. al., 1992b) chains 
have been isolated and sequenced to date. The entire human 
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al (IV) gene has been characterised and shown to contain 52 
exons and to be more than 100 kb in length (Soininen et. al., 
1989). Based on their structure, the five a-chains can be 
divided into two classes, namely, the alpha-1-like [al(IV), 
a3(IV) and a5(IV)] and alpha-2-like [a2(IV) and a4(IV)] 
classes (Mariyama et. al., 1992a) . The al (IV) and a2 (IV) 
chains contain a considerable number of interruptions in the 
triple helical domains. At least half of the interruptions 
are larger than a deletion or insertion of a single amino 
acid. 
long. 
Some of the insertions can be up to 24 amino acids 
Most of the exons encoding the · triple helical domain 
contain non-random split codons which always involves the 
first G of the gly codon. The 9 bp rule is usually adhered 
to in these exons but the exon sizes are different to those 
found in the fibrillar collagen genes (Soininen et. al• t 
1989) . There are also extensive differences in the exon 
organisation of the 3'-end of the al(IV} and a2 (IV) collagen 
genes (Hostikka and Tryggvason, 1987). 
Type VI collagen is a component of the microfibrillar network 
in the extracellular matrix of a wide variety of tissues. 
The protein, a heterotrimer consisting of three distinct 
a-chains [al(VI), a2(VI) and a3(VI}], forms a dumbell shaped 
molecule consisting of two large globular domains separated 
by a short triple helical region. The non-collagenous 
domains comprise about 80% of the total protein (reviewed by 
Engel et. al., 1990). 
The corresponding cDNAs for all three chains of the human 
type VI collagen has been cloned and sequenced (Chu et. al., 
1988, 1989, 1990). The al{VI} and a2(VI) chains are similar 
in structure where the large 230 amino acid N-terminal and 
the 430 amino acid c-terminal globular domains are separated 
by a short triple helix of 335 and 336 amino acids 
respectively. The N- and C-globular domains are divided into 
subdomains of about 200 amino acid residues. The subdomains 
are separated from each other or from the collagenous domain 
by short cysteine-rich connecting segments of 25 to 30 
residues long. The entire 36 Kb human a2(VI) collagen gene 
consists of 30 exons (Saitta et. al., 1990, 1991a, 1992) with 
exons lA and 2 separated by the largest intron of 12. 5 Kb 
{Saitta et. al., 1992). Six exons encode the signal peptide 
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and N-globular domain. Exon 5 is a N-terminal junction exon 
which encodes for the transition of the non-collagenous to 
the collagenous domains (Saitta et. al., 1992). The 
c-terminal globular domain is also encoded by 6 exons and is 
subject to alternate splicing. In contrast with most of the 
other collagen genes there is no junction exon in the al(VI) 
and a2(VI) genes (Saitta et. al., 1990). All the individual 
structural domains of the N- and c-terminal globular domains 
are encoded by separate exons (Saitta et. al., 1990, 1992) 
The triple helical domain which contains two short 
interruptions is encoded by the remaining 18 exons (Saitta 
et. al., 1991). The organisation of the exons that encode 
the triple helical domains of the human al (VI) and a2 (VI) 
chains are very similar. With the exception of those 
encoding regions with imperfections in the triple helix, the 
exons in both genes adhere to the 9 bp rule and have sizes 
ranging from 27 to 90 bp. Contrary to the fibrillar collagen 
genes, the predominant exon size is 63 bp. Contrary to many 
of the non-fibrillar collagen genes, the introns are 
positioned between complete codons so that the al (VI) and 
a2 (VI) genes do not contain split codons in their triple 
helical domains (Saitta et. al., 1991). 
The N-terminal domain of the larger aJ (VI) chain contains 
nine 200 amino acid subdomains while the c-terminal domain 
contains two 200 amino acid subdomains and three unrelated 
subdomains (Chu et. al., 1990; Stokes et. al., 1990) . A 
partial 26 Kb genomic clone of the entire N-terminal .globular 
domain of the human aJ(VI) chain showed that the Nl subdomain 
is encoded by two exons of 417 bp and 146 hp, while 
subdomains N2 to N9 are encoded by separate exons of about 
600 bp each (Stokes et. al., 1990). Exons encoding 
subdomains N7 and N9 are subject to tissue-specific alternate 
splicing (Stokes et. al., 1990). Single copies of the COL6Al 
and COL6A2 genes exist as a cluster on chromosome 21q22. J 
(Francomano et. al., 1991), while the COL6AJ gene has been 
mapped to 2q37 (see Vuorio and de Crombrugghe, 1990). 
The homotrimeric type VII collagen, [al{VII)] 3 , consists of a 
central collagenous domain consisting of 52 Gly-X-Y repeats, 
a c-terminal non-collagenous domain {NCl) and a N-terminal 
non-collagenous domain (NC2). The NCl and NC2 domains 
consist of 186 and 439 amino acids respectively. 
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This 
collagen is found in the basement membrane zone beneath the 
stratified epithelia where it forms part of the anchoring 
fibrils (Burgeson, 1988; van der Rest and Garrone, 1991). A 
human cDNA clone corresponding to the al(VII) chain has been 
successfully isolated and characterised (Parente et. al., 
1991). A 8 kb genomic clone, consisting of 34 exons of the 
carboxyl end of the molecule, has recently been characterised 
(Greenspan et. al., 1993). Consistent with other non-
f ibrillar collagens, the triple helical domain of type VII 
collagen contains a number of imperfections where 1 to 3 
amino acids are inserted or deleted. The COL 7 Al gene has 
been mapped to chromosome 3p21.1-21.3 (Parente et. al., 1991; 
Greenspan et. al., 1993).9 
1.3 REGULATION OF COLLAGEN GENE EXPRESSION 
The mechanisms that regulate the production of the various 
collagen types are complex and diverse. Although 
transcriptional control mechanisms are probably the most 
important and predominant, other mechanisms also play 
significant roles. These other mechanisms, including 
chromatin structure, DNA methylation status, mRNA processing, 
mRNA stability, translational control and post-translational 
processes, will be discussed briefly. 
1.3.1 CHROMATIN CONFORMATION 
Eukaryotic DNA is packaged into the nucleus in a highly 
organised manner (reviewed by Fisher, 1989) and unfolding of 
this structure must proceed transcription. Differences must 
therefore exist between the structure of transcriptionally 
active, potentially active and inactive genes. 
Transcriptionally and potentially active genes have a more 
open conformation which is easily accessible to the 
transcription apparatus. Due to its more open conformation, 
active chromatin is also more sensitive to nucleases such as 
DNase 1 and Sl nuclease and is a measure of the activation 
status of genes (reviewed by Weisbrod, 1982; Gross and 
Garrard, 1987, 1988; Patient and Allan, 1989). DNase 1 
hypersensitive sites have been identified in the type I 
collagen genes and shown to bear a strong correlation with 
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their expression (reviewed by Bornstein and Sage, 1989; 
Raghow and Thompson, 1989). This technique has been used to 
identify discrete regions in the chromatin around the mouse 
a2 (I) procollagen promoter (Liau et. al., 1986). Mc Keon 
et. al. (1984) have found a DNase 1 hypersensitive site in 
the chicken a2(I) procollagen promoter region in fibroblast 
but not in brain chromatin, which corresponds to the 
transcriptional activity of this gene in these tissues. 
1.3.2 METHYLATION STATUS 
There is an inverse correlation between the methylation 
status of a gene and its transcriptional activity. 
Transcriptionally active genes are generally under-methylated 
at certain CpG dinucleotides within their regulatory elements 
(reviewed by Doerfler, 1983; Cedar, 1988; Boyes and Bird, 
1991). With some exceptions (Mc Keon et. al., 1982), 
hypermethylation of the type I collagen genes is associated 
with their inactivation (Parker et. al., 1982, 1986; Smith 
and Marsilio, 1988; Guenette et. al., 1992). In vitro 
methylation of the human al(I) procollagen promoter and 
enhancer also results in transcriptional inactivation of this 
gene (Thompson et. al., 1991). Although a controversial 
issue, DNA methylation may be an important mechanism for 
regulating collagen gene expression. 
1.3.3 POST-TRANSCRITIONAL CONTROL MECHANISMS 
In comparison with the initiation of transcription (section 
1.3.6) and post-transcriptional control mechanisms (reviewed 
by Prockop et. al., 1979; Bornstein and Sage, 1989), little 
is known about the regulation of collagen mRNA stability and 
turnover. These events may include splicing, capping, 
polyadenylation, sequence editing, nuclear-cytoplasmic 
transport, stability and turnover (for reviews on mRNA 
stability and turnover see Cleveland, 1989 and Klausner and 
Harford, 1989). As illustrated by the following examples, 
collagen mRNA stability and turnover is regulated at a number 
of levels. In differentiated chicken chondrocytes, for 
example, unprocessed al(I) mRNA is found predominantly in the 
nucleus and is not transported to the cytoplasm (Saxe 
et. al., 1985) . Doz in et. al. ( 1990) have shown that an 
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increase in the half-life of al(II) procollagen mRNA causes 
accumulation of the message in chicken chondocytes. since 
several transcripts, which differ only in their 3'-UTR, are 
often produced from collagen genes (reviewed by Vuorio and 
de Crombrugghe, 1990), it is almost certain that the 3'-UTR 
plays an important role in the stability and turnover of the 
al{I) and a2(I) procollagen mRNA. In support of this 
hypothesis, Maatta et. al. {1991) have shown that the 3'-UTR 
of the COLlAl gene binds cell-specific nuclear proteins. 
Finally, Furth et. al. (1991) have shown that a post-
initiation block prevents the accumulation of type I collagen 
mRNA in HeLa cells. 
1.3.4 REGULATION BY EXOGENOUS FACTORS 
Collagen gene expression is also regulated by many exogenous 
factors such as growth factors, cytokines, hormones and 
vitamins. These agents can affect collagen mRNA levels by 
altering either the transcription rates or mRNA stability and 
turnover. Cytokines such as, interferon 'Y ( IFN--y) , tumour 
growth factor B (TGF-B), tumour necrosis factor a (TNF-a), 
interleukin 1 and hormones such as glucocorticoids, may 
modulate collagen mRNA stability and turnover (reviewed by 
Bornstein and Sage, 1989; Slack et. al., 1993). The effect 
of exogenous factors on type I collagen gene expression has 
also been extensively reviewed (Adams, 1989; Bornstein and 
Sage, 1989; Slack et. al., 1993). Several exogenous factors 
can regulate collagen synthesis by independent mechanisms and 
the combined action of these effects play an important role 
in regulating collagen synthesis during wound healing and 
tissue repair (Narayanan et. al., 1989). In addition TNF-a 
and IFN--y synergistically suppress the stimulatory effect of 
TGF-B on type I collagen synthesis by two distinct 
mechanisms. TNF-a suppresses the activity of the a2 (I) 
procollagen promoter while IFN--y probably functions at the 
post-transcriptional level (Kahari et. al., 1990). The 
synthesis of other collagen types is also affected by 
exogenous factors. In culture, TGF-B up-regulates type VII 
collagen gene expression in normal and transformed epidermal 
keratinocytes (Ryynanen et. al., 1991) and type VI 
collagen in human dermal fibroblasts {Heckmann et. al., 
1992). Often co-expressed collagen types can be 
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affected; the cytokine, melanoma growth-stimulatory activity 
( (MGSA) /GRO], down-regulates the expression of types I and 
III collagens in a dose-dependent manner in fibroblasts 
(Unemori et. al., 1993). 
1.3.5 TRANSFORMED CELLS 
The transformation of fibroblasts by RNA and DNA tumour 
viruses causes changes in cell morphology, cell growth and 
synthesis of distinct groups of proteins. The synthesis of 
type I collagen (reviewed by Bornstein and Sage, 1989) and 
other collagens, such as type VI (Schreir et. al., 1988), are 
markedly reduced upon transformation. Secondly, one of the 
two type I collagen genes is often transcriptionally 
inhibited when epithelial cells and fibroblasts are 
chemically transformed (reviewed by Bornstein and Sage, 
1989). In addition, the expression of different collagen 
types, such as types I and III (Liau et. al., 1985), or the 
expression of the different chain components of a specific 
collagen type, such as al(!) and a2(I) chains (Majmudar 
et. al. , 1988) , are not always co-ordinately regulated in 
transformed cells. Both chemically and virally transformed 
fibroblasts have been used to study the mechanisms that 
regulate the expression of collagen genes (Parker et. al., 
1989; Guenette et. al., 1992). 
1.3.6 TRANSCRIPTION FACTORS 
Eukaryotic gene transcription is regulated predominantly by 
the interaction of cis-acting DNA elements with sequence-
specific DNA-binding proteins. These recognition sequences 
are located within functionally distinct elements such as 
promoters, enhancers and silencers (Dynan, 1989) . While 
promoters are situated upstream of the transcription start 
site, enhancers can function over considerable distances in 
either orientation to increase promoter activity (reviewed by 
Khoury and Gruss, 1983; Serfling et. al., 1985; Jeang and 
Khoury, 1988; Milller et. al., 1989). Silencer elements 
function in a position and orienatation-independent manner to 
negatively regulate gene expression. This is achieved by the 
binding of repressors to their recognition sequences within 
these elements (Renkawitz, 1990). Silencers were first 
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identified within a 589 bp region upstream of the porcine PDl 
promoter (MHC class I gene) (Ehrlich et. al., 1988). These 
investigators showed that removal of this PDl silencer 
element resulted in increased promoter activity. 
One of the most common cis-acting DNA elements is the TATA 
box, which is usually located approximately 30 bp upstream of 
the transcription start site and is the binding site for RNA 
polymerase and the rest of the general transcriptional 
machinery (reviewed by Conaway and Conaway, 1991). Other 
common recognition elements include the CCAAT and GC boxes 
while less common cis-elements include hormone and growth 
factor response elements. Numerous lower-abundance, 
structurally di verse sequence-specific DNA-binding proteins 
(Spl, OCT-1, OCT-2, NF-1, Jun, Fos, CBF, etc) bind to their 
respective recognition elements to either activate or repress 
gene expression (reviewed by Maniatis et. al., 1987; Mitchell 
and Tjian, 1989). DNA-binding proteins have a number of 
functionally distinct domains. The first is a DNA-binding 
domain, which, in numerous trans-acting factors, has been 
localised to a relatively small region of the protein. Based 
on their structure, these DNA-binding motifs can be divided 
into several classes such as helix-turn-helix, zinc-finger, 
basic region of the leucine-zipper and others (reviewed by 
Struhl, 1989; Johnson and Mc Knight, 1989; Harrison, 1991). 
Many trans-acting factors bind to recognition elements as 
mul timers and therefore also contain a dimerisation domain 
such as the leucine zipper (Landschulz, et. al., 1988). All 
transcription factors also contain a functionally distinct 
transcriptional activator, or repressor, domain which could 
be an acidic, a glutamine-rich or a proline-rich domain 
(Tasset et. al., 1990). 
A combination of both positive and negative trans-acting 
factors are frequently responsible and vital for regulating 
gene expression (Boam et. al., 1990; Chow and Schwartz, 
1990). It is . generally accepted that transcription 
activators transmit a positive signal to the transcription 
initiation complex when they bind to cis-elements within 
promoters and enhancers of a gene. Al though, many of · the 
components and mechanisms involved are not known, it is more 
than likely that intermediate factors, which themselves do 
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not bind DNA, act as a bridge between the positive factor and 
the initiation complex. It is also possible that the 
activator interacts directly with the initiation complex to 
stimulate transcription (reviewed by Ptashne, 1988; Muller 
et. al., 1989; Ptashne and Gann, 1990). Transcription 
repress ors on the other hand, can function via one of at 
least three broad mechanisms which include the inhibition of 
activator binding, blocking of activation or direct DNA-
binding to achieve silencing (reviewed by Levine and Manley, 
1989; Renkawitz, 1990). There are many different mechanism 
whereby repressors prevent the binding uf positive factors to 
their recognition element (reviewed in Renkawitz, 1990). A 
classical example is the competition of a CCAAT displacement 
protein (a repressor) with the binding of a CCAAT binding 
factor (an activator) to overlapping cis-elements within the 
sea-urchin H2B-1 promoter (Barberis et. al., 1987). 
Interestingly, there are examples where transcriptional 
repression is caused by competition between two positive 
factors (reviewed in Renkawitz, 1990). Alternatively, a 
repressor can prevent an activator from binding to its 
recognition element by forming stable protein-protein 
complexes. Inhibitory POU (I-POU), for example, does not 
bind to DNA, but forms a stable heterodimer with Cfl-a (a 
POU-domain protein) to inhibit DNA-binding and 
transcriptional activation ability of Cfl-a {Treacy et. al., 
1991, 1992). An inhibitory protein, IkB, prevents the 
binding of a transcriptional activator, NF-kB, to its cis-
element via a different mechanism. !kB binds to NF-kB in the 
cytoplasm and prevents NF-kB from entering the nucleus. 
After activation, !kB releases NF-kB into the nucleus where 
it activates several genes (Zabel and Baeuerle, 1990). Other 
repressors inhibit the transcriptional activation properties 
of DNA-binding proteins via several mechanisms (reviewed by 
Renkawitz, 1990). Finally, activators and repressors can be 
produced from the same gene (reviewed by Foulkes and 
Sassone-Corsi, 1992) or due to post-translational 
modification of t ·ranscription factors. A twin of I-POU, for 
example, is produced by alternative splicing and forms a 
homodimer which activates a distinct group of genes (Treacy 
et. al. , 1992) . The regulation of transcription by 
phosphorylation of transcription factors has been reviewed by 
Hunter and Karin (1992). 
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Transient transfection experiments using sequences upstream 
of the start site of initiation and/or intronic segments 
fused to reporter genes have been used to define the 
functional promoter, enhancer and silencer elements of a 
number of collagen genes. Deletion constructs, together with 
other DNA-binding techniques, have identified cis-acting 
elements within the promoters, enhancers and silencers of 
collagen genes. A number of investigators have identified, 
purified and characterised the trans-acting factors which 
bind to these regulatory elements. 'Fhe micro-injection of 
chimeric genes into mouse oocytes to generate transgenic mice 
has and will continue to play an important role in 
understanding the tissue-specific, temporal and spatial 
expression of genes during embryogenesis and in the adult 
organism. Hopefully, the identification and characterisation 
of regulatory elements and their DNA-binding proteins, will 
help to determine the mechanisms governing the co-ordinated 
expression of the various collagen genes under normal and 
pathological conditions. 
1.3.6.1 TYPE I COLLAGEN GENE 
The transcriptional mechanisms which regulate the cell-type 
and tissue-specific expression of the type I collagen genes 
have been well studied. The mouse COL1A2 gene is the best 
studied gene. Transient transfection experiments ( Schimdt 
et. al., 1986) and transgenic mice (Khillan et. al_., 1986) 
were initially used to show that the mouse a2 (I) promoter 
(between -2000 and +54) was sufficient in directing the 
expression of a reporter gene in a cell- or tissue-specific 
manner. Although considerably weaker, the expression of the 
COL1A2-dr i ven reporter gene mimics that of the endogenous 
gene. It is therefore possible that additional enhancer 
elements, located either upstream or downstream of this 
promoter fragment, are required for high-level expression of 
the mouse a2(I) procollagen gene (Schmidt et. al., 1986; 
Goldberg, H. et. al., 1992). This 2000 bp promoter fragment, 
never the less, is sufficient for its tissue-specific 
expression. The minimal DNA-sequences required for tissue-
specific expression of the mouse a2(I) procollagen gene have 
been shown to be located between -350 and +54 (Niederreither 
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et. al., 1992). Although the overall activity was less than 
that of the -2000 bp promoter, the -350 -bp proximal promoter 
was able to mimic the temporal and spatial expression of the 
endogenous gene during embryogenesis in transgenic mice. 
Additional upstream sequences seem to be required for the 
tissue-specific repression of the a2(I) procollagen gene in 
the brain since expression of this construct was not 
repressed in this tissue (Goldberg, H. et. al., 1992). Boast 
et. al. (1990) have shown in tissue culture experiments that 
only the proximal 350 bp of the human a2 (I) procollagen 
promoter is required for the cell-type specific expression of 
a reporter gene. · Interestingly, there is a high degree of 
sequence identity (86%) between the human and mouse -350 bp 
proximal promoters (Dickson et. al., 1985). This high 
sequence identity between these promoters is lost further 
upstream (M.I. Parker, unpublished data). 
Several cis-acting DNA-elements such as a TATA box (-30 to 
-25), an inverted CCAAT box (-84 to -80), a 5 'cAGA3 ' sequence 
(-250 to -247) and a NF-1-like site (-315 to -295) have been 
identified in the mouse proximal a2(I) procollagen promoter 
(Karsenty et. al., 1988). Interestingly, all these elements 
are conserved in the human promoter ( see chapter 2) . DNA-
binding factors present in NIH-3T3 nuclear extracts have been 
shown to bind to these regulatory elements. Al though the 
factor ( s) which bind to the 5 'CAGA 3 ' sequence has not been 
identified, the substitution of this motif with other 
nucleotides (AAAG or ATAG} almost abolishes COL1A2 promoter-
driven expression of a reporter gene and DNA-binding activity 
(Karsenty et. al., 1988) • A heterotrimeric trans-acting 
factor, the activating CCAAT binding factor (CBF}, which 
binds to the inverted CCAAT box, was initially indemnified in 
NIH-3T3 extracts (Hatamochi et. al., 1988; Maity et. al., 
1988, 1992). Subsequently this factor has been purified from 
rat liver and characterised in some detail (section 1.4.3). 
A direct correlation exists between the binding of a highly 
purified preparation of CBF to the CCAAT box and its ability 
to stimulate transcription in an in vitro reconstituted 
transcription assay (Maity et. al., 1988) . CTF /NF-1 or a 
related protein binds to the NF-1-like site at -300 and has 
been shown to mediate the stimulatory effect of TGF-B on 
type I collagen gene expression (Oikarinen et. al., 1987; 
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Rossi et. al., 1988) . A 3 bp substitution mutation within 
the NF-1-like binding site also prevents the induction of the 
mouse a2 (I) procollagen promoter by TGF-B (Rossi et. al., 
1988) . However, there appears to be no difference in the 
formation of the of NF-1-like complex between either TGF-8 
treated or non-treated cells (de Crombrugghe et. al., 1990). 
In electrophoretic mobility shift assays, the levels of 
complexes that binds to the NF-1-like sequence are higher in 
fibroblast than in myeloma nuclear extracts {Goldberg, H. 
et. al., 1992). These results suggest that this element 
probably plays an important role in the cell-specific 
expression of the mouse a2 (I) procollagen gene in 
fibroblasts. Mutations in both the CCAAT and NF-1-like 
motifs decreases DNA-binding of the cognate proteins and also 
decreases promoter activity in transfection assays (Karsenty 
et. al., 1988). Although NF-1 can bind to sequences that 
contain a CCAAT motif, CTF/NF-1 and CBF only bind to their 
respective recognition elements, namely the NF-1-like site or 
the inverted CCAAT box, within the mouse a2 (I) procollagen 
promoter (Oikarienen et. al., 1987). Ristiniemi and 
Oikarinen (1989) have purified a factor, which may be 
histone Hl, that binds to the NF-1-like sequence in the mouse 
a2(I) procollagen promoter. 
A segment of the mouse COL1A2 first intron, between +418 and 
+1524, functions in an orientation independent manner as a 
transcriptional enhancer in transient transfection 
experiments in NIH-3T3 cells but not in the S194 _lymphoid 
cell line (Rossi and de Crombrugghe, 1987). Since this 
intronic enhancer is also active in a number of other cell 
types, including human cervical carcinoma cells {HeLa) and 
African Green Monkey cells {CV-1) (Pogulis and Freytag, 
1993), it is possible that it may only function in cell types 
that synthesise type I collagen. Goldberg, H. et. al. 
( 1992), on the other hand, have shown that this intronic 
fragment is not essential for the tissue-specific expression 
of a COL1A2-driven reporter gene in transgenic mice. 
Recently, two consensus sequences have been identified within 
the intronic enhancer {Pogulis and Freytag, 1993). The first 
element contains a 5 'TGTTTTAA3 ' motif ( initially identified 
within the c-mos and human papilloma virus enhancers) between 
nucleotides +992 and +999. A collagen intron-binding factor 
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I {CIBF-I) which is present in mouse fibroblast, HeLa and 
CV-1 nuclear extracts, binds to this element. The second 
cis-acting element is a "GT box" (nucleotides +871 to +880) 
that binds to affinity-purified Spl and to a Spl-like protein 
present in NIH-3T3 and other nuclear extracts (Pogulis and 
Freytag, 1993). The binding of both CIBF-I and Spl to their 
respective intronic recognition elements contribute to the 
stimulation of the mouse a2{I) procollagen gene. 
In contrast to the mouse first intron, the human first intron 
does not contain any enhancer activity: On the contrary, it 
causes a decrease in promoter activity {Sherwood et. al., 
1990) • Comparative studies of the human and mouse a2 (I) 
procollagen first introns identified very little sequence 
homology {Sherwood et. al., 1990). The human first intron 
contains two potential AP-1 consensus sequences and a long GT 
stretch, which are both absent in the mouse. 
Transient transf ection experiments have suggested that the 
mouse proximal al{I) procollagen promoter {220 bp) contains 
sufficient information for the tissue-specific expression of 
this gene (Rippe et. al., 1989). The human al (I) proximal 
promoter (from -300 to +100) is also able to effectively 
direct transcription of a reporter gene in a tissue-specifc 
manner (Bornstein et. al., 1987; Rossouw et. al., 1987). The 
human, chicken and mouse proximal promoters contain an intact 
TATA box and additional upstream promoter sequences (Finer 
et. al., 1987; Dickson et. al., 1987; Brenner et. al-, 1989). 
The human minimal promoter comprises the CCAAT box, potential 
Spl . binding sites and a pyrimidine-rich element (Rossouw 
et. al., 1987). The chicken promoter contains CCAAT boxes, 
but lacks the pyrimidine-rich element (Finer et. al., 1987). 
Two inverted CCAAT boxes, one between nucleotides -9 6 and 
-100 and the other between nucleotides -122 to -126, are also 
located within the mouse al (I) proximal promoter (Brenner 
et. al., 1989; Karsenty and de Crombrugghe, 1990). The 
transcriptional activator, CBF, of the mouse a2(I) 
procollagen gene, binds to the downstream, but not the 
upstream, CCAAT box to activate transcription of the al (I) 
gene (Karsenty and de Crombrugghe, 1990) • It is possible 
that CBF plays a vital role in the co-ordinate regulation of 
the type I collagen genes. The downstream CCAAT box is 
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extending from nucleotides -124 to -113 and -94 to -83. The 
12 bp repeats resemble the binding sites for Spl, MLTP ( a 
trans-activating factor in the adenovirus major late and 
r-fibrinogen promoters) or AP-2 (Nehls et. al., 1991). 
Karsenty and de Crombrugghe (1990), however, have shown that 
purified Spl does not bind to this site or that an AP-2 
consensus sequence did not compete with this sequence for 
DNA-protein complex formation. Inhibitory factor-2 (IF2), a 
metaloprotein, binds to these 12 bp GC-rich repeats (Karsenty 
and de Crombrugghe, 1990). Methylati~n interference assays 
indicated that the upstream 12 bp repeat is the major region 
for DNA-protein contact and that the downstream repeat is 
less important for binding. There is mutually exclusive 
binding of IF2 and CBF to their respective recognition 
elements, which could play an important role in the 
regulation of al(I) procollagen gene expression. Nehls 
et. al. (1991) have subsequently shown that another factor, 
NF-1, and not CBF is the major factor that interacts with the 
mouse al(I) procollagen promoter. Since there is a striking 
similarity between the downstream, and to a lesser extent the 
upstream, CCAAT boxes with the NF-1 consensus sequence, 
these investigators have classified both these elements as 
NF-1 sites. Binding and mutation analysis have shown that 
the downstream NF-1 site is more important in activating the 
gene (Nehls et. al., 1991) . Contrary to previous studies 
(Karsenty and de Crombrugghe, 1990), Nehls et. al. (1991, 
1992) have demonstrated that Spl actually binds to the 12 bp 
repeat and that NF-1 and Spl, like CBF and IF2, bind in a 
mutually exclusive manner to their respective binding sites. 
Over-expression of Spl in NIH-3T3 fibroblasts reduces basal 
promoter activity by about 2-fold, whereas over-expression of 
NF-1 resulted in enhanced transcription. These investigators 
therefore postulated that the mouse al(I) procollagen gene is 
regulated by the relative levels of Spl and NF-1. 
A second transcriptional repressor, inhibitory factor 1 
(!Fl}, binds to two or more upstream adjacent sites. one of 
these sites, element A, is situated between nucleotides -190 
and -170, while the other, element B, extends from 
nucleotides -160 to -130. Competition experiments have shown 
that IFl binds more readily to element A than to element B 
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(Karsenty and de Crombrugghe, 1990). Transient transfection 
experiments where 5 1 -flanking sequences (up to -2500) of the 
human (Boast et. al., 1990) and mouse (Rippe et. al., 1989; 
Karsenty et. al., 1990) al(I) procollagen promoters have been 
added to their proximal promoters resulted in decreased 
expression of the chimeric constructs. Contrary to these 
results, microinj ection of constructs into xenopus oocytes 
caused an increase in transcription (Rossouw et. al., 1987). 
These investigators have suggested that both positive and 
negative elements are present within these 5'-flanking 
regions. one of these factors is ·an inhibitory factor 
present in type I collagen producing cell lines and binds to 
a recognition element situated between nucleotides -339 to 
-361 in the mouse promoter. This factor is probably 
involved, together with cell-specific activators, in the 
tissue-specific regulation of the mouse al (I) procollagen 
expression (Ravazzolo et. al., 1991). An Spl consensus 
sequence (-466 to -459) have been identified within the 
distal human promoter and binds purified Spl (Bornstein 
et. al., 1987; Liska et. al., 1992). A strong tissue-
specific enhancer element has also been identified between 
-2300 and -444 (Slack et. al., 1991). Ritzenthaler et. al. 
(1991) have identified a TGF-B activating element (TAE) at 
-1600 within the rat al(I) procollagen promoter which 
resembles NF-1 and AP-2 binding sites. A 82 KDa TAE-binding 
protein, which is different to either NF-1 or AP-2, has been 
identified in human fibroblast nuclear extracts (Ritzenthaler 
et. al., 1993). In an attempt to study the tissue-specific 
expression of type I collagen in bone, Lichtler et. al. 
(1989) have shown that the rat al(I) promoter carries the 
necessary information for the cell-specific regulation by the 
calcitrophic hormone, 1,25-dihydroxyvitamin o3 , in bone cells 
but not in fibroblasts. More recently, Pavlin et. al. (1992) 
have identified potential osteoblast and odontoblast specific 
stimulatory elements located between -3521 and -1672 in the 
rat promoter. 
Sequences within the first introns of the mouse and human 
al(I) procollagen genes are also involved in modulating 
transcription. Unfortunately, controversy exists as to the 
nature and effect of the intronic sequences on al(I) 
procollagen gene expression. Both positive and negative 
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regulatory elements are located within the first intron of 
the mouse and human gene (Bornstein et. al., 1987, 1988; 
Bornstein and Mc Kay, 1988; Rippe et. al., 1989; Liska 
et. al., 1990; Boast et. al., 1990). A 274 bp fragment 
(nucleotides +820 to +1093) which inhibits the al(I) 
procollagen promoter activity in an orientation-dependent 
manner, has been identified within the 3'-half of the first 
intron of the human gene (Bornstein et. al., 1987; Rossouw 
et. al., 1987). Bornstein et. al. (1988) have postulated 
that this element inhibits gene expression by interacting 
with promoter sequences through co-operative DNA-protein 
interactions. Simkevich et. al. (1992) have also postulated 
that orientation-dependent interactions between cis-acting 
elements within the promoter and the first intron determine 
the tissue-specific expression of the human al(I) procollagen 
gene. Several cis-elements, including a Spl motif (+925 to 
+934), a viral core enhancer element (+999 to +1007) and a 
DNase 1 protection footprint extending from nucleotides +951 
to +978, have been identified within this negative element 
(Bornstein et. al., 1987; Rossouw et. al., 1987) . Liska 
et. al. (1992) have shown that purified Spl binds 
independently to the Spl motif and to a GC-rich region just 
5' of the viral core enhancer element. The first intron of 
the human gene also contains a positive orientation-dependent 
element extending from +292 to +670. This element contains 
an AP-1 consensus sequence at approximately +600 (Liska 
et. al., 1990). Interestingly, the chicken promoter and 
first intron contains two unique DNA sequences; · fifteen 
tandem repeats of the sequence 51 GGGGAGA31 have been 
identified within the first intron and at least 25 copies of 
a polymorphic, 23 bp tandemly repeated sequence within the 
distal promoter (Finer et. al., 1987). 
Most cells of mesenchymal origin produce type I collagen, 
while ectodermal, endodermal or hematopoietic lineage cells 
do not (Adams, 1989). Type I collagen is present in almost 
all connective tissues although quantitative differences may 
exist. As an example of the tissue-specific expression of 
type I collagen, the mechanisms for the inhibition of type I 
collagen synthesis in hyaline cartilage have been studied. 
Interestingly, type I collagen mRNA has been identified in 
cultured chicken chondrocytes and is found exclusively in the 
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nucleus, apparently unprocessed (Saxe et. al., 1985). In 
contrast, a smaller a2(I) mRNA product is processed and 
transported to the cytoplasm where it is found primarily 
associated with ribosomes (Bennett and Adams, 1987) . 
Chondrocytes synthesise a non-collagenous product from the 
a2 (I) mRNA which is transcribed from an alternate promoter 
and transcription start site situated in the second intron of 
the COL1A2 gene. This alternate promoter contains a CCAAT 
box but lacks a TATA box. The first two exons of the COL1A2 
gene are replaced by a novel 96 bp exon so that the new mRNA 
contains four open reading frames which are all out of frame 
with the collagen coding sequences (Bennett and Adams, 1990). 
1.3.6.2 TYPE II COLLAGEN GENE 
During the differentiation of mesenchymal cells into 
chondrocytes, type II collagen synthesis is initiated and the 
synthesis of type I collagen ceases (reviewed by 
von der Mark, 1980; Linsenmayer, 1981). Transient 
transfection assays, using chondrocytes and other cell types, 
have been used to identify a weak promoter, a cell-specific 
enhancer and silencer elements within the type II collagen 
gene (Horton et. al., 1987; Savanger et. al., 1990). The 
550 bp enhancer element, which increases the activity of the 
rat al(II) procollagen promoter in chondrocytes, but not in 
fibroblasts and myoblasts, has been identified within the 
first intron and shown to be activated during the 
differentiation of mesenchyme cells to chondrocytes (Horton 
et. al., 1987). Experiments with transgenic mice have 
confirmed that the tissue-specific expression of the type II 
collagen gene is dependent on the enhancer and promoter 
(reviewed by Yamada et. al., 1990). Furthermore, similar 
studies have shown that both these elements are sufficient 
for the regulation of the gene during development (Palmiter 
et. al., 1987; Breitman et. al., 
1989). Finally, Savagner et. al. 
1987; Bruggeman et. al., 
(1990) have identified two 
silencer elements, between -360 and -460, and -620 and -700, 
within the rat ai(II) procollagen promoter. The tissue- and 
developmental-specific expression of the type II procollagen 
gene is therefore controlled by both negative and positive 
cis-elements. 
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The rat cxl (II) procollagen promoter contains a TATA box, 
several GC-rich sequences and an enhancer core element. The 
enhancer core element is located around -280, while direct 
and inverted Spl hexanucleotide consensus sequences are 
situated between -450 and the TATA box (Kohno et. al., 1985). 
There is considerable homology between the rat and human 
cxl(II) procollagen promoters (Nunez et. al., 1986). The 
enhancer contains a GC box, a glucocorticoid response 
element, a NF-1 consensus sequence and many direct and 
inverted repeats. DNA-binding studies with chondrocyte 
nuclear extracts suggest that a number·of regions within the 
enhancer interacts with distinct nuclear proteins (Yamada 
et. al., 1990). Wang et. al. (1991) have identified a 
decamer sequence 5 'cACAATGCAT3 ' in the middle of the enhancer 
that binds a chondrocyte-specific protein(s) which is 
required for enhancer activity. The DNA-binding activity of 
this protein ( s) was induced during differentiation of limb · 
bud mesenchymal cells into chondrocytes. The silencer 
elements contain consensus sequences that are found in 
silencers of other genes. DNA-binding studies have shown 
that trans-acting factors in non-chondrocytic nuclear 
extracts, such as HeLa, but not in chondrocyte nuclear 
extracts interact with DNA fragments containing the silencer 
elements (Savagner et. al., 1990). 
1.3.6.3 TYPE III COLLAGEN GENE 
In contrast to the type I collagen genes, relatively little 
is known about the mechanisms that regulate the expression of 
the COL3Al gene (reviewed by de Crombrugghe et. al., 1990). 
Al though types III and I collagens are co-ordinately 
expressed in many tissues, the ratios of these two collagen 
types varies from tissue to tissue and also during 
development (Fessler and Fessler, 1978; Kuhn, 1981). The 
levels of both collagen types are similarly affected by TGF-B 
(Ignotz and Massague, 1986) and hepatic fibrogenic factor 
{Choe et. al., 1987). Fibroblasts transformed with Rous 
sarcoma virus and v-mos oncogenes synthesise less type I and 
type III collagen mRNA (Howard et. al., 1978; Schmidt 
et. al., 1985) . It can therefore be postulated that the 
mechanisms that regulate the expression of types III and I 
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collagen genes may share common regulatory elements, or that 
they may be controlled by a "master" gene. 
A 2.3 Kb mouse al(III} procollagen promoter fragment fused to 
a reporter gene was used in transient transfection studies to 
identify the cis-acting elements that regulate the expression 
of the type III collagen gene (Mudryj and de Crombrugghe, 
1988}. In contrast to the mouse a2(I) procollagen promoter, 
deletion analysis of the al (III) promoter suggested that 
regulation is predominantly by negative regulatory elements. 
Although the precise location of these ~lements is not known, 
one of them lies within a 50 bp region between -350 and -300 
(Mudryj and de Crombrugghe, 1988). Two positive recognition 
elements, located at -122 to -106 and at -83 to -61, have 
been identified in the proximal 150 bp of the mouse al(III} 
promoter. Cis-elements in the mouse al(I} and a2(I} 
procollagen promoters, such as the CCAAT box, are not present 
in the mouse al(III) promoter and the heterotrimeric CBF does 
not bind to this 150 bp region of the al(III) promoter 
(Hatamochi et. al., 1986; Maity et. al., 1988). Contrary to 
expectations, these observations suggest that different 
mechanisms regulate the expression of the type I and type III 
procollagen genes. AP-1 or a related factor probably binds 
between -122 and -116 to activate transcription (Ruteshouser 
and de Crombrugghe, 1989). A monomeric, heat-resistant, 
95 KDa factor (the B element-binding factor or BBF) has been 
purified from HeLa and NIH-3T3 cells and shown to bind 
between -83 and -61 (Ruteshouser and de Crombruggha, 1992}. 
Binding of BBF to its recognition element is probably 
modulated by other factors such as an inhibitor of BBF DNA-
binding activity (Ruteshouser and de Crombrugghe, 1992}. 
Additional work needs to be done to fully understand the role 
of these and other factors in the co-ordinated control of 
type III and type I collagen gene expression. 
1.3.6.4 TYPE IV COLLAGEN GENE 
The transcriptional regulation of type IV collagen and other 
basement membrane protein genes is more extensively studied 
in F9 teratocarcinoma stem cells which differentiate into 
parietal endoderm-like cells when treated with retinoic acid 
and dibutyryl-cAMP (Strickland et. al., 1980}. since 
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differentiation is associated with a co-ordinated increase in 
the synthesis of basement membrane proteins, these cells 
serve as an ideal model system for studying the regulation of 
type IV collagen genes (Burbelo et. al., 1990 and references 
therein) . 
The expression of type IV collagen is tightly regulated, both 
spatially and temporally, during development when 
extracellular deposition is important for cell migration and 
differentiation (Timpl and Dziadek, 1986). The co-ordinate 
regulation of both the human and mouse al (IV) and a2 (IV) 
collagen genes have a number of unique characteristics; 
firstly, both genes are located on the same chromosomal 
region in a head to head configuration and are separated by 
approximately 130 bp of DNA (Poschl et. al., 1988; Burbelo 
et. al., 1988). Comparison of the 130 bp mouse and human 
region revealed a high level of sequence homology (nearly 
90%) (Poschl et. al., 1988; Burbelo et. al., 1988) . Since 
this region is able to direct the expression of a reporter 
gene in an orientation independent manner, it serves as a 
common bidirectional promoter for both genes, although with a 
low transcriptional activity (Poschl et. al., 1988; Burbelo 
et. al., 1988). Two DNA-binding sites have been identified 
within the short TATA box-less bidirectional promoter 
(Bruggeman et. al., 1992). The first is a consensus sequence 
situated within an interrupted dyad symmetry in the centre of 
the promoter. The other site is a novel 5 'cccTccc3 ' motif 
which is present in several other extracellulaL matrix 
promoters, including the a2(I) procollagen promoter 
(chapter 4). Factors from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma protein extracts interact with both these recognition 
elements (Bruggeman et. al., 1992). 
A cell-specific 210 bp enhancer, which stimulates the common 
promoter of both the al ( IV) and a2 ( IV) collagen genes, has 
been identified within the first intron of the mouse COL4Al 
gene. Two cis-acting elements (A and B) have been identified 
within the enhancer (Burbelo et. al., 1988). Two putative 
positive acting factors, one of 37 KDa and the other of 
94 KDa, which bind to element A (51 CCTTATCTCTGATGG31 ) has 
been purified and shown to be required for the effective 
transcription of both genes (Burbelo et. al., 1991). A 
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putative negative cis-element is probably present in the 
third intron of the human COL4A2 gene (Posch! et. al., 1988). 
Both positive and negative factors, therefore, probably 
regulate the co-ordinated expression of the two major type IV 
collagen genes. Methylation status and/or chromatin 
structure of the type IV collagen promoter and/ or enhancer 
may also play an important role in silencing the expression 
of these genes in cells that do not synthesise type IV 
collagen (Burbelo et. al., 1990, 1991). 
1.3.6.5 TYPE V COLLAGEN GENE 
As already discussed (section 1.2.1), type V collagen is co-
expressed with type I collagen and probably plays a role in 
regulating the diameter of type I containing collagen fibres. 
To understand the mechanisms that regulate the expression of 
type V collagen and to gain insight into its co-ordinated 
expression with other collagen types, the regulatory elements 
within the a2{V) procollagen gene have been studied and 
characterised. Greenspan et. al. (1991b) have isolated a 
17 kb genomic clone containing the 5 '-portion of the human 
a2(V) procollagen gene and nucleotide sequence analysis 
revealed remarkable similarity between the promoter, the 
first exon and the 5 1 -end of the first intron of the al(III) 
gene. The homologous regions include the -120 bp proximal 
promoters, especially near the TATA box between -37 and -27, 
the transcription start sites and 5'-untranslated regions of 
the two genes. This promoter, like the al (III) promoter, 
does not contain a CCAAT box (Greenspan et. al., 1991b; 
Truter et. al., 1992b). 
More recently, Truter et. al. {1992a) have identified a 52 bp 
region of the human a2{V) procollagen promoter that is 
essential for the cell type-specific expression of a reporter 
gene in transient transf ection assays. This region of the 
human promoter is highly homologous with the equivalent 
region of the mouse promoter. Two novel nuclear factor 
binding sites, FP-A (-115 to -99) and FP-B (-149 to -118), 
have been identified in this short region of the human 
promoter {Truter et. al., 1992a). Both FP-A and FP-B 
binding factors are transcriptional 
cis-acting elements have also been 
activators. Negative 
identified within the 
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first intron and 5 '-flanking sequences of the human COL5A2 
gene (Greenspan et. al., 1991b). 
1.3.6.6 TYPE VI COLLAGEN GENE 
Type VI collagen gene expression is independently regulated 
from those of the other major constituents of the 
extracellular matrix, such as types I and III collagens 
(Hatamochi et. al., 1988; Oono et. al., 1993). Furthermore, 
the two type VI collagen genes, al(VI) and a2(VI), which are 
located on human chromosome 21 are co~ordinately regulated, 
whereas the a3(VI) gene on chromosome 2 is regulated 
independently (Schreir et. al., 1988; Hatamochi et. al., 
1989; Oono et. al., 1993). 
The human a2(VI) collagen promoter contains a TATA box, 
located between -40 and -50, flanked by SPl consensus 
sequences and two potential CCAAT boxes {Saitta et. al., 
1992). Four mRNA species that differ in sequences at their 
5 '-UTRs are synthesised from the human a2 (VI) gene. 
Transcription of one of the mRNA species starts at exon 1, 
while three minor species are transcribed from the second 
exon ( exon lA) . It is highly likely that the minor mRNA 
species are transcribed from an alternative promoter. This 
hypothetical promoter, which lacks a TATA and CCAAT boxes, 
contains several SPl consensus sequences (Saitta et. al., 
1992) . 
Contrary to other collagen genes, the chicken promoter is 
structurally very different from the human promoter (Koller 
et. al., 1991; Saitta et. al., 1992). The chicken promoter 
lacks both the TATA and CCAAT boxes. Instead it contains 
several Spl and ETF (Kageyama et. al., 1989) consensus 
sequences and, like most TATA box-less genes, has multiple 
transcription initiation sites distributed over 75 bp of DNA. 
The CpG dinucleotide occurs with a high frequency within the 
5 '-flanking region of the gene. A 207 bp region of the 
promoter containing the entire CpG island and all the 
transcription initiation sites has strong promoter activity 
when linked to a reporter gene in transient transfection 
assays (Koller et. al., 1991). The chicken a2(VI) collagen 
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upstream promoter also contains a 403 bp purine/pyrimidine 
motif of unknown function (Koller et. al., 1991). 
1.3.6.7 TYPE IX COLLAGEN GENE 
Two tissue-specific forms of type IX collagen are produced by 
the alternative use of two transcription start sites and 
alternative splicing. The shorter corneal form of the al(IX) 
chain lacks the N-terminal globular domain, which is present 
in the cartilage form. Approximately 20 kb of genomic DNA, 
containing exons 1 to 6, separate the·cartilage and corneal 
transcription initiation sites in the chicken al(IX) collagen 
gene. The corneal-specific promoter is situated near the 
3 1 -end of the sixth intron and contains a TATA box 
(approximately -13), CCAAT box (-46 to -42) and an AP-1 
binding site (-341 to -334). The cartilage-specific promoter 
is structurally different in that it contains a Spl consensus 
sequence (-93 to -88) and other motifs at -so, -630 and -107 
which are similar to sequences within the apoE promoter and 
the immunoglobulin enhancer (Nishimura et. al., 1989). 
1.4 THE CCAAT BOX BINDING FACTORS 
Most eukaryotic promoters contain a CCAAT box in either a 
direct or inverted orientation in which flanking sequences 
may differ tremendously (Chodosh et. al., 1988a; Dorn 
et. al., 1988; Santoro et. al., 1988). Some promoters even 
contain two or more functional CCAAT boxes (Park .et. al., 
1990; Liu et. al., 1991). A number of structurally distinct 
families of transcription factors bind to CCAAT boxes to 
either activate or repress transcription (Dorn et. al., 1988; 
Raymondjean et. al., 1988). A single cell type can contain 
several CCAAT binding factors which bind to different CCAAT 
boxes (Dorn et. al., 1988). This is possible because the 
flanking sequence of the CCAAT motif probably determine the 
affinity of a transcription factor for a specific CCAAT box. 
Based on their structural complexity and function these 
factors can be divided into several families of CCAAT box 
binding proteins such as CTF/NF-1, C/EBP, the hetero-
multimeric factors and others. 
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1.4.1 CCAAT TRANSCRIPTION FACTOR/NUCLEAR FACTOR 1 (CTF/NF-1) 
Nuclear factor 1 (NF-1), also known as CCAAT transcription 
factor (CTF) and CTF /NF-1, is a family of sequence-specifc 
DNA-binding proteins which can either function as positive or 
negative transcription factors (Jones et. al., 1987; Gil 
et. al., 1988; Angel et. al., 1988) or as factors in DNA 
replication (Nagata et. al., 1983) • Rosenfeld and Kelly 
(1988) used DNA-affinity chromatography to purify the factor 
from HeLa cells to apparent homogeneity, and have shown that 
NF-1 comprises a population of related polypeptides with 
apparent molecular weights ranging from 52 to 66 KDa. In 
humans the individual members of this family of proteins, 
containing highly conserved N-termini and variable c-termini, 
may be produced by alternate splicing of a single gene 
product (Santoro et. al., 1988). Chicken NF-1 proteins, on 
the other hand, are encoded by at least three distinct genes, 
designated NF-1-A, NF-1-B and NF-1-C (Rupp et. al., 1990) . 
Both the forms and levels of NF-1 vary in different cell 
lines (Goyal et. al., 1990). 
The 499 amino acid long CTF-1 factor contains a number of 
functional domains. The praline-rich transcriptional 
activation domain is situated in the c-terminal region while 
the DNA-binding, protein dimerisation and DNA-replication 
domains are all situated in the N-terminal 240 amino acids of 
the protein (Mermod et. al., 1989) . The DNA-binding and 
dimerisation domains are situated on the N-terminal and 
c-terminal portions of this 240 
respectively (Gounari et. al., 1990). 
amino acid region 
NF-1 binds as a dimer to the recognition sequence 
51
TGGN6_7GCCAA
31 (Jones et. al., 1987; Gounari et. al., 
1990). The flanking sequences and the length of the 6 to 
7 bp spacer region can greatly modulate binding efficiency 
(Gronostajski, 1986). NF-1 may also bind to NF-1-like sites, 
such as the inverted NF-1-like site within the mouse a2 (I) 
procollagen promoter which binds to NF-1 or a NF-1-like 
protein with lower affinity (Oikarinen et. al., 1987). 
Zorbas et. al. ( 1992) have shown that NF-1 can bind to the 
5 'GGGN6GCCAG
3 ' motif in the human a-globin gene promoter. 
Since the 3 '-end of the NF-1 motif resembles a CCAAT box, 
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NF-1 can bind to some CCAAT boxes and has therefore been 
classified as a CCAAT box binding factor (Jones et. al., 
1987). Often promoters contain both NF-1 and CCAAT motifs 
which independently bind NF-1 and other CCAAT box binding 
factors {Oikarinen et. al., 1987; Zorbas et. al., 1992). 
1.4.2 CCAAT/ENHANCER BINDING PROTEIN (C/EBP) AND RELATED 
PROTEINS 
C/EBP, which is not related to NF-1, is a sequence-specific 
DNA-binding protein that was originally shown to bind to the 
CCAAT box within the herpes virus thymidine kinase promoter 
and the murine sarcoma virus long terminal repeat and called 
the CCAAT binding protein {CBP) {Graves et. al., 1986). The 
same factor, which bound to the enhancer core element 
(51 TGTGGWWWG31 ) present in many viral enhancers, was purified 
independently from rat liver nuclei and called the enhancer 
binding protein (EBP) (Johnson et. al., 1987). This heat-
stable 42 KDa factor is now referred to as the CCAAT/enhancer 
binding protein {C/EBP) and is known to be a family of 
related factors which include C/EBPa, C/EBPB, C/EBPo and 
C/EBP--y (Lamb and McKnight, 1991 and references therein). 
C/EBP can also bind to a third element, which resembles the 
enhancer core element, the ATF/CRE elements (Bakker and 
Parker, 1991). The binding sites for C/EBP, therefore, have 
the consensus sequence 5 'TKNNGVAAK3 ' (Yuh and Ting, 1991). 
Several C/EBP-like factors, which have DNA-binding 
specificities similar to those of C/EBP, have a~so been 
identified and are believed to be members of a C/EBP super-
family of transcription factors. These factors include 
AGP /EBP {Chang et. al., 1990) , the IL-6DBP family (Poli 
et. al. , 1990) , DBP {Muller et. al., 1990) , LAP (Descombes 
et. al., 1990) and the C/ATF family (Vallejo et. al., 1993). 
The regulation of gene expression during different stages of 
cell differentiation and growth is probably tightly 
controlled by the C/EBP and C/EBP-like factors. 
The DNA-binding domain of this super-family of factors is 
bipartite, consisting of a dimerisation interface, the 
leucine zipper, and a DNA-binding basic region (Landschulz 
et. al., 1988, 1989). Members of the C/EBP family can 
interact with each other to form heterodimers (reviewed by 
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Lamb and Mc Knight, 1991). They can also form heterodimers 
with C/EBP-like proteins, such as the C/ATF family (Vallejo 
et. al., 1993). The DNA-binding domain of C/EBP can also be 
phosphorylated by protein kinase c in a ca2+ and lipid 
dependent manner (Wegner et. al., 1992; Mahoney et. al., 
1992) . Post-translational modifications are becoming 
increasingly important in modulating the DNA-binding ability 
and the transcription activational properties of C/EBP. 
C/EBP and the related proteins are present in various tissues 
including liver, lung, adipose, gut an~ placenta (Birkenmeier 
et. al., 1989). It has been postulated that C/EBP activity 
is normally associated with only fully differentiated, non-
proliferating cells that metabolise lipids and cholesterol at 
high rates (Birkenmeier et. al., 1989; Christy et. al., 1989, 
Friedman et. al., 1989). The factor may function exclusively 
in these cells by activating genes responsible for a 
specialised phenotype (Friedman et. al., 1989). Although 
C/EBP activity is present in differentiated cells it does not 
appear to be expressed early in the differentiation pathway 
or to regulate the initiation of differentiation, but 
probably helps to maintain the differentiation status of a 
cell (Birkenmeier et. al., 1989; Friedman et. al., 1989). A 
number of tissue-specific genes, like the serum albumin gene 
(Friedman et. al., 1989), the human clotting factor IX gene 
(Crossley and Brownlee, 1990) and the phospho-enolpyruvate 
carboxykinase (PEPCK) gene (Park et. al., 1990;), are 
activated when C/EBP binds to cis-elements within their 
promoters. In fact C/EBP binds to several sites along the 
PEPCK promoter (Park et. al., 1990; Liu et. al., 1991). 
C/EBP may also play a direct role in regulating the genetic 
programme responsible for the termination of cell growth such 
as the termination of meiotic growth of adipoblasts (Umek 
et. al., 1991) and other pluripotent cells (Taylor and Jones, 
1979) . 
1.4.3 THE HETERO-MULTIMERIC CCAAT BINDING FACTORS 
A large number of related and in some cases even identical 
CCAAT binding factors, which are distinct from CTF /NF-1 or 
C/EBP, have been purified and characterised independently by 
several of investigators. These factors include NF-Y (Dorn 
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et. al., 1987), CBF {Hatamochi et. al., 1988), CPl {Chodosh 
et. al., 1988a), aCPl {Kim and Sheffery, 1990), the yeast 
Hap-2, 3, 4 factors {Forsbery and Guarente, 1989) and others 
{table 1. 2). Based on their structural complexity, these 
factors belong to a distinct category of CCAAT binding 
factors with heterologous subunits. Initially these 
complexes were identified as heterodimers but recent evidence 
has shown that an ever increasing number of these factors are 
actually heterotrimers. The structure and function of a few 
of these hetero-multimeric factors are explained in detail. 
Table 1.2 Subunit composition of the hetero-multimeric 
factors. Tabulation of the species and tissue or cell types 
from which these factors have been identified. Subunit C of 
some of these factors (n.d.) has not been identified or 
characterised to date. 
SUBUNITS 
FACTOR SPECIES SOURCE 
B A C 
a-CPl Mouse MEL cells "( 6 a 
CBF Rat liver CBF-B CBF-A CBF-C 
CBF Mouse NIH-3T3 CBF-B CBF-A CBF-C 
CPl Human HeLa cells CPlB CPlA n.d. 
EFI Chick Embryos EFIB EFIA n.d. 
EFI Rat liver EFIB EFIA n.d. 
NF-Y Mouse Ubiquitous NF-YA NF-YB n.d. 
Hap-2,3,4 Yeast Hap-2 Hap-3 Hap-4 
In yeast, a heterotrimeric transcription factor, Hap-2,3,4, 
binds to a CCAAT box in the upstream activation site, UAS2, 
of the CYCl gene to activate transcription {Forsburg and 
Guarente, 1989 and references therein). 
The transcriptional activator, a-CPl, which binds to the 
a-globin promoter was initially identified and purified from 
murine erythroleukemia (MEL) cells {Cohen et. al., 1986; 
Barnhart et. al., 1988). a-CPl constitutes at least seven 
polypeptides which have been divided into three distinct 
classes designated a, B and "f· The a class consists of a 
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single 35 KDa polypeptide while two polypeptides (27 KDa and 
28 KDa} make up the B class. The 'Y class comprises four 
related polypeptides with apparent molecular masses of 3 3, 
34, 37 and 38 KDa. One polypeptide from each class forms a 
functional heterotrimeric factor which has a native molecular 
mass of ±101 KDa. The a and B polypeptides form an inactive 
core complex which is stable at moderately high ionic 
strengths. The 'Y polypeptide is weakly associated with the 
stable aB core and required for a-CPl activity (Kim and 
Sheffery, 1990}. 
The transcriptional activator, a-CPl, competes with a 
stronger monomeric activator, a-CP2, for binding to distinct 
overlapping recognition sites in a mutually exclusive manner 
to regulate the a-globin gene (Kim et. al., 1990; Lim 
et. al., 1992}. Interestingly, CCAAT-binding factors can 
also compete with transcriptional repressors for overlapping 
binding sites in a mutually exclusive manner to regulate gene 
expression (Barberis et. al., 1987). 
The heterotrimeric CCAAT binding factor, CBF, was initially 
identified in NIH-3T3 fibroblasts (Hatamochi et. al., 1986; 
Oikarinen et. al., 1987} and later p~rified to homogeneity 
from rat liver nuclear extracts (Hatamochi et. al. , 1988} . 
CBF is also a transcription activator which binds to the 
proximal CCAAT box in the mouse al(!} and a2(I} procollagen 
promoters (Maity et. al., 1988}. The interaction of three 
distinct polypeptides (~BF-A, CBF-B and CBF-C} are required 
for CBF DNA-binding activity. CBF-A forms a stable non-
covalent, anionic and heat labile complex with the 4 o KDa 
CBF-C subunit which can only be dissociated by denaturing 
agents. The cationic and heat stable CBF-B subunit forms an 
easily dissociable complex with the CBF-A.CBF-C complex 
(Hatamochi et. al., 1988; Maity et. al., 1992). Full-length 
CBF-A and CBF-B cDNA clones have been isolated and a protein 
of 207 amino acid with a calculated molecular weight 25 KDa 
is encoded by the CBF-A cDNA. There is a high sequence 
identity between significant portions of CBF-A and the yeast 
Hap-3 polypeptide (Vuorio et. al., 1990). The CBF-B cDNA 
clone contains an open reading frame of 1023 bp encoding a 
protein of 341 amino acids with a calculated molecular mass 
of 41 KDa. The c-terminal portion of this polypeptide is 
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highly homologous with a portion of the Hap-2 protein (Maity 
et. al., 1990). 
The transcription factor CPl has been partially purified from 
HeLa cell extracts (Chodosh et. al., 1988a) • CPl binds to 
the consensus sequence, 51 YN6RRCCAATCANYK
31
, within the human 
a-globin promoter, the human hsp70 promoter, H-2K promoter, 
adenovirus MLP and MSV LTR. CPl consists of at least two 
subunits, CPlA and CPlB, which are both required for CPl DNA-
binding activity and, like the other hetero-multimeric 
factors, forms a complex independently bf a CPl binding site. 
The CPlA and CPlB · subunits are functionally similar to the 
yeast Hap-3 and Hap-2 proteins respectively (Chodosh et. al., 
1988b) . CPlA and CPlB can also form functionally stable 
hybrid complexes with their complementary subunits of the 
yeast CCAAT binding factor Hap-2,3,4. 
Enhancer factor I (EFI), a transcriptional activator, which 
binds to an inverted CCAAT box within the Rous sarcoma virus 
LTR (Sealy and Chalkley, 1987), is also a hetero-multimeric 
factor consisting of at least two subunits, EFIA and EFIB, 
which forms a heterodimer that binds with high affinity to 
its recognition sequences (Faber and S~aly, 1990). A second 
DNA-binding form of EFI, probably a multimer of EFIA, is 
present in avian nuclear extracts under certain conditions 
(Ozer et. al., 1990). The molecular weight of the avian EFIA 
subunit has been reported to be between 43 and 60 KDa (Faber 
and Sealy, 1990). The rat EFIA cDNA encodes a 322 amino acid 
protein (35 KDa) (Faber and Sealy, 1990) and is nearly 
identical to two previously described human CCAAT box binding 
proteins, dbpB (Sakura et. al., 1988) and YB-1 (Didier 
et. al., 1988) . These proteins contain a novel structural 
motif containing alternating regions of positively and 
negatively charged amino acid residues separated by short 
glutamine-rich regions (Ozer et. al., 1990). 
Nuclear factor Y (NF-Y) is a ubiquitous CCAAT box binding 
factor which binds to the consensus sequence 5 'RRCCAATCAG3 ' 
either in the direct or inverted orientation in a variety of 
promoters (Wuarin et. al., 1990; Li et. al., 1992 and 
references therein). NF-Y was originally identified as a 
sequence-specific DNA-binding protein that recognises the y 
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box within the major histocompatibility complex (MHC) 
class II gene, Ea (Dorn et. al., 1987). The binding and 
physical properties and subunit composition {NF-YA and NF-YB) 
of NF-Y have been reported {Hoeft van Huijsduijnen, 1987, 
1990). The NF-YA and NF-YB genes contain at least 9 and 5 
exons respectively {Li et. al., 1992) and different forms of 
NF-YA are produced by alternative tissue-specific splicing. 
Certain forms are more predominant in the brain, liver, lung 
and in fibroblast and teratocarcinoma cells, while other 
forms predominate in the thymus and spleen and in B lymphoid 
cell lines. NF-YA and NF-YB are also homologous to Hap-2 and 
Hap-3 respectively (Li et. al., 1992). 
1.4.4 CCAAT BINDING PROTEINS AND CELL CYCLE REGULATION 
A number of cell-cycle regulated genes whose expression 
increases at the G1/s phase boundary, contain CCAAT boxes 
within their proximal promoters. These include, amongst 
others, the thymidine kinase {TK) {Flemington et. al., 1987), 
histone Hl (Gallinari et. al., 1989) and hsp70 genes 
(Wu, B.J. et. al., 1987). The expression of these three 
genes is coupled with the onset of DNA synthesis {Milarski 
and Morimoto, 1986). The human proximal TK promoter contains 
two inverted CCAAT boxes located at -36 and -67, both of 
which, especially the distal one, are required for TK gene 
expression (Lipson et. al., 1989; Kim and Lee, 1991). 
Inverted and/ or tandem CCAAT boxes are also found in other 
cell-cycle regulated genes {Busslinger et. al., 198Q; Harvey 
et. al., 1982; sierra et. al., 1983) and are recognised by 
specific CCAAT box binding factors which stimulate their 
expression (Lum et. al., 1990; Gallinari et. al., 1989). 
Several CCAAT binding proteins which activate cell-cycle 
regulated genes have been purified and/or characterised from 
a variety of cell lines and tissues and have been shown to be 
distinct from C/EBP or from the hetero-multimeric factors 
(table 1. 3) . In contrast a factor which may be related to 
ubiquitous NF-Y binds to the CCAAT boxes within the human TK 
promoter (Arcot et. al., 1989). Investigators have also 
shown that several distinct or related CCAAT binding proteins 
can bind in vitro to the same promoter element ( table 1. 3) 
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(Jones et. al., 1985; Graves et. al., 1986; Morgan et. al., 
1987; van Wijnen et. al., 1988; Lum et. al., 1990) 
Table 1. 3 CCAAT box binding proteins and cell cycle 
regulation. Several cell-cycle genes are regulated by 
different CCAAT box binding proteins. The molecular weights 
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The transcriptional activation properties of some or even all 
of these CCAAT binding factors are cell-cycle regulated and 
correlates with the activation of their target genes. These 
factors may therefore stimulate transcription of the cell-
cycle regulated genes during the G1 /s phase boundary of the 
cell cycle. 
the CCAAT 
The cell-cycle dependent DNA-binding activity of 
binding protein for the TK gene (CBP/tk) may 
activate the TK gene prior to the onset of DNA synthesis 
(Pang and Chen, 1993). Alternatively, during the cell-cycle 
when these genes are not expressed, a repressor protein ( s) 
binds directly to the DNA-bound CCAAT-binding protein to 
inhibit transcription. The repressor protein(s) dissociates 
from the CCAAT binding factor during the G1 /s phase 
transition and the cell-cycle genes are activated. At the 
end of the activation period the repressor protein 
reassociates with the bound CCAAT binding factor to 
inactivate the gene. Knight et. al. (1987) have shown, for 
example, that although a murine CCAAT binding factor 
interacts with the human TK promoter throughout the cell-
cycle, the nature of this DNA-protein complex is cell-cycle 
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dependent. Secondly, the human hsp70 gene is 
transcriptionally repressed when wild-type p53 interacts with 
CBF {Agoff et. al., 1993). The adenovirus Ela protein, on 
the other hand, activates the hsp70 gene via protein-protein 
interactions with DNA-bound CBF. Ela could nullify the 
activity of the repressor and allow CBF to activate the gene 
or, alternatively, it may mimic the function of a coactivator 
{Lum et. al., 1992). 
1.4.5 OTHER CCAAT BINDING PROTEINS 
The a subunit CCAAT binding factor (aCBF) activates the a 
subunit gene of the pituitary and placental glycoprotein 
hormone. This transcription factor was identified in human 
choriocarcinoma cells and is also present in other cells such 
as HeLa and HepG2 cells. Monomeric aCBF has an apparent 
molecular weight of 53 KDa and is probably not related to 
CTF/NF-1, C/EBP or one of the hetero-multimeric CCAAT-binding 
factors (Kennedy et. al., 1990). CCAAT-binding proteins may 
also regulate the age-dependent decreased expression of some 
genes. The age-related decrease in TK gene expression, for 
example, is coupled to a similar decrease in CBP /tk DNA-
binding activity {Pang and Chen, 1993). 
In summary, the CCAAT box is not recognised by a single 
protein but by a class of structurally distinct proteins 
whose inter-relationships are not clear. CCAAT binding 
proteins play an important role in a variety of physiological 
processes, w~ich include regulation of the cell-cycle, lipid 
and cholesterol metabolism, DNA replication, cell growth 
arrest, etc. Interestingly, related factors appear to 
regulate a specific subset of these functions and can also 
compete with other transcription factors (both activators and 
repressors) for binding to distinct sites in a mutually 
exclusive manner to regulate gene expression. Activators and 
repressors can also bind directly to CCAAT-binding factors 
via protein-protein interactions to regulate gene expression. 
CHAPTER 2 
IDENTIFICATION OF DNA-BINDING PROTEINS WHICH INTERACT 
WITH THE PROXIMAL a2(I) PROCOLLAGEN PROMOTER 
2.1 INTRODUCTION 
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The synthesis of type I collagen by a normal diploid human 
embryonic lung fibroblast cell line (WI-38) (ATCC CCL-75) and 
two .transformed WI-38 cell lines, one transformed with simian 
virus 40 (SVWI-38) (de Haan et. al., 1986) and the other by 
l-radiation (CT-1) (Namba et. al., 1980), has previously been 
investigated (Parker et. al., 1989). This study showed that 
the WI-38 and CT-1 fibroblasts produce similar quantities of 
the heterotrimeric type I collagen, while the SVWI-38 cells 
produce only 20-25% of the total collagen synthesised by 
their normal counterparts. Similar observations were 
reported by other investigators, who have also shown a 
decrease in collagen synthesis in var~ous transformed cell 
lines (Hata and Peterkofsky, 1977 and Sandmeyer et. al., 
1981). 
SDS-polyacrylamide gel electrophoresis and cyanogen bromide 
peptide analysis showed that the SVWI-38 fibroblasts .produced 
only overmodified al (I) chains, while no detectable a2 (I) 
collagen chains were produced. DEAE-cellulose ion exchange 
chromatography identified the product as a homotrimer of type 
I collagen consisting of three overmodified al(I) chains 
(Parker et. al., 1989) . Sundarraj and Church ( 1978) have 
also demonstrated an increase in the post-translational 
modification of type I procollagen in another SV40-
transformed human fibroblast line (GM637). 
Nothern blotting analysis revealed that al (I) procollagen 
mRNA was present in SVWI-38 and WI-38 cells, while a2 (I) 
transcripts could only be detected in WI-38 fibroblasts. 
Although SVWI-38 fibroblasts produce only 20%-25% of the 
collagen produced by their WI-38 counterparts, the al (I) 
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procollagen mRNA levels in these cells were similar to those 
in WI-38 cells (Parker et. al., 1989). If the translation 
rate of the al (I) procollagen mRNA is normal in SVWI-38 
fibroblasts then the excess al{I) chains produced by these 
cells are probably degraded prior to homotrimer formation. 
Alternatively, an accumulation of free al{!) procollagen 
chains, due to the slower rate of type I homotrimer 
formation, or an increase in degradation products of the 
excess al{I) chains may play a role in feedback inhibition of 
translation of al (I) procollagen mRNA. Bennett and Adams 
{1987) have demonstrated such a control mechanism for a2{I) 
procollagen mRNA translation in chicken vertebral 
chondroblasts. 
Karyotype analysis revealed that SVWI-38 cells contain only 
28 normal chromosomes while gross chromosomal aberrations 
were noted in the remaining 18 chromosomes. Chromosomes 7 
and 17, which contain the a2{I) and al{I) procollagen genes 
respectively, appeared to be normal (Junien et. al., 1982; 
Huerre et. al., 1982; Retief et. al., 1985) The SV40 
genome is covalently integrated within a stretch of 21 Kb of 
the SVWI-38 fibroblast genome as a series of partial tandem 
repeats {Goldberg, Y.P. et. al., 1992). Restriction mapping 
of the entire a2{I) procollagen gene and its promoter did not 
reveal any gross deletions, insertions, rearrangements or 
integration of large fragments of SV40 DNA within the body of 
the gene or its promoter (Parker et. al., 1989). It is 
possible that the inactivation of this gene is due to the 
integration of a small fragment or fragments of SV40 DNA, 
which cannot be easily detected by restriction mapping. 
However, it is unlikely that both alleles of the same gene 
would be affected in the same way in the same cell. 
' 
Previous studies have shown that hypermethylation of the type 
I procollagen genes is associated with the inactivation of 
these genes (Parker et. al., 1982; Smith and Marsilio, 1988; 
Guenette et. al., 1992). The methylation of the a2{I) 
procollagen gene .in WI-38 and SVWI-38 fibroblasts showed that 
the gene was methylated to the same extent in both cell types 
in both the 5 ' - and 3 ' -reg ions. Al though Guenette et . al . 
{1992) have demonstrated that DNA hypermethylation is 
responsible for inactivation of the a2{I) procollagen gene in 
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a chemically transformed rat liver epithelial-like cell line, 
W8, which also secretes a type I collagen homotrimer, 
aberrant methylation is probably not responsible for 
inactivation of this gene in SVWI-38 fibroblasts. 
Transient transfection studies indicated that the a2(I) 
promoter is inactive in SVWI-38 cells. Since the a2 (I) 
procollagen gene in SVWI-38 fibroblasts is intact, a trans-
acting factor or factors is most probably responsible for the 
repression of this gene in this cell line (Parker et. al., 
1989 and Smith, 1989). In an attempt to identify regions of 
the a2 (I) procollagen gene to which these negative trans-
acting factors bind, the activity of 5'-deletions of the wild 
type promoter was measured in transient transfection assays 
(Parker et. al., 1992). The transfection data on CT-1 cells 
were similar to those obtained for normal fibroblasts (Boast 
et. al., 1990), while the overall activity of all the 
constructs was much lower in SVWI-38 fibroblasts. Although 
several areas containing negative cis-acting elements were 
identified in the upstream sequences, the smallest construct 
containing the proximal promoter (-107 to +58) showed the 
greatest relative inhibitory effect in SVWI-38 cells. 
This overall decrease in promoter activity in SVWI-38 cells 
could be titrated out when these cells were co-transfected 
with an excess a2{I) procollagen promoter (nucleotides -3800 
to +58). A smaller fragment of the proximal promoter 
(nucleotides -107 to +58) containing an inverted CCAAT box 
and flanking sequences was also able to titrate out this 
inhibitory effect. 
Since a negative trans-acting factor or factors are 
responsible for the inactivation of the a2 (I) procollagen 
gene in SVWI-38 fibroblasts, the aim of this study was to 
identify, characterise and purify the trans-acting factors 
which regulate the expression of this gene in SVWI-38 and 
CT-1 fibroblasts. 
Subcloning and sequencing of the SVWI-38 proximal a2(I) 
procollagen promoter and identification of protein complexes 
from a number of cell lines which bind to this region of the 
promoter is described in this chapter. 
2.2 RESULTS 





Extensive restriction mapping of the entire a2(I) procollagen 
gene and its promoter did not reveal any gross deletions, 
insertions, rearrangements or integration of large fragments 
of the SV40 DNA within this gene or its promoter 
(Parker et. al., 1989) . Secondly, the transfection 
experiments suggested that a trans-acting factor (s) which 
binds between nucleotides -107 to +58 of the a2 (I) 
procollagen gene plays an important role in the inactivation 
of this gene in SVWI-38 fibroblasts (Parker et. al., 1992) . 
Although both these sets of experiments strongly suggest that 
trans-acting factors are responsible for the inactivation of 
this gene in SVWI-38 fibroblasts, the -351 bp proximal 
promoter of the gene from these cells was subcloned and 
sequenced to rule out any possibility that point mutations, 
small deletions or insertions in this functionally important 
region of the promoter could play a role in the inactivation 
of this gene. 
2.2.1.1 Subcloning 
Plasmids pUCT-1 and pUCT-2, containing a 4.2 Kb Eco Rl 
fragment of the a2(I) procollagen promoter isolated from 
SVWI-38 fibroblasts (Smith, 1989), were digested with Pst 1 
and Eco Rl to release, amongst others, a 651 bp Pst 1 -
Eco Rl fragment. The digested plasmids were resolved on a 1% 
low melting agarose gel and the 651 bp fragment eluted using 
the QIAEX extraction protocol as described in Materials and 
Methods (7.1.1.4). The eluted Pst 1 - Eco Rl fragments were 
cloned into pUC19 to produce plasmids pUCT-1-600 and 
pUCT-2-600 respectively (Figure 2.1). 
These plasmids contain the -351 bp proximal promoter, the 
first exon and the 5 '-portion of the first intron of the 
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Fig 2.1 Subcloning of the a2(I) proximal promoter. (A) 
A schematic outline showing the subcloning of the 651 bp 
Pst 1 (P) - Eco Rl (E) fragment from plasmids pUCT-1 and 
pUCT-2 into pUC19 (refer to Materials and Methods 
section 2.2.1.1) to produce plasmids pUCT-1-600 and 
pUCT-2-600 respectively. The 651 bp fragment contains 
the proximal promoter up to -351 (clear box), exon 1 and 
the 5' portion of the first intron (shaded box). The 
polylinker of pUC19 is shown as a hatched box, while the 
Hind III site is indicated with a H. (B) An ethidium 
bromide stained 1% agarose gel containing undigested (U) 
plasmids pUCT-1, pUCT-1-600, pUCT-2 and pUCT-2-600 and 
Eco Rl and Hind III digested (D) pUCT-1-600 and 
pUCT-2-600. The 651 bp fragment produced by digestion is 
indicated by the arrow. 
50 
2.2.1.2 sequence analysis 
Plasmids pUCT-1-600 and pUCT-2-600 were sequenced using the 
Sanger dideoxy method as described in Materials and Methods 
(7 .1. 6}. The nucleotide sequence of the -351 bp proximal 
promoter, exon 1 and the 5'-portion of intron 1 of the a2(I} 
procollagen gene from SVWI-38 fibroblasts is shown in 
figure 2.2. The sequences of plasmids pUCT-1-600 and 
pUCT-2-600 were identical to the sequence of the 
corresponding region of the gene from normal cell lines which 
produce the a2 chain (Dickson et. al.·, 1985} . This result 
supports the hypothesis that trans-acting factors, and not 
mutations in this functionally important region of the 
promoter, are responsible for inactivation of the a2(I} 
procollagen gene in SVWI-38 fibroblasts. 
2. 2. 2 Candidate transcription factors which could regulate 
expression of the a2(I) procollagen gene 
In order to identify candidate transcription factors which 
could regulate the expression of the human a2(I} procollagen 
gene, a database of transcription factors TFD sites (release 
4.3} (Ghosh, 1990}, was used to analys~ the -351 bp proximal 
promoter of this gene. 
A CCAAT box is located between nucleotides -201 and -195, 
while an inverted CCAAT box is present at the conventional 
distance between nucleotides -84 and -so. A total of three 
hexanucleotide Spl sequences are present in the -351 bp 
proximal promoter extending from nucleotides -305 to -298, 
-295 to -288, and -278 to -271. However, none of these Spl 
sequences are the true decanucleotide consensus sequences 
required for Spl binding (Kadonaga et. al., 1986}. A 
potential inverted AP-1 sequence and an AP-4 consensus 
sequence were identified between nucleotides -258 and -251 
and nucleotides -123 and -114 respectively. Furthermore, 
four AP-2 sequences are situated between nucleotides -104 and 
-95, -115 and -108, -136 and -129, and -187 and -180, while 
two inverted AP-2 sequences occur between nucleotides -282 
and -273, and -305 and -296. A TATA box consensus sequence 
is present between nucleotides -33 and -27. 
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-350 -340 -330 -320 -310 
I I I I I 
C TGCAGAGCAC TCCGACGTGT CCCATAGTGT TTCCAAACTT GGAAAGGGCG 
1300 1290 1280 1270 1260 1250 
GGGGAGGGCG GGAGGATGCG GAGGGCGGAG GTATGCAGAC AACGAGTCAG AGTTTCCCCT 
1240 1230 1220 1210 1200 1190 
TGAAAGCCTC AAAAGTGTCC ACGTCCTCAA AAAGAATGGA ACCAATTTAA GAAGCCAGCC 
- 180 -170 -160 -150 -140 -130 
I I I I · I I 
CCGTGGCCAC GTCCCTTCCC CCATTCGCTC CCTCCTCTGC GCCCCCGCAG GCTCCTCCCA 
-120 -110 -100 -90 -80 -70 
I I I I I I 
GCTGTGGCTG CCCGGGCCCC CAGCCCCAGC CCTCCCATTG GTGGAGGCCC TTTTGGAGGC 
-60 -50 -40 -30 -20 -10 
I I I I I I 
ACCCTAGGGC CAGGGAAACT TTTGCCGTAT AAATAGGGCA GATCCGGGCT TTATTATTTT 
il ilO i20 i30 i40 i50 i60 
AGCACCACGG CAGCAGGAGG TTTCGGCTAA GTTGGAGGTA CTGGCCACGA CTGCATGCCC 
+70 +80 +90 +100 +110 +120 
I I I I I I 
GCGCCCGCCA GGTGATACCT CCGCCGGTGA CCCAGGGGCT CTGCGACACA AGGAGTCTGC 
+130 +140 +150 +160 +170 +180 
I I I I I I 
ATGTCTAAGT GCTAGACATG CTCAGCTTTG TGGATACGCG GACTTTGTTG CTGCTTGCAG 
+190 +200 +210 +220 +230 +240 
I I I I I I 
TAACCTTATG CCTAGCAACA TGCCAATgta agtgccttca gcttgtttgg gggagactgg 
+250 +260 +270 +280 +290 +300 
I I I I I I 
gtagagaggt tagatgggag ggcaccctgc cctgaaaagg aaaacctgta acctgaattc 
Fig 2.2 Nucleotide sequence of a 651 bp Pst 1 Eco R1 
fragment of plasmids pUCT-1-600 and pUCT-2-600. This 
fragment contains the -351 bp proximal promoter (uppercase 
letters), the first exon (bold) and the 5' portion of the 
first intron (lower case letters) of the a2(I) procollagen 
gene isolated from SVWI-38 fibroblasts. The 651 bp Pst 1 -
Eco Rl fragment was subcloned into pUC19 as described in 
section 2.2.1.1 and sequenced using the universal M13 
forward and reverse primers, ·oligonucleotide Cl (doubly 
underlined) and oligonucleotide 02 (underlined) as described 
in section 7.1.6. 
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In addition to the inverted CCAAT box, two other elements 
have been identified in the mouse proximal promoter as being 
important in the regulation of a2(I) procollagen gene 
expression (Karsenty et. al., 1988). One of these sequences, 
a CAGA element situated between nucleotides -253 and -250 is 
also present in the human promoter. 
inverted NF-1-like binding site 
The other sequence, 
(51 TCGCCCTTGCCAA31 ), 
an 
is 
present in the human promoter between nucleotides -311 and 
-299, but with a two-base mismatch (51 CCGCCCTTTCCAA31 ). NF-1 
binds to this sequence in the mouse· promoter to activate 
transcription (Oikarinen et. al., 1987). 
The result of this analysis is tabulated in appendix A and 
summarised in figure 2.3. 
2.2.3 Subcloning the proximal human a2(I) 
promoter 
procollagen 
In order to identify, characterise and purify the trans-
acting factors which regulate the expression of the human 
a2 (I) procollagen gene, several DNA fragments of the a2 (I) 
procollagen gene promoter were subcloned and used in DNA-
binding assays. 
Plasmids pNJ-59, pNJ-230 and pNJ-170 were subcloned from 
either plasmids pNJs400 19A or pNJs400 19B, containing a 
409 bp fragment cloned into pUC19 in both orientations as 
shown in figure 2.4 (Smith, 1989). 
2.2.3.1 Plasmid pNJ-59 
Plasmid pNJs400 19B was digested with Sma 1 to release a 
191 bp Fragment (nucleotides -107 to +58) which was eluted 
from a 7% non-denaturing polyacrylamide gel as described in 
Materials and Methods (7.1.1.1) and digested with Bst Nl to 
produce a 59 bp Sma 1 - Bst Nl and a 132 bp Bst Nl - Sma 1 
fragments. The 59 bp fragment was subcloned into the Sma 1 
site of pUC19 after blunt ending with Klenow DNA polymerase 
(section 7.1.2.1) to produce plasmid pNJ-59 (Figure 2.4). 
This plasmid contains a 65 bp fragment (-110 to -46) of the 
human a2(I) procollagen promoter. 
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-350 -340 -330 -320 -310 
I I I I I 
C TGCAGAGCAC TCCGACGTGT CCCATAGTGT TTCCAAACTT GGAAAGGGCG 
NF-1 
Uspl 
-300 -290 -280 -270 -260 -250 
I I I I I I 
GGGGAGGGCG GGAGGATGCG GAGGGCGGAG GTATGCAGAC AACGAGTCAG AGTTTCCCCT 
• Usp1-1.J L-AP-2__J CAGA Box 














TGAAAGCCTC AAAAGTGTCC ACGTCCTCAA AAAGAATGGA ACCAATTTAA GAAGCCAGCC 
LcCAATJ LAP-2-
-180 -170 -160 -150 -140 -130 
I I I I I I 
CCGTGGCCAC GTCCCTTCCC CCATTCGCTC CCTCCTCTGC GCCCCCGCAG GCTCCTCCCA 
_J L-AP-2_] 
1120 1110 1100 190 180 170 
GCTGTGGCTG CCCGGGCCCC CAGCCCCAGC CCTCCCATTG GTGGAGGCCC TTTTGGAGGC 
L_AP-2_] L-AP-2__J --- CCAAT Box 
-AP-4_] LHC3_J 
-60 -50 -40 -30 -20 -10 
I I I I I -1 
ACCCTAGGGC CAGGGAAACT TTTGCCGTAT AAATAGGGCA GATCCGGGCT TTATTATTTT 
TATA Box 
Fig 2.3 A summary of the major transcription factor 
binding motifs (underlined L__J ) , in the -351 bp 
proximal promoter of the a2(I) procollagen gene. These 
sequences were identified by searching a database of 
transcription factors tabulated in appendix A. The DNA 
sequence elements identified in the mouse gene as being 
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Figure 2. 4 Subcloning plasmid pNJ-59. (A) A schematic diagram of the subcloning of the 59 bp Sma 1 (S) - Bst Nl (Bn) fragment from plasmid pNJs400 19B into the Sma 1 site of pUC19 to produce plasmid pNJ-59, · as described in section 2.2.3.1. The a2(I) procollagen promoter, the 5 1 portion of exon 1 and the polylinker of pUC19 are shown as clear boxes, shaded boxes and hatched boxes respectively. The restriction sites Pvu II (P), Sph 1 (Sp) , Hind III (H) and Eco Rl (E) are indicated with arrows. (B) Nucleotide sequence of the 116 bp Hind III -Eco Rl fragment of plasmid pNJ-59, containing the polylinker of pUC19 (lowercase letters) and a 65 bp fragment of the promoter from nucleotides -110 to -46 (uppercase letters). 
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2.2.3.2 Plasmid pNJ-230 
pNJs400 19A was linearised with Bam Hl and digested with 
Bst Xl to remove a 193 bp fragment containing 166 bp of the 
promoter (-351 to -180) (A. Smith, unpublished data). The 
fragments were separated on a 1% agarose gel, the larger 
fragment (vector and -179 to +58) was electro-eluted from the 
gel, blunt ended with Klenow DNA polymerase as described in 
Materials and Methods (7.1.1.2 and 7.1.2.1) and self ligated 
to produce plasmid pNJ-230 containing 58 bp of exon 1 and 
179 bp of the collagen proximal promoter (nucleotides -179 to 
+58) (Figure 2.5). 
2.2.3.3 Plasmid pNJ-170 
pNJs400 19B was digested with Bam Hl and Bst Xl. The Bam Hl 
and Bst Xl sticky ends were blunt ended with T4 DNA 
polymerase as described (section 7.1.2.2). The two fragments 
were resolved on a 1% agarose gel and the larger fragment was 
eluted according to the method of Errington (1990) as 
described in Materials and Methods (7.1.1.3). This fragment 
was self ligated to produce plasmid pNJ-170 containing a 
169 bp Pst 1 - Bst Xl (nucleotides -3?1 to -183) fragment of 
the human a2(I) procollagen promoter (figure 2.6). 
2.2.4 Analysis of DNA-Protein interaction by electrophoretic 
mobility shift assays (EMSA) 
EMSA (Fried and Crothes, 1981) was used to identify DNA-
protein complex formation from crude nuclear extracts of 
SVWI-38, CT-1 and WI-38 fibroblasts and of a non-collagen 
producing mouse tumour macrophage cell line, p388D1 (Koren 
et. al., 1975). This simple, rapid and sensitive technique 
proved to be ideal for the initial identification of DNA-
protein complexes (section 7.4.2). 
The methods of Dignam et. al. (1983) or Lee and Green (1990), 
as described in Materials and Methods (7. 3) , were used to 
isolate nuclear proteins fro~ SVWI-38, CT-1, WI-38 and p388D1 
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Figure 2.6 Subcloning plasmid pNJ-170. (A) A schematic 
diagram of the subcloning of a 169 bp Pst 1 (P) - Bst Xl 
(Bx) fragment from plasmid pNJs400 19B into pUC19 to 
produce plasmid pNJ-170, as described in section 2.2.3.3. 
The a2(I) procollagen promoter, the 5' portion of exon 1 
and the pUC19 polylinker are shown as clear, shaded and 
hatched boxes respectively. The restriction sites Sph 1 
(Sp), Hind III (H), Eco Rl (E) and Bam Hl (B) are 
indicated with arrows. (B) Nucleotide sequence of a 
207 bp Hind III - Eco Rl fragment of plasmid pNJ-170 
containing the pUC19 polylinker (lowercase letters) and a 
169 bp fragment of the promoter from nucleotides -351 to 
-183 (uppercase letters). 
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SDS-polyacrylamide gels (figure 2. 7) prior to use in EMSA. 
Similar distribution of polypeptides was observed in crude 
nuclear extracts, indicating that minimal degradation of the 
proteins had occurred during the extraction procedure. 
The 114 bp Eco Rl - Hind III fragment of pNJ-59 (fragment E}, 
the 203 bp Eco Rl - Hind III fragment of pNJ-170 (fragment 
A}, the 78 bp Sma 1 fragment of pNJ-230 (fragment B}, the 
225 bp Hha 1 - Eco Rl fragment of pNJs400 19B (fragment C} 
and the 190 bp Sma 1 fragment of pNJs400 19B (fragment D} 
were radioactively labelled as described in Materials and 
Methods (7.4.1} and used as probes in the EMSA (Figure 2.8). 
Similar DNA-protein complexes were observed when SVWI-38 and 
CT-1 nuclear extracts were allowed to bind to DNA fragments A 
and Bas shown in figure 2.8. Occasionally, an extra complex 
was observed when CT-1 nuclear extracts were assayed with 
fragment B (figure 2.8). 
Two major DNA-protein complexes, designated complexes I and 
III, were identified in CT-1 nuclear extracts complexed with 
fragments D (-107 to +58) or E (-110 to -46), while an 
additional complex, complex II, was observed in SVWI-38 
nuclear extracts (figure 2.8). This SVWI-38 specific complex 
was occasionally observed in longer exposures of CT-1 
autoradiograms, suggesting that low levels of this protein 
are present in collagen producing cells. Complex III was 
also present at lower levels in SVWI-38 than in CT-1 cells. 
When fragment c (-140 to +58) was used with SVWI-38 and CT-1 
nuclear extracts, an extra complex was still· observed in 
SVWI-38 nuclear extracts (figure 2. 8). This fragment was 
tested in order to rule out the possibility that the AP-2 
consensus sequence which was destroyed upon digestion with 
Sma 1 might be involved in formation of other complexes. The 
remaining complexes were similar in SVWI-38 and CT-1 
extracts. It is therefore unlikely that this AP-2 site is 
responsible for the formation of any extra complexes. 
The transient transfection experiments strongly suggested 
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Fig 2.7 SDS-polyacrylamide gel electrophoresis of crude 
nuclear extracts. Nuclear extracts of SVWI-38 (SV), CT-1 
(CT}, WI-38 (WI) and p388D1, (M~) cell lines were 
prepared as described in section 8.3. 40 ug of nuclear 
extracts were resolved on 10% SDS-polyacrylamide gels and 
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Fig 2.8 Dissection of the a2(I) promoter for DNA-binding 
activity. (A) A schematic diagram of the proximal 
promoter ( clear box ) and the 5 ' portion of exon 1 
(shaded box) of the a2(I) procollagen gene. DNA 
fragments A, B, c, D and E were generated by digesting 
the promoter with the appropriate restriction enzymes as 
described in section 2. 2. 4. (B) DNA-protein complexes, 
were analysed in duplicate by electrophoretic mabili ty 
shift assays (lanes 1 and 2) by incubating the indicated 
end-labelled DNA fragment with 3-4 ug nuclear extract and 
analysis of the complexes on 5% non-denaturing 
polyacrylamide gels as described in section 7.4.2. The 
dried gels were exposed to X-ray film for 16 hrs. The 
DNA complexes formed with fragments D (nucleotides -107 
to +57) and E (nucleotides -107 to -46) are labelled as 
I, II and III, with complex II being largely SVWI-38 
specific. The autoradiograph for fragment E was 
overexposed in order to show the trace amounts of 
complex II in CT-1 cells. The additional complex 
identified in SVWI-38 extracts with fragment c 
(nucleotides -140 to +57) is indicated by the arrow. The 
additional complex observed in CT-1 nuclear extracts with 
fragment B was not consistent. 
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-107 to +58 of the proximal promoter is responsible for 
inactivation of the a2(I) procollagen gene in SVWI-38 
fibroblasts (Parker et. al., 1992). The results of the EMSAs 
clearly showed the presence of an extra DNA-protein complex 
(complex II) in the nuclear extracts of SVWI-38 fibroblasts, 
which could bind to an inhibitory element between nucleotides 
-110 to -46 of this gene. It is therefore possible that 
complex II, together with other factors, is responsible for 
inhibition of the a2 (I) procollagen gene in SVWI-38 
fibroblasts. The low levels of complex II in the collagen 
producing CT-1 cell line suggests that- this complex probably 
plays an important general inhibitory role in the regulation 
of this gene. 
In order to determine whether there was any correlation 
between the levels of complex II in nuclear extracts and the 
ability of a cell line to synthesise type I collagen, the 
presence of the three complexes in nuclear extracts of WI-38 
fibroblasts and a non-collagen producing mouse tumour 
macrophage cell line, p388D1 , was assayed. Complexes I and 
III were present in the extracts of collagen-producing WI-38 
cells, while only complexes I and II were identified in 
P388D1 extracts (figure 2. 9). This result also strongly 
supports the proposal that complex II is a negative trans-
acting factor which may be responsible for the inactivation 
or modulation of the a2(I) procollagen gene. 
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Fig 2.9 The identification of complexes I, II and II in 
WI-38 (WI), CT-1 (CT), SVWI-38 (SV) and a mouse tumour 
macrophage, p38SD1 , (M</)) cell lines. 3-4 ug of crude 
nuclear extracts were incubated with 4 ug 
poly didC.poly didC and 1 ng (104 cpm) of end-labelled 
fragment E (nucleotides -107 to -46) of the a2(I) 
procollagen promoter as described in section 7.4. 
Duplicate samples (lanes 1 and 2) were electrophoresed on 
5% non-denaturing polyacrylamide gels at 40 C in 
0.5 X TBE. The dried gels were exposed to X-ray film for 




Although only the -351 to +300 bp region of the SVWI~38 a2{I) 
procollagen gene was sequenced and shown to be completely 
normal, it is unlikely that mutations in this gene or its 
promoter are responsible for its inactivation in SVWI-38 
fibroblasts. This hypothesis is supported by the work of 
Boast et. al. (1990), Niederreither et. al. {1992) and 
Goldberg, H. et. al. ( 1992) who have demonstrated that the 
minimal regulatory elements sufficient for tissue and cell-
specific expression of the human and mouse a2(I) procollagen 
genes lie within the -351 bp proximal promoter. Secondly, 
86% sequence homology exists between the mouse and human 
-351 bp proximal promoters of this gene (Dickson et. al., 
1985). This high sequence homology between the two promoters 
was lost further upstream (M. I. Parker, unpublished data) , 
suggesting that the proximal region of the promoter is 
probably functionally more important. Finally, transient 
transfection experiments showed that the a2 (I) procollagen 
gene promoter from SVWI-38 fibroblasts is functional in 
normal collagen producing cell lines {Smith, 1989). 
The results shown in figures 2.8 and ~.9 suggested that the 
levels of complex II is indirectly proportional to the amount 
of type I collagen produced. Also, cells that do not 
synthesise a2(I) procollagen chains appeared to have no 
detectable amounts (macrophages) or lower levels {SVWI-38) of 
complex III than collagen producing cells. These 
observations suggested that the relative ratios of complexes 
II and III, and not merely the absence or presence of complex 
II, may be important in determining whether the a2{I) 
procollagen gene is expressed or not. Barnhart et. al. 
{1988) have shown that the relative activities of three 
trans-acting factors, a-CPl, a-CP2 and 
the human a-globin gene is expressed. 
a-IRP changes when 
Three potential DNA sequences recognised by sequence-specific 
transcription factors were identified in this 65 bp region 
{nucleotides -110 to -46) of the a2(I) procollagen promoter. 
An inverted CCAAT box is situated between nucleotides -84 to 
-80 and an inverted HC3 sequence between nucleotides -82 and 
-77 {Augereau and Chambon, 1986) and a potential AP-2 
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consensus sequence between nucleotides -104 and -95 (Imagawa 
et. al., 1987) . The importance of these sequences in the 
regulation of the gene will be discussed in chapter 4. 
Although Hatamochi et. al. (1988) and Maity et. al. (1988) 
have identified only one complex, a CCAAT binding factor 
(CBF), in mouse NIH-3T3 nuclear extracts which binds to the 
-108 to +54 sequences of the mouse a2(I) procollagen 
promoter, our studies demonstrated the formation of both 
complexes I and II when mouse macrophage or fibroblast 
nuclear extracts were used in EMSA (V. Leaner, unpublished 
data). This finding appears to be inconsistent with the 
hypothesis that complex II proteins are a transcriptional 
repressor, since mouse fibroblasts do synthesis a2(I) 
collagen. The significance of this finding will be discussed 
in chapter 4. 
Goldberg, H. et. al. (1992) have postulated that a CTF/NF-1 
binding element situated around -300 (
51 TCGN5GCCAA
31 ) in the 
mouse a2(I) procollagen promoter may play a role in the cell 
specific expression of this gene. They have shown that 
collagen producing murine cells have higher levels of NF-1 
activity than cells which do not produce collagen. This 
inverted NF-1 like element is also present in the human 
5 I 3 I , promoter ( CCGN5TCCAA ) between nucleotides -311 and -299, 
but there it contains base mismatches, making it less similar 
than the mouse NF-1 site to the published NF-1 recognition 
sequence (51 TGGN6_7GccAA
31 ) (Jones et. al., 1987). It is not 
known how this diversity in the sequence of the human NF-1 
site affects the role of NF-1 in the regulation of the human 
a2(I) procollagen gene. In contrast, it is possible that the 
following may modulate the cell-specific expression of the 
human gene: (1) binding of a negative trans-acting factor to 
the proximal/minimal promoter, ( 2) the relative ratios of 
complex II and III, and (3) other transcription factors, like 
NF-1, which bind further upstream. 
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CHAPTER 3 
THE PARTIAL PURIFICATION OF 
FIBROBLAST DNA-BINDING PROTEINS 
3.1 INTRODUCTION 
Eukaryotic gene expression is mediated in part by sequence-
specific DNA-binding proteins that bind to promoters and 
enhancers (Maniatis et. al., 1987; Mitchell and Tjian, 1989). 
The identification and characterisation of these proteins is 
an important step towards understanding how they regulate 
transcription. In order to characterise these low-abundance 
transcription factors, it is necessary to purify these 
proteins from nuclear extracts. A combination of sequence-
specific DNA-affinity chromatography and conventional 
chromatographic techniques has made it possible to purify 
these proteins to homogeneity (Kadonaga and Tjian, 1986). 
The purification of transcription factors, like the CCAAT 
binding factor {CBF) {Hatamochi et. al., 1988), has made it 
possible to determine the biochemical properties of these 
proteins. The polypeptide composition, molecular weight, 
binding specificity and other parameters have been d~termined 
for a large number of transcription factors (reviewed in 
Jones et. al., 1988). Partial protein sequence analysis of a 
number of purified factors has been successfully used to 
clone the genes 
factors include 
et. al., 1988) 
et. al., 1991) . 
for these proteins. Examples of cloned 
Spl (Kadonaga et. al., 1987; Kadonaga 
and TFIIE {Ohkuma et. al., 1991; Hideki 
The structural features of both these 
factors have been determined from the nucleotide and 
predicted amino-acid sequence of the cDNAs that encode these 
proteins. 
Before DNA-binding proteins can be successfully purified by 
DNA-affinity chromatography, the proteins should be partially 
purified using other conventional chromatographic techniques 
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to remove nucleases and other activities that might affect 
the yield and activity. Ion exchange chromatography such as 
Heparin-agarose (Davison et. al., 1979) and phosphocellulose 
(Dynan and Tjian, 1983) or gel filtration on Sephacryl S-300 
(Cohen et. al., 1986) are a few of the many techniques which 
have been routinely used in the partial purification of 
transcription factors. 
The partial purification of complex I, II and III proteins 




3.2.1 Differential salt extraction of nuclear proteins 
SVWI-38 nuclei were differentially extracted with either 0.1, 
0.2, 0.3 or 0.4 M NaCl as described in Materials and Methods 
(7.3.3), to determine whether it was possible to 
differentially solubilise complex I, II and III proteins 
during the preparation of nuclear extracts. The 
electrophoretic mobility shift assay (EMSA) (section 7.4.2) 
was used to test for the presence of DNA-binding activity in 
the different fractions with fragment E (see figure 2.8) of 
the a2(I) procollagen promoter. Trace amounts of complex I 
protein was extracted in Dignam buff er C containing O. 1 M 
NaCl (figure 3.1). Complex II and III proteins started to be 
co-extracted with complex I proteins in buffer containing 
0.2 M NaCl, but all three complexes were still co-extracted 
in buffer containing O. 4 M NaCl. Although complex I was 
extracted with a slightly lower salt concentration, the 
yields would be very low and it would therefore not be useful 
to separate the complexes this way during the preparation of 
nuclear extracts. 
3.2.2 Heparin-agarose chromatography 
Heparin-agarose cation-exchange chromatography (Davison 
et. al., 1979) was used to separate and partially purify the 
DNA-binding complexes (complexes I, II and III) from SVWI-38 
and CT-1 extracts. The heparin-agarose columns were packed 
and prepared as described in section 7. 3. 4. The method of 
Dignam et. al. (1983) was used to prepare milligram amounts 
(±30 mg) of crude nuclear extracts from SVWI-38 and CT-1 
fibroblasts, as described in Materials and Methods (7.3.1). 
In order to determine the optimal salt concentrations 
required for binding of the three complexes to heparin-
agarose and their subsequent elution from the matrix, 3 mg of 
crude SVWI-38 nuclear extract was applied to a 1 ml column. 
The column was washed with 7 ml of 0.1 M CB (see section 7.7 
for composition) to remove the bulk of the protein. EMSA 
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Fig 3.1 Differential salt extraction of nuclear 
proteins. SVWI-38 fibroblast nuclei were sequentially 
extracted with buffers containing O .1 M, O. 2 M, _ o. 3 M 
and o. 4 M NaCl as described in Materials and Methods 
(7.3.3). 3-4 ug of crude extract of the differentially 
solubilised fractions were \ncubated with 4 ug 
poly didC.poly didC and 1 ng (10 cpm) of end-labelled 
fragment E (see figure 2. 8) as described in section 
7. 4. The samples were electropho6esed on 5% non-denaturing polyacrylamide gels at 4 C using o. SX TBE 
and the dried gels exposed to X-ray film for 16 hrs. 
The position of complexes I, II and III are indicated. 
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binding activity in the 0.1 M CB wash (figure 3.2). Complex 
I proteins eluted from the column with 0.2 M KCl, while the 
0.3 M KCl fraction contained complex I, II and III proteins. 
In order to achieve separation of complex I proteins from 
complex III proteins, CT-1 protein was eluted from the 
heparin-agarose column with buffer CB containing 0.25 M KCl. 
The remaining bound protein was eluted stepwise with O. 4 M 
and o. 5 M KCl in CB and regenerated with 1. o M KCl in CB. 
The O. 1 M, o. 25 M and O. 4 M heparin-agarose fractions were 
concentrated using centricon-10 microconcentrators, the salt 
concentration adjusted to 0.1 M KCl and assayed by EMSA using 
fragment E as a probe. Complex I and III proteins co-eluted 
in 0.25 M KCl (figure 3.3). This batch of CT-1 extract also 
contained trace amounts of complex II which eluted from the 
column together with complexes I and III. Complex II band 
appears to be strong because of overexposure of the gel. 
These preliminary experiments (figures 3.2 and 3.3) suggested 
that it would be possible to separate complex I from 
complexes II and III using this technique if the bound 
protein was initially eluted from the column with 0.2 M KCl 
and perhaps washed long enough to remove all complex I 
proteins (figure 3.2). 
Complex I, II and III proteins from SVWI-38 extracts and 
complex I and III proteins from CT-1 extracts were partially 
separated and purified as described in section 7. '.:l. 4. As 
shown in figures 3 . 4 and 3 . 5 this approach proved to be 
satisfactory for the partial purification and separation of 
complex I proteins from complex II and III proteins. 
As illustrated in tables 3. 1 and 3. 2, 60 to 65% of the 
nuclear extract did not bind to heparin-agarose in 0.1 M KCl. 
No detectable amounts of complex I, II and III proteins were 
present in this fraction (figures 3.4 and 3.5). About 20% of 
the loaded protein eluted from the column in the o. 2 M KCl 
buffer and contained complex I proteins. The o. 4 M KCl 
buffer was used to elute complex II and III proteins from the 
column and contained about 10 to 15% of the loaded protein. 
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Fig 3. 2 Fractionation of SVWI-38 extract on heparin-
agarose. (A) 3 mg of nuclear extract was applied to a 
1 ml column in buffer CB containing o .1 M KCl. The 
bound proteins were eluted stepwise with buffer CB 
containing 0.2 M, 0.3 M, 0.4 M, 0.5 M or 1.0 M KCl as 
described in section 3. 2. 2. (B) 3-4 ug crude SVWI-38 
and concentrated 0.1 M, 0.2 M, 0.3 M KCl heparin-
agarose fractions were incubated with 4 ug 
poly didC.poly didC and 1 ng (104 cpm) of end-labelled 
fragment E as described in section 7. 4. The samples 
were electrophoresed on 5% non-denaturing 
polyacrylamide gels at 4 O C using O. 5X TBE and the 
dried gels exposed to X-ray film for 16 hrs. The 
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Fig 3.3 Elution of CT-1 extract from heparin-agarose. 
(A) Crude nuclear extract was applied to a 1 ml column 
in buffer CB containing 0.1 M KCl. The bound protein 
was eluted stepwise with buffer CB containing o. 25 M, 
o. 4 M, O. 5 M and 1. o M KCl as described in section 
3.2.2. (B) 3-4 ug crude CT-1 and concentrated ~.1 M, 
o. 25 M, O. 4 M KCl heparin-agarose fractions were 
incubated with 4 ug poly didC.poly didC and 1 ng 
(104 cpm) of end-labelled fragment E as described in 
section 7. 4. The samples were electrophoresed on 5% 
non-denaturing polyacrylamide gels at 40 c using 
0.5X TBE and the dried gels were exposed to X-ray film 
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Fig 3. 4 Partial purification of SVWI-38 extracts by 
heparin-agarose chromatography. (A) Crude nuclear 
extracts were applied to the column in buffer CB 
containing o .1 M KCl. The bound protein was eluted 
from the column with buffer CB containing 0.2 M, 0.4 M 
or 1. O M KCl as described in section 7. 3. 4. ('B) The 
fractions were concentrated using centricon-10 
microconcentrators and the final salt concentration 
adjusted to 0.1 M KCl. The electrophoretic mobility 
shift assay was used to assay the various heparin-
agarose fractions for DNA-binding activity as described 
in section 7.4.2. The positions of complexes I, II and 
III are indicated. (INSET) 20 ug of crude nuclear 
extract and heparin-agarose fractions were resolved on 
10% SDS-polyacrylamide gels and stained with Coomassie 
brilliant blue as described in section 7.5. 
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Fig 3.5 Partial purification of CT-1 extracts by 
beparin-agarose chromatography. (A) Crude nuclear 
extracts were applied to the column in buffer CB 
containing o. 1 M KCl. The bound protein was eluted 
from the column with buffer CB containing 0.2 M, 0.4 M 
or 1. o M KCl as described in section 7. 3. 4. (B) The 
fractions were concentrated using centricon-10 
microconcentrators and the final salt concentration 
adjusted to O. 1 M KCl. The electrophoretic mobility 
shift assay was used to assay the various heparin-
agarose fractions for DNA-binding activity as described 
in section 7.4.2. The positions of complexes I and III 
are indicated. (INSET) 20 ug of crude nuclear extract 
and heparin-agarose fractions were resolved on 10% SDS-
polyacrylamide gels and stained with Coomassie 
brilliant blue as described in section 7.5. 
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TABLE 3.1 Purification summary of SVWI-38 nuclear proteins. 
Heparin-agarose chromatography was used to partially purify 
crude nuclear extracts as described in section 7. 3. 4. The 
fractions were concentrated and the salt concentration 
adjusted to 0.1 KCl. Data shown was obtained from one of the 
numerous fractionations. 
STAGE OF PROTEIN TOTAL PROT. 
PURIFICATION FRACTION VOLUME CONC. PROTEIN YIELD 
(ml) (ug/ul) (mg) 
1 Crude SVWI-38 2.0 ·5. 90 11. 8 100% 
nuclear extract 
2a Heparin-agarose 4.8 0.56 2.7 23% 
0.2 M KCl fraction 
2b Heparin-agarose 3.4 0.49 1. 7 14% 
0.4 M KCl fraction 
3a Centricon cone. 0.6 3.63 2.2 19% 
0. 2 M KCl fraction 
3b Centricon cone. 0.3 3.62 1.1 9% 
0.4 M KCl fraction 
TABLE 3.2 Purification summary of CT-1 nuclear proteins. 
Heparin-agarose chromatography was used to partially purify 
crude nuclear extracts as described for SVWI-38 cells in 
table 3 . 1. Data shown is representative of one of the 
numerous fractionations. 
STAGE OF PROTEIN TOTAL PROT. 
PURIFICATION FRACTION VOLUME CONC. PROTEIN YIELD 
(ml) (ug/ul) (mg) 
1 Crude CT-1 1.5 4.54 6.8 100% 
nuclear extract 
2a Heparin-agarose 4.4 0.32 1.4 21% 
0.2 M KCl fraction 
2b Heparin-agarose 3.5 0.26 0.9 13% 
0.4 M KCl fraction 
3a Centricon cone. 0.4 1. 74 0.7 10% 
0.2 M KCl fraction 
3b Centricon cone. 0.3 2.41 0.7 10% 
0.4 M KCl fraction 
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have expected to obtain about a 5-fold purification of 
complex I and a 7 to 10-fold purification of complex II and 
III proteins from crude nuclear extracts. No more than a 2, 
3 and 5-fold purification of complex I, II and III proteins, 
respectively, was obtained. Since up to 50% of protein was 
lost while concentrating the fractions on centricon-10 
microconcentrators, it is most likely that the low yields 
obtained is due to this concentration step. 
The protein integrity of the various fractions were checked 
on 10% SDS-polyacrylamide gels ( inset:s in figures 3. 4 and 
3.5) as described in section 7.5. As shown in the insets the 
0.2 Mand the 0.4 M fractions still contained large amounts 
of contaminating proteins. These contaminating proteins 
would have to be removed by other chromatographic techniques 
to obtain a homogeneous preparation of these complexes. 
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3.3 DISCUSSION 
Heparin-agarose chromatography proved to be an ideal 
technique for the partial purification of complex I, II and 
III proteins from SVWI-38 and CT-1 nuclear extracts. The 
three complexes bound to the column in buffer containing 
0.1 M KCl. During this step about 60 to 65% of the loaded 
protein was removed from these complexes. Complex I proteins 
eluted from the column in buffer containing 0.2 M KCl, while 
complex II and III proteins co-eluted from the column in 
buffer containing 0.4 M KCl. Hatamochi et. al. (1988) have 
eluted a CCAAT-binding factor (CBF) which binds to the 
equivalent region of the mouse a2 (I) procollagen promoter 
from a heparin-agarose column using buffer containing 0.35 M 
KCl. It is possible that one of the three complexes is 
similar to the mouse CBF. 
Since the protein concentration of the eluted fractions were 
low, these fractions were concentrated using centricon-10 
microconcentrators. Unfortunately, up to 50% of the protein 
was lost during this step, resulting in substantial loss of 
the DNA-binding activities. Secondly, the loss is DNA-
binding activity could also be due to degradation caused by 
the long time period required to concentrate the fractions. 
This poor recovery of DNA-binding activity may be avoided by 
eliminating the concentration step by applying larger amounts 
of protein to the column Secondly, decreasing the flow rate 
can also minimise the dilution of separated Qroteins. 
Alternatively, other concentration procedures such as 
ammonium sulphate precipitation and dialysis, could be used. 
Some of the biochemical properties of the three complexes 
using the partially purified heparin-agarose fractions will 
be covered in chapters 4 and 5. Detailed biochemical 
characteristics can only be determined once the proteins have 
been purified to homogeneity by sequence-specific DNA-
affinity chromatography. Partial amino acid sequencing of 




BINDING-SITES WITHIN THE PROXIMAL 
HUMAN a2(I) PROCOLLAGEN PROMOTER 
4.1 INTRODUCTION 
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The promoters and enhancers of eukaryotic genes are made up 
of multiple positive, negative, inducible and/or tissue 
specific transcriptional regulatory elements. Different 
combinations of these cis-elements are present and may be 
scattered both upstream and downstream of the transcription 
start site. The number, type, orientation and distance 
between regulatory cis-elements are unique for each of the 
thousands of genes in a cell. Sequence-specific DNA-binding 
proteins, which function as either activators or repressors, 
bind to these recognition sequences and interact with one 
another, other nuclear proteins and RNA polymerases to 
regulate gene expression (reviewed by Maniatis et. al., 1987; 
Mitchell and Tjian, 1989). 
Many RNA polymerase II-dependent promoters contain an AT-rich 
region centered about 25-30 base pairs upstream of the 
initiation site (Goldberg, 1979) . This conserved element, 
the TATA box, the pentanucleotide CCAAT sequence and many 
others ( section 1. 3. 6. 1) , have also been identified within 
the proximal promoters of the human and mouse al(!) and a2(I) 
collagen genes (Dickson et. al., 1985; Rossouw et. al., 1987; 
Mai ty et. al., 1988) . Examples where gene expression is 
regulated by the competition of positive and negative 
transcription factors for distinct (Karsenty and 
de Crombrugghe, 1989), overlapping (Liu et. al., 1989; 
Barberis et. al., 1987) or the same (Harada et. al., 1989) 
regulatory elements have been characterised. Karsenty and 
de Crombrugghe (1989) have shown that the binding of an 
inhibitory factor (IF2) to its consensus sequence is 
inhibited by the binding of a transcriptional activator (CBF) 
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to a CCAAT box containing element. The IF2 and CBF elements 
are distinct and situated within a 55 bp segment of the mouse 
al(I) procollagen promoter. 
The identification and characterisation of cis-acting 
transcription elements in the human a2(I) procollagen 
promoter has helped in elucidating the mechanism(s) 
responsible for regulating the expression of this gene. The 
development of techniques such as the electrophoretic 
mobility shift assay (Fried and Crothers, 1981), methylation 
interference assay (Siebenlist and ~ilbert, 1980) and a 
multitude of other techniques (Ausubel et. al., 1987; 
Hennighausen and Lubon, 1987) has made it possible to analyse 
the sequence-specific binding of proteins to DNA. 
Electrophoretic mobility shift assays and modifications of 
this technique, such as competition binding assays (Carthew 
et. al., 1985; Singh et. al., 1986) , have been widely used 
for the identification of DNA-protein complexes. Since the 
methylation of guanine and adenine residues in DNA-binding 
sites can interfere with binding of transcription factors, 
methylation interference assays were initially used to 
identify which purines in the T7 promoter prevented the 
binding of RNA polymerase (Siebenlist and Gilbert, 1980). 
Subsequently, many investigators have used this technique, 
coupled with the EMSA, to study the interaction of sequence-
specific DNA-binding proteins with their binding elements in 
a variety of promoters and enhancers. 
The identification and characterisation of two distinct but 
overlapping cis-acting elements involving the human a2 (I) 
procollagen CCAAT box and the interaction of the candidate 
SVWI-38-specific transcriptional repressor with the proximal 
DNA-element is described. 
79 
4.2 RESULTS 
4. 2 .1 Analysis of cis-elements in the proximal human a2 (I) 
procollagen promoter 
Three potential consensus sequences recognised by sequence-
specific transcription factors were identified in the 65 bp 
region between -110 and -46 in the human a2 (I) procollagen 
promoter. An inverted CCAAT box is situated between -so to 
-84 and an inverted HC3 (Augereau and Chambon, 1986) element 
between -82 and -77 (figure 4.1). An.AP-2 (Imagawa et. al., 
1987) consensus sequence occurs between nucleotides -104 and 
-95. Further inspection of this short region of the promoter 
revealed the following potential DNA-elements which could 
also be involved in DNA-protein complex formation with 
fibroblast extracts: (1) an AP-2-like sequence containing a 
single base mismatch is located between -98 to -89, (2) GGAGG 
and inverted GGAGG boxes within a region of inverted dyad 
symmetry centered at -82, (3) 
between -79 and -61 and ( 4) 
between -59 to -52 (figure 4.1). 
- 110 -100 - 90 -80 
I I I I 
AP-2-LIKE 
a TGGAGGC repeat situated 
a short CCCTAGGG palindrome 
-70 -60 -50 
I I I 
===;> 
CCCGGGCCCC CAGCCCCAGC CCTCCCATTC3 GTGGAGGCCC TTTTGGAGGC ACCCT AGGGC CAGGGAAACT GGGCCCGGGG GTCGGGGTCG ,8GAGGGTAAC CACCTCCGGG AAAA CCTCCG TGG TCCCG GTCCCTTTGA 
I .._1-~I 
Sma 1 AP-2 HC3 
Bst N1 
Fig 4.1 Potential cis-acting elements within the 
proximal human a2(I) procollagen promoter. The Sma 1 -
Bst Nl promoter fragment contains an inverted CCAAT box 
(shown in bold), an AP-2 consensus sequence, HC3 motif 
and an AP-2-like sequence. The fragment also contains a 
GGAGG and inverted GGAGG boxes within a region of 
inverted dyad symmetry ( open arrows) , a direct TGGAGGC 
repeat (hatched boxes) and a short CCCTAGGG palindrome 
(shaded arrows). 
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4.2.2 Identification of DNA-elements involved in DNA-protein 
complex formation 
Nuclear extracts from SVWI-38 and CT-1 fibroblasts formed two 
complexes with fragment E of the human a2 (I) procollagen 
promoter (figure 2.8). In addition to complexes I and III, 
an additional complex (complex II) was identified in SVWI-38 
extracts. Since sequence-specific DNA-binding proteins could 
potentially bind to a number of elements within this region 
of the promoter, competition binding experiments were 
performed to determine which of these elements were involved 
in complex I, II and III formation. 
The ability of increasing molar excesses of unlabelled 
double-stranded oligonucleotides A, B, C or D (section 7.4.5 
and figure 4.2) to compete with labelled fragment E for 
complex formation with SVWI-38 or CT-1 extracts was tested by 
EMSA as described in section 7.4.2. 
Oligonucleotide c, corresponding to the 5'-flanking sequences 
containing the AP-2 and AP-2-like consensus sequences failed 
to compete out the formation of any of the complexes (figures 
4.2 and 4.3). This finding is supported by previous studies 
{Smith, 1989). Similarly, no competition was observed with 
oligonucleotide B, containing the inverted CCAAT box and the 
5'-flanking sequences (figures 4.2 and 4.3). These results 
eliminated the possibility that AP-2 or an AP-2-like protein 
was responsible for complex I, II or III formation with 
fragment E. Figures 4.2 and 4.3 also show a similar lack of 
detectable competition with oligonucleotide D. Therefore the 
TGGAGGC repeat and the CCCTAGGG palindrome, which are present 
in this oligonucleotide, are not involved in DNA-protein 
complex formation. This finding is also supported by the 
finding that a double-stranded 30 bp oligonucleotide, 
extending from position -77 to -48, was unable to compete 
out complexes I, II or III when SVWI-38 extracts were 
assayed {Smith, 1989). This lack of competition is 
maintained even at a 400-fold molar excess of this 30 bp 
oligonucleotide. 
Oligonucleotide A, containing the inverted CCAAT box together 
with 5'- and 3'-flanking sequences, competed very effectively 
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Fig 4. 2 CT-1 competition assays. (A) Double-stranded oligonucleotides (oligo) A, B, C and D, corresponding to the indicated regions of fragment E (nucleotides -110 to -41) of the human a2(I) procollagen promoter, were prepared as described in section 7.4.5. (B) Increasing molar excesses of double-stranded oligonucleotides were incubated with CT-1 nuclear extracts for 10 min prior to the addition of labelled probe (fragment E) as described in section 7.4.2. The DNA-protein complexes were electrophoresed on 5% non-denaturing polyacrylamide gels at 40 c in 0.5X TBE, the gels dried and exposed to X-ray film for 16 hrs. The position of complexes I and III are indicated. 
A 1 lU 100 ·90 ·80 -70 60 ',U 
I I I I I 
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Fig 4.3 SVWI-38 competition assays. (A) Double-stranded 
oligonucleotides (oligo} A, B, C and D, corresponding to 
the indicated regions of fragment E (nucleotides -110 to 
-41) of the human a2(I} procollagen promoter, were 
prepared as described in section 7. 4. 5. (B) Increasing 
molar excesses of double-stranded oligonucleotides were 
incubated with SVWI-38 nuclear extracts for 10 min prior 
to the addition of labelled probe (fragment E} as 
described in section 7. 4. 2. The DNA-protein complexes 
were electrophoresed on 5% non-denaturing polyacrylamide 
gels at 40 c in O.SX TBE, the gels dried and exposed to 
X-ray film for 16 hrs. The position of complexes I, II 
and III are indicated. 
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for complex I formation in both CT-1 and SVWI-38 extracts. 
This competition was observed with a low molar excess 
(25-fold) of the oligonucleotide, suggesting that complex I 
proteins bound to this oligonucleotide with a high affinity. 
There was also weaker competition for complex III (figures 
4.2 and 4.4). With SVWI-38 extracts on the other hand, there 
was an initial increase in the intensities of complexes II 
and III followed by a gradual decrease in the intensity of 
complex III (figures 4.3 and 4.5). The initial increase in 
the intensities of complexes II and III suggested that all 
three complexes did not form on the same DNA molecule. The 
preferential inhibition of complex I formation with the 
competing oligonucleotide probably caused more probe to be 
available for complex II and III formation, resulting in an 
initial increase in their intensities. At higher molar 
excesses of oligonucleotide A, after the competitor had bound 
to all the available complex I proteins, the vast excess free 
oligonucleotide competed weakly with complex III proteins, 
causing a reduction in its intensity. 
If the above explanation is valid, then complex III would be 
competed out more effectively by oligonucleotide A when 
limiting amounts of protein was used in the binding 
reactions. As shown in figures 4. 4b and 4. Sb there is a 
marked decrease in the intensity of complex III when less 
SVWI-38 or CT-1 protein was used. There was also a reduction 
in the intensity of complex II when lower SVWI-38 protein 
concentrations were assayed (figure 4.5b). 
Competition of the O. 2 M SVWI-38 heparin-agarose fractions 
containing partially purified complex I proteins with 
oligonucleotide A resulted in a drastic reduction in the 
intensity of complex I at a low molar excess (25-fold) of 
oligonucleotide (figure 4.6). Oligonucleotide A competed out 
complexes II and III very weakly when the o. 4 M heparin-
agarose fractions were similarly assayed. These competition 
experiments suggested that oligonucleotide A contains the 
minimal elements required for complex I and some of the 
sequences for complex II and III formation. The inverted 
CCAAT box, together with 5'- and 3'-flanking sequences, are 
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Fig 4.4 The competition kinetics of CT-1 complexes I and III with oligonucleotide A. (A) Increasing molar excess of double-stranded oligonucleotide A was incubated with 4 ug CT-1 nuclear extracts and labelled . probe (fragment E) (section 7.4.2). The position of complexes I and III are indicated in the inset. The autoradiograms were scanned and the average percentage binding and standard deviation (n=4) of complexes I and III at each molar excess of oligonucleotide A assayed was plotted. Complex I is represented by (•---•), while (X--X) represents complex III. (B) As for (A) except that O. 6 ug of CT-1 nuclear extracts were assayed. The percentage binding and standard deviation were calculated from three separate experiments. 
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Fig 4.5 The competition kinetics of SVWI-38 complexes I, 
II and III with oligonucleotide A. (A) Increasing molar 
excess of double-stranded oligonucleotide A was incubated 
with 4 ug SVWI-38 nuclear extracts and labelled probe 
(fragment E) (section 7.4.2). The position of complexes 
I, II and III are indicated in the inset. The 
autoradiograms were scanned and the average percentage 
binding and standard deviation (n = 3 or 4) of complexes 
I, II and III at each molar excess of oligonucleotide A 
assayed was plotted. Complex I is represented by(•--•), 
(•···•) represent complex II while, (X--X) represents 
complex III. (B) As for (A) except that 0.6 ug of SVWI-
38 nuclear extracts were assayed. The percentage binding 
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Fig 4. 6 The competition kinetics of partially purified 
complexes I, II and III with oligonucleotide A. (A) An 
increasing molar excess of double-stranded 
oligonucleotide A was incubated with 4 ug partially 
purified complex I proteins (0.2 M SVWI-38 heparin-
agarose fractions) and labelled probe (fragment E) 
(section 7.4.2). The position of complexes I is 
indicated in the inset. The autoradiograms were scanned 
and the percentage binding at each molar excess of 
oligonucleotide A assayed was plotted. (B) As for (A) 
except that 4 ug of partially purified complex II and III 
proteins (O. 4 M SVWI-38 heparin-agarose fractions) were 
assayed. Complex II is represented by (•···A), while 
(X--X) represent complex III. 
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To confirm the competition experiment results, 
electrophoretic mobility shift assays were done with SVWI-38 
or CT-1 nuclear extracts and radioactively labelled 
oligonucleotides as described in section 7.4.2. In addition 
to the four oligonucleotides (A, B, C and D) used in the 
competition experiments, a 21-mer oligonucleotide E (-74 to 
-94) and a 47-mer oligonucleotide F (-107 to -61) were used 
in the binding studies (section 7.4.5). As shown in figures 
4.7 and 4.8 none of the complexes formed with oligonucleotide 
C, whereas trace amounts of complex I was visible after 
longer exposures ( 2 days) of the autoradiograms of 
oligonucleotide B complexes. Since this oligonucleotide 
contains the inverted CCAAT box and 5 '-flanking sequences, 
this result suggested that the recognition element for 
complex I probably also extended into the 3'-flanking region. 
In the case of oligonucleotide D, trace amounts of complex 
III (figure 4.7) was visible in longer exposures (3 days) of 
the autoradiograms. These results implied that the 
3'-flanking sequences are required for complex III formation. 
Under these conditions no detectable amounts of complex III 
was identified when SVWI-38 extracts were assayed with this 
oligonucleotide (figure 4. 8) • Since previous experiments 
suggested that the concentrations of complex III proteins is 
lower in SVWI-38 extracts than in CT-1 extracts (chapter 2), 
these results were not surprising. 
As expected from the competition data, all three complexes 
formed on oligonucleotides A, E and F, with complex I being 
more predominant than II and III. All three of these 
oligonucleotides contain the inverted CCAAT box and varying 
lengths of the 5 1 - and 3'-flanking sequences. The smallest 
oligonucleotide, oligonucleotide E, containing 21 bp of the 
a2{I) procollagen promoter (-94 to -74), most probably 
contains the minimal elements required for complex I, II and 
III formation. When compared with the binding results of 
oligonucleotides A or F, the intensities of complexes II and 
III were lower when extracts were assayed with 
oligonucleotide E (figure 4. 8) . This observation implies 
that additional sequences present in oligonucleotides A and F 
are required for complex II and III formation. An inverted 
CCAAT box, an inverted GGAGG repeat flanking the CCAAT box 
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Fig 4.7 Binding assays between labelled oligonucleotides and CT-1 nuclear extracts. (A) Double-stranded oligonucleotides (oligo) A, B, C, D, E and F, corresponding to the regions indicated were labelled as described in sections 7.4.5 and 7.4.1. (B) 4 ug of CT-1 nuclear extracts ( lanes marked +) were incubated with labelled probe (oligo) and the DNA-protein complexes electrophoresed, together with free probe (lanes marked -), on 5% non-denaturing polyacrylamide gels as described in section 7.4.2. The dried gels were exposed to X-ray film for the indicated period of time (exposure). The position of complexes I and III are indicated. 
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Fig 4.8 Binding assays between SVWI-38 nuclear extracts 
and labelled oligonucleotides. (A) Double-stranded 
oligonucleotides {oligo) A, B, c, D, E and F, 
corresponding to the regions indicated were labelled as 
described in sections 7.4.5 and 7.4.1. (B) 4 · ug of 
SVWI-38 nuclear extracts {lanes marked+) were incubated 
with labelled probe {oligo) and the DNA-protein complexes 
electrophoresed, together with free probe {lanes marked 
-), on 5% non-denaturing polyacrylamide gels as described 
in section 7.4.2. The dried gels were exposed to X-ray 
film for the length of time indicated {exposure). The 
position of complexes I, II and III are indicated. 
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and an inverted HC3 motif are all present in this short 
fragment of the collagen promoter. It is possible that some 
or all three of these motifs are important for complex I, II 
and III formation. 
The binding experiments also showed that the complex I and 
III recognition elements are distinct. The element 
responsible for complex I formation appears to be upstream to 
the element responsible for complex III formation 
(figure 4.7). These experiments were not sensitive enough to 
determine the relative position of ·the complex II cis-
element. 
4.2.3 Mutually exclusive DNA-protein complex formation 
The following observations suggested that there is mutually 
exclusive formation of complexes I, II and III with cis-
elements in the human cx2 (I) procollagen promoter:- ( 1) The 
initial increase in the intensities of complexes II and III 
when oligonucleotide A was used in competition studies 
(figure 4.5). (2) The minimal sequences required for complex 
I, II and III formation are located within a short 21 bp 
region of the cx2 (I) procollagen promoter. To examine the 
possibility that the formation of one of the DNA-protein 
complexes prevented the simultaneous binding of the remaining 
transcription factors, mutually exclusive binding assays were 
done (see section 7.4.3). 
Increasing amounts of partially purified CT-1 (figure 4.9) or 
SVWI-38 (figure 4.10) complex I proteins pre-bound to 
fragment E, resulted in decreased formation of complexes II 
and III upon the addition of partially purified complex II 
and III proteins (0.4 M KCl heparin-agarose fractions). 
Similarly, saturating fragment E with partially purified CT-1 
complex III (figure 4.9) or SVWI-38 complex II and III 
proteins (figure 4.10a) was accompanied by a decrease in the 
formation of complex I. These results showed that complex I, 
II or III proteins do not bind simultaneously to their 
respective cis-regulatory elements. When partially purified 
complex I, II or III proteins were added to bind to 
fragment E simultaneously all three complexes formed 
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ug 0.2M Fraction 3 3 5 10 15 
ug 0.4M Fraction 3 3 5 10 15 20 
ug dldC 4 4 6 5 10 15 5 10 15 20 
0.2M Fraction added 3 3 3 3 
after complex formation 
0.4M Fraction added 3 3 3 
after complex formation 
ill 
Fig 4.9 Mutually exclusive binding assays with partially 
purified complex I and III proteins. Fragment E (-110 to 
-46) was incubated with increasing amounts of· partially 
purified complex I (0.2 M CT-1 heparin-agarose fraction) 
or complex III (0.4 M CT-1 heparin-agarose fraction) 
proteins for 20 min on ice as described in section 7.4.3. 
Three ug of partially purified complex III ( O. 4 M CT-1 
heparin-agarose fraction) or complex I proteins ( O. 2 M 
CT-1 heparin-agarose fraction) were added, incubated for 
a further 20 min on ice, the DNA-protein complexes were 
electrophoresed on 5% non-denaturing polyacrylamide gels, 
the gels dried and exposed to X-ray film for 16 hrs 
(section 7.4.2). Binding of complex I or III proteins on 
their own or mixing equal amounts of the two fractions 
are shown in the first three lanes. The position of 
complexes I and III are indicated. 
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Fig 4.10 Mutually exclusive binding assays with partially purified complex I, II and III proteins. (A) 
Fragment E (-110 to -46) was incubated with increasing amounts of partially purified complex I (0.2 M SVWI-38 heparin-agarose fractions) or complex II and III (0.4 M SVWI-38 heparin-agarose fractions) proteins prior to the addition of 3 ug of partially purified complex II and III proteins or complex I proteins as described in the legend 
of figure 4.9. The position of complexes I, II and III 
are indicated. (B) Increasing amounts of partially 
purified complex III proteins (0.4 M CT-1 heparin-agarose 
fraction) were pre-bound to fragment E prior to the addition of 3 ug of partially purified complex II and III proteins (0.4 M SVWI-38 fraction) and assayed as in (A). The CT-1 and SVWI-38 0.4 M heparin-agarose fractions were also assayed without adding other protein fractions. The position of complexes II and III are indicated. 
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presumably each on separate DNA molecules (figures 4. 9 and 
4. lOa) . 
Figure 4.10b shows that prior binding of increasing amounts 
of partially purified complex III proteins to fragment E 
abolished the formation of complex II. This result suggested 
that complex III proteins also do not bind simultaneously 
with complex II proteins to their regulatory elements either. 
These results support the hypothesis that complex I, II and 
III formation occur in a mutually exclusive manner. 
4.2.4 Methylation interference analysis 
As already discussed, complex I, II and III proteins interact 
with sequences located within a 21 bp segment extending from 
nucleotides -94 to -74. This 21 bp fragment contains an 
inverted CCAAT box, an inverted GGAGG repeat and an inverted 
HC3 motif. Since the competition and gel retardation assays 
failed to show which of these three DNA-elements were 
responsible for DNA-protein complex formation, methylation 
interference assays were performed ( section 7. 4. 4) . This 
assay was used to identify the relative importance of 
individual purine residues in complex formation. 
Methylation of all the guanine and most of the adenine bases 
on both strands between nucleotides -92 and -72 interfered to 
some degree with complex I formation when CT-1 (figures 4.11 
and 4.12a) or SVWI-38 (figures 4.13 and 4.14a) extracts were 
assayed. In both CT-1 (figure 4 .12a) and SVWI-38 (figure 
4.14a) complex I proteins bound to a 21 bp recognition 
element, 51 GCCCTCCCATTGGTGGAGGcc3 ', extending from -92 to -72 
(figure 4.15). This tripartite recognition element contains 
a GGAGG box and its inverted counterpart (CCTCC) flanking the 
CCAAT box. Since purines in both the GGAGG boxes and the 
CCAAT box are involved in DNA-protein contacts, this 
recognition element will be referred to as a GGAGG/CCAAT 
binding element (G/CBE), while complex I proteins will be 
called a GGAGG/CCAAT box factor (G/CBF) . Although purine 
residues within the HC3 motif, which is also present in the 
G/CBE, are involved in DNA-protein contacts, the methylation 
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Fig 4.14 Histogram of the SVWI-38 Methylation interference data. Methylation interference analysis were performed as described in the legend to figure 4.13. The autoradiograms were scanned and the -average percentage interference for each purine residue was determined as described in the legend of figure 4 .12. Both the coding (top) and non-coding (bottom) strands are shown. Interference by methylation of an adenine residue is indicated as 50% interference. The inverted CCAAT box is underlined. (A) Methylation pattern of complex I (n = 3) . (B) Methylation pattern of complex II (n = 3) . (C) Methylation pattern of complex III (n = 3). 
and Chambon, 1986). 
complex I is related 
extracts which binds 
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It is, therefore, unlikely that 
to the unknown· protein from HeLa 
to the HC3 motif in the mouse 
immunoglobulin heavy-chain enhancer. Interestingly, the 
results presented in figures 4.12a and 4.14a also indicates 
that methylation of the non-coding strand interfered more 
strongly with complex formation than methylation of the 
coding strand. Al though purines in both the upstream and 
downstream GGAGG boxes were involved in DNA-protein contacts, 
the upstream inverted GGAGG and CCAAT boxes appeared to be 
more important for complex I formation.· 
Methylation of the four guanine bases in the downstream GGAGG 
box reduced the formation of complexes II and III as did 
methylation of the two guanines at positions -72 and -73 and 
the four A's between nucleotides -70 and -67 on the non-
coding strand. The nucleotides at positions -72 and -73 
appeared to form the core of this recognition sequence. The 
guanine at -71 does not appear to be involved in DNA-protein 
contacts (figures 4.11 and 4.13}. As illustrated in figures 
4.12b, 4.14b and 4.14c and summarised in figure 4.15, the 
similarity of the complex II and III interference patterns 
suggested that they bind to the same DNA-element. since 
complex II and III proteins are most probably a 
transcriptional repressor and an activator respectively 
(section 2.3), it is proposed that their recognition element 
be called a collagen modulating element (CME). The 12 bp CME 
situated between nucleotides -78 to -67, 5 'GGAGGCCCTTTT3 ', 
contains the downstream GGAGG box and 3 1 -flanking sequences. 
The data in figures 4. 12b, 4. 14b and 4. 14c also suggested 
that purines upstream of this GGAGG box were weekly involved 
in complex II and III DNA-protein contacts. Since this GGAGG 
box and two of the 3 '-flanking nucleotides (5 'GGAGGcc3 ') 
also form part of the G/CBE, the human a2 (I) procollagen 
promoter contains two distinct but overlapping cis-elements 
situated around the CCAAT box. 
Since the N3 of adenine and N7 of guanine are methylated by 
dimethyl sulphate in the minor and major grooves respectively 
(Siebenlist and Gilbert, 1980), complex I, II and III 
proteins bound in both the major and minor grooves of DNA. 
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Fig 4 .15 summary of the methylation interference data. (A) The 70 bp fragment of the human a2 (I} procollagen promoter (nucleotides -110 to -41} showing the inverted CCAAT box (bold) and the purines that interfere with complex I (top sequence) and complexes II and III - (bottom sequence) formation; open circles show 25 to 70% interference and solid circles >70% interference. Methylation of the guanine indicated with an arrow enhanced complex formation. (B) A schematic diagram of the G/CBE and CME (open box) within the human a2 (I) procollagen promoter. The inverted CCAAT box is shown as a solid box, while the upstream inverted and downstream GGAGG boxes are shown as hatched boxes. 
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Complex I and II proteins were also identified in a non-
collagen producing mouse macrophage tumour cell line, p388D1 (figure 2.9). Figure 4.17 shows that these murine proteins 
are related to or identical to the human complex I and II 
proteins because they bound in an identical manner to the 
G/CBE and CME of the human a2(I) procollagen promoter. 
Hatamochi et. al. ( 1986, 1987) have shown that only CBF in 
NIH-3T3 nuclear extracts binds to the equivalent region of 
the mouse a2(I) procollagen promoter. This and other studies 
(V. Leaner, unpublished data), on the other hand, identified 
proteins responsible for complex I and · II formation with the 
highly homologous human promoter in murine macrophage, 
fibroblast and myeloma nuclear extracts. 
The presence of complex I proteins in a number of mouse and 
human cell lines together with the homology between the 
murine CBF recognition element and the human G/CBE (figure 
4.16}, strongly suggested that the proteins responsible for 
complex I (G/CBF) formation maybe identical or similar to the 
CBF in NIH-3T3 cells (Hatamochi et. al., 1986; Maity et. al., 
1988) (see chapter 5). CME on the other hand, contains a 
crucial three-base mismatch between the human and mouse 
promoters (figure 4.16) and therefore probably will not form 
complex II, although these proteins are present in many 
murine cell lines. 
Human 
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CCCGGGCCCCCAGCCCCAGCCCTCCCATTGGTGGAGGCCCTTTTGGAGGC 
L- CME __J 
1111111111 11111 111111111111111 I I I I I 1111111111 
Mouse CCCGGGCCCCTAGCCCTAGCCCTCCCATTGGTGGAGACGTTTTTGGAGGC 
L- CBF binding site _J 
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Fig 4.17 Methylation interference analysis of p388D1 complex I and II formation. DNA was end-labelled with 
,,-32P-ATP, partially methylated with OMS and incubated 
with crude mouse tumour macrophage, p388D1, nuclear 
extracts as described in section 7. 4. 4. DNA-protein 
complexes were resolved on 5% non-denaturing 
polyacrylamide gels from which the free and complexed DNA 
was extracted, cleaved with piperidine and resolved on 
12% urea/polyacrylamide sequencing gels as described in 
Materials and Methods (section 7. 4. 4). The dried gels 
were exposed to X-ray film for at least 16 hrs. The 
lanes marked with G's represent DNA cleaved OMS to 
indicate the guanines in the sequence. (A) The DNA 
sequence of the coding strand between nucleotides -107 
and -4 7. The guanine residues which are important for 
complex I and II formation are shown with asterisks. The 
CCAAT box is in bold. (B) The DNA sequence of the coding 
strand between nucleotides -107 and -50. The guanine 
residues which are important for complex formation are 
indicated as in (A). The autoradiogram on the left is a 
longer exposure in order to show the protected adenines. 
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4.2.S Mutation analysis 
As summarised in figure 4 .16, the methylation interference 
assays identified two distinct overlapping elements in the 
human a2(I) procollagen promoter. Methylation of purines in 
these elements interfered to varying extents with complex 
formation. Double-stranded oligonucleotides containing 
mutated GGAGG and CCAAT boxes were used in EMSA to test the 
relative importance of these motifs in complex I, II and III 
formation (sections 7.4.2 and 7.4.5). 
Mutating the inverted CCAAT box from ATTGG to CTTGC resulted 
in a significant reduction in complex I (81 ± 12%} and III 
(37 ± 7%) in CT-1 (figure 4.18} and SVWI-38 (figure 4.19} 
nuclear extracts. Similar mutations in the mouse a2 (I) 
procollagen CCAAT box also abolished CBF binding {Karsenty 
et. al., 1988). The slight reduction in complex III 
formation supported the observation from the methylation 
interference assays that sequences 5' of the CME, which 
includes the CCAAT box, were weakly involved in DNA-protein 
contacts {figures 4.12b and 4.14c). Binding of complex II 
proteins to the MUT-CCAAT oligonucleotide was virtually 
unaffected when compared to binding with the wild-type 
oligonucleotide {oligonucleotide F} {98 ± 22%). 
The upstream and downstream GGAGG boxes were mutated to TTATT 
in the oligonucleotides MUT-US and MUT-CME respectively. As 
expected from the methylation interference data, for~ation of 
complex II was reduced (68 ± 13%) and complex III was 
abolished {98%) on MUT-CME {figure 4.19}. This was 
accompanied by a drastic increase in the binding {147 ± 44%) 
of complex I proteins {G/CBF} to this oligonucleotide. This 
implied that the downstream GGAGG box is not vital for 
complex I formation. This result confirmed the methylation 
interference data which suggested that this motif was not as 
important as the upstream motifs for G/CBF binding. 
Complex I formation was virtually abolished when the upstream 
inverted GGAGG box was mutated to TTATT {oligonucleotide 
MUT-US, 5 ± 4% binding). Since this GGAGG box does not form 
part of the CME, there was no reduction in the formation 
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Fig 4 .18 Mutation analysis of CT-1 complex formation. 
(A) Double-stranded oligonucleotides, containing mutated 
GGAGG boxes (MUT-CME, MUT-US), CCAAT box (MUT-CCAAT) and 
the cytosine dinucleotides at -72 and -73 (MUT-CME2) , 
were used in EMSA. (B) 3-4 ug of crude CT-1 nuclear 
extract was incubated with 1 ng (104 cpm) labelled 
double-stranded oligonucleotide (+) or without added 
protein (-) and electrophoresed on 5% non-denaturing 
polyacrylamide gels as described in section 7.4.2. The 
gels were fixed in 10% acetic acid for at least 20 min, 
dried and exposed to X-ray film for at least 16 hrs. The 
positions of complexes I and III are indicated. 
Complex I is over-exposed in the figure. (C) The 
autoradiograms were scanned and the average relative 
percentage binding and standard deviation for each 
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Fig 4.19 Mutation analysis of SVWI-38 complex formation. (A) Double-stranded oligonucleotides were prepared and radioactively labelled as described in the legend of figure 4.18. (B) 3-4 ug of crude SVWI-38 nuclear extracts were incubated with 1 ng (10 4 cpm) labelled probe (+) or without added protein (-) and electrophoresed on 5% non-denaturing polyacrylamide gels as described in section 7. 4. 2. The gels were fixed in 10% acetic acid for at least 20 min, dried and exposed to X-ray film for at least 16 hrs. The positions of complexes I, II and III are indicated. Complex I is over-exposed in the figure. (C) The autoradiograms were scanned and the average relative percentage binding and standard deviation for each complex was plotted. 
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CT-1 or SVWI-38 extracts were assayed. There was, however, a 
puzzling reduction (63 ± 19%} in the formation of complex II 
on this mutated oligonucleotide (figure 4.19}. This implied 
that certain sequences upstream of the CME are also required 
for complex II formation (figure 4.14b}. 
Since the two cytosine residues at positions -72 and -73 form 
the core of the CME, they were mutated to AA in 
oligonucleotide MUT-CME2 and used as a probe in EMSA. 
Figures 4.18 and 4.19 shows that the formation of complexes 
II and III (11 ± 5% and 1.5 ± 1.5% binding respectively} was 
virtually abolished with this oligonucleotide. Since these 
two residues form part of the G/CBE, it was not surprising 
that a 34 ± 11% reduction complex I formation was observed. 
The formation of complex I was abolished or drastically 
reduced when the single cytosine spacer nucleotide between 
the inverted upstream GGAGG and CCAAT boxes was removed 
(figures 4. 2 0 and 4. 21} . This mutated oligonucleotide was 
also unable to compete out SVWI-38 or CT-1 complex I 
formation in competition binding assays (data not shown). 
To summarise, mutations in the upstream GGAGG box, the CCAAT 
box and the cytosines at positions -72 and -73 resulted in 
reduction in the binding of G/CBF to the G/CBE (complex I). 
The integrity of these three motifs in the G/CBE was 
essential for G/CBF binding. The single cytosine nucleotide 
separating the inverted upstream GGAGG and CCAAT boxes also 
appeared to be important for complex I formation, while no 
reduction of complex I formation was observed when the 
downstream GGAGG box was mutated. It is possible that the 
single cytosine deletion is so deleterious because is 
destroys the spatial arragement between the GGAGG and CCAAT 
boxes that are important for complex formation. · Mutations in 
the downstream GGAGG box and nucleotides -72 and -73 resulted 
in significant reduction in complex II and III formation on 
the CME. These mutation results also suggested that 
sequences upstream of the CME are involved in the formation 
of complexes on the collagen promoter. 
4.2.6 Delineation of G/CBE and CME 
Competition assays showed that oligonucleotide D was unable 
to compete out complex II and III (figures 4. 2 and 4. 3) 









OLIGO WT MUT - dUS 





Fig 4. 2 o Deletion of a single cytosine residue in the G/CBE abolishes complex I formation in CT-1 ~uclear extracts. (A) Double-stranded mutated (MUT-dUS) and wild-type (WT) oligonucleotides containing the G/CBE used in this study. The single cytosine residue between the upstream GGAGG and CCAAT boxes was deleted in MUT-dUS. (B) 3-4 ug of {rude CT-1 nuclear extracts were incubated with 1 ng (10 cpm) of labelled probe (+) or without added proteins (-) and electrophoresed on 5% non-denaturing polyacrylamide gels as described in section 7. 4. 2. The gels were fixed in 10% acetic acid for at least 20 min, dried and exposed to X-ray film for 16 hrs. The positions of complexes I and III are indicated. 














Fig 4. 21 Deletion of a single cytosine residue in the 
G/CBE abolishes complex I formation in SVWI-38 nuclear 
extracts. (A) Double-stranded mutated (MUT-dUS) and 
wild-type (WT) oligonucleotides containing the G/CBE used 
in this study. The single cytosine residue between the 
upstream GGAGG and CCAAT boxes was deleted in MUT-dUS. 
(B) 3-4 ug of crude ;vwI-38 nuclear extracts were 
incubated with 1 ng (10 cpm) of labelled probe (+) or 
without added protein (-) and electrophoresed on 5% non-
denaturing polyacrylamide gels as described in section 
7. 4. 2 . The gels were fixed in 10% acetic acid for at 
least 20 min, dried and exposed to X-ray film for 16 hrs. 
The positions of complexes I, II and III are indicated. 
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amounts of complex III proteins bound to oligonucleotide D 
(figure 4.7). Since the methylation interference data showed 
that this oligonucleotide contains the minimal DNA-element 
(-78 to -66) for complex II and III formation, these trans-
acting factors are expected to bind to this oligonucleotide 
(figure 4.15). In order to test the possibility that non-
specific 5'-flanking sequences were sufficient for complex II 
and III formation, the double-stranded oligonucleotide D was 
cloned into the Sma 1 site of pUC19 to produce plasmid pNJ-D. 
This insert contains a 33 bp fragment between nucleotides -78 
to -46 containing the downstream GGAGG box and 3'-flanking 
sequences (figures 4.22c and 4.23). The insert was released 
with Eco Rl and Hind III so that pUC19 sequences were 
attached to the probe fragments used in EMSA. Figures 4.24 
and 4. 25 show that complexes II and III formed with such a 
probe containing non-specific pUC19 polylinker sequences. 
Several lines of evidence suggested that the addition of non-
specific 3'-flanking sequences to oligonucleotide B may 
increase the binding of complex I proteins {G/CBF) to this 
oligonucleotide:- (1) The oligonucleotide contains the most 
important motifs in the G/CBE for complex I formation, namely 
the inverted distal GGAGG and CCAAT boxes; (2) mutations in 
the downstream GGAGG box did not cause a reduction in 
complex I formation (figures 4.18 and 4.19); (3) trace 
amounts of complex I was detected on longer exposures of 
autoradiograms when oligonucleotide B was used as a probe in 
electrophoretic mobility shift assays (figures 4. 7 a_nd 4. 8) . 
The double-stranded oligonucleotide was therefore cloned into 
the Sma 1 site of pUC19 to produce plasmid pNJ-B (figures 
4. 22b and 4. 23). Complex I formation was observed when a 
Hind III - Eco Rl fragment of plasmid pNJ-B was used as a 
probe with CT-1 (figure 4.24) or SVWI-38 (figure 4.25) 
nuclear extracts in EMSA. The adjacent pUC19 sequences are 
not homologous to the deleted promoter sequences, and 
therefore could not be crucial in the formation of complex I. 
Plasmid pNJ-F contains a 50 bp fragment extending from 
nucleotides -110 to -60 of the collagen promoter (figures 
4.22a and 4.23) which includes the G/CBE and CME responsible 
for complex I, II and III formation. As expected complexes 
I, II and III in SVWI-38 nuclear extracts (figure 4.25) and 
A 
aagcttgcat gcctgcaggt cgactctaga ggatccCCCG GGCCCCCAGC 
I I I I 
Hind III Bam Hl 







aagcttgcat gcctgcaggt cgactctaga ggatccccGC CCCCAGCCCC I I I I 
Hind III Bam Hl 
C 
AGCCCTCCCA TTGGTGGgta ccgagctcga attc 
I I 
Kpn 1 Eco Rl 
Plasmid pNJ-B 
gaattcgagc tcggtacccG GAGGCCCTTT TGGAGGCACC CTAGGGCCAG I I I I 
Eco Rl Kpn 1 
GGgggatcct ctagagtcga cctgcaggca tgcaagctt 
I I I I 
Bam Hl Hind III 
Plasmid pNJ-0 
Fig 4.22 Nucleotide sequences of promoter inserts in 
plasmids pNJ-F (A), pNJ-B (B) and pNJ-0 (C) . The 
three plasmids were cloned by ligating phosphorylated 
double-stranded oligonucleotides F, B and D (figure 
4. 7) into the Srna 1 site of pUC19 as described in 
section 7. 1. 2. 3. The polylinker of pUC19 is in 
lowercase letters while the oligonucleotide sequences 
are shown as uppercase letters. Various restriction 
sites are also indicated. 
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-110 -100 -90 -80 -70 -60 -50 -46 
I I 
pNJ-59 CCCGGGCCCC CAGCCCCA 
1111111111 11111111 pNJ-F ccCGGGCCCC CAGCCCCA 
11 11111 11111111 
I I I 
GC CCTCCCATTG GT GGAGG CCC TTTT 
11111111-111-111 11111 111 1111 
GC CCTCCCATTG GT GGAGG CCC TTTT 
11111111-111-111 11 11 I 
I I I 
GGAGGC ACCCTAGGGC CAGGGta 
111111 I I I 
GGAGGC gggtaccgag ctcgaat 
11 pNJ-B tccccGCCCC CAGCCCCA GC CCTCCCATTG GT GGgta ccg agct 1-1- 11111 111 1111 
cgaatt c--------- ---- - --
111111 1111111111 11111 pNJ-D ---------- - --gaatt cg agctcggtac cc GGAGG CCC TTTT GGAGGC ACCCTAGGGC CAGGGgg 
G/CBE 
(CO!!'plex I) CME 
(CO!!'plexes II and Ill) 
Fig 4.23 sequence comparison of plasmid pNJ-59 with 
plasmids pNJ-F, pNJ-B and pNJ-D. Plasmid pNJ-59 (section 
2.2.3.1), containing a 65 bp fragment (nucleotides -110 
to -46) of the human a2(I) procollagen promoter is 
compared with the corresponding regions of plasmids 
pNJ-F' pNJ -B and pNJ-D. The G / CBE and CME are boxed 
while the inverted CCAAT box is underlined. Sequences 
originating from the pUC19 polylinker are shown as 
lowercase letters. Alignment with the pNJ-59 sequence 
are indicated by the vertical line. 
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complexes I and III in CT-1 nuclear extracts (figure 4. 24) 
formed with this fragment. An additional complex, which 
migrates slightly faster than complex I, was observed when 
this fragment was used as a probe. 
complex will be discussed in chapter 5. 
The identity of this 
These results supported the hypothesis that there are 
distinct adjacent DNA-binding elements in this region of the 
human a2 (I) procollagen promoter. The upstream GGAGG and 
inverted CCAAT boxes are the most important components of the 
G/CBE because mutations in the downstream GGAGG box or 
replacing it with non-homologous sequences does not abolish 
binding of complex I proteins (G/CBF) to the G/CBE. Finally, 
non-homologous 5'-flanking sequences are sufficient for 
complex II and III proteins to bind the CME. In addition, 
the elements responsible for complex I and II/III formation 
have been separated. 
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'------------ ---___, pNJ.59 
- - - - -- - ----~ pNJ-F 
- - -------' pNJ-8 
pNJ-0 L_ _ _ _____ __, 
111 
B r----r----.--.------,------, 
Probe pNJ ·59 pNJ · F pNJ·B pNJ·D 
Protein Added + 
I 
Unbound 
Fig 4.24 Delineation of G/CBE and CME. (A) A schematic 
diagram of the G/CBE (complex I} and CME (complex II and 
III). The inverted CCAAT box is shown in bold, while the 
GGAGG boxes are hatched. The nucleotide sequence of a 
60 bp fragment extending from position -110 to -41 ·of the 
human a2 {I) procollagen promoter is also shown. The 
cloned inserts in plasmids pNJ-59, pNJ-F, pNJ-B and pNJ-D 
are indicated. (B) Hind III - Eco Rl fragments of the 
four plasmids were prepared and radioactively labelled as 
described in sections 1.1.1.1 and 7.4.1. 3-4 ug of crude 
CT-1 nuclear extracts were incubated with 1 ng (104 cpm) 
labelled probe (+) or without added protein {-) and 
electrophoresed on 5% non-denaturing polyacrylamide gels 
as described in section 7.4.2. The gels were dried and 
exposed to X-ray film for 16 hrs. The positions of 
complexes I and III are indicated. The identity of the 
extra band which migrated slightly faster than complex I 
will be discussed in chapter 5. 
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Fig 4.25 Delineation of G/CBE and CME. (A) A schematic diagram of the G/CBE {complex I) and CME {complex II and III). The inverted CCAAT box is shown in bold, while the GGAGG boxes are hatched. The nucleotide sequence of a 60 bp fragment extending from position -110 to -41 'of the human a2 {I) procollagen promoter is also shown. The cloned inserts in plasmids pNJ-59, pNJ-F, pNJ-B and pNJ-D are indicated. (B) Hind III - Eco Rl fragments of the four plasmids were prepared and radioactively labelled as described in sections 7.1.1.1 and 7.4.1. 3-4 ug of crude SVWI-38 nuclear extracts were incubated with 1 ng (10 4 cpm) labelled probe{+) or without added protein(-) and electrophoresed on 5% non-denaturing polyacrylamide gels as described in section 7.4.2. The gels were dried and exposed to X-ray film for 16 hrs. The positions of complexes I, II and III are indicated. The identity of the extra band which migrated slightly faster than complex I will be discussed in chapter 5. 
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4.3 DISCUSSION 
DNA-protein complexes which form on a 60 bp fragment of the 
human a2(I) procollagen promoter have been identified in 
nuclear extracts prepared from human fibroblasts. In a SV40-
transformed WI-38 cell line in which no a2 (I) procollagen 
chains are produced, an additional complex (complex II) was 
identified. Several lines of evidence suggested that the 
SVWI-38 specific complex II is a transcriptional repressor, 
which is partially or totally responsible for the 
inactivation of the a2{I) procollagen ~ene in this cell line 
(Chapter 2). Competition, electrophoretic mobility shift and 
methylation interference assays were used to identify two 
distinct but overlapping DNA-recognition elements within this 
region of the collagen promoter. Complex I, II and III 
proteins were shown to bind to these overlapping cis-
elements. 
Complex I proteins complexed with a 21 bp element extending 
from position -92 to -72, named the G/CBE. The methylation 
interference assays, mutation analysis and binding studies 
suggested that the inverted upstream GGAGG and the CCAAT 
boxes were the most important motifs for complex I formation. 
Deletion of a single cytosine which separates these two 
motifs also abolished or drastically reduced the formation of 
complex I. Al though the methylation interference patterns 
showed that the downstream GGAGG box formed part of the 
recognition element, mutation or replacement of thj.s motif 
did not significantly reduce complex I formation. 
Several distinct factors which bind to cis-elements 
containing a CCAAT box have been identified and this complex 
may well be a member of this family of CCAAT box binding 
factors. The complex I protein(s) has therefore been called 
a GGAGG/CCAAT box factor {G/CBF) which could be different 
from, related to or identical to previously identified CCAAT 
box binding factors (section 1.4). The specificity of a 
particular CCAAT box binding protein for a cis-element 
containing a CCAAT motif is probably determined by the 
flanking sequences. Comparison of the human G/CBE with the 
mouse CBF recognition element in the a2(I) procollagen 
promoters showed that these elements are highly homologous 
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(figure 4.16) (Hatamochi et. al., 1986; Maity et. al.,1988). 
Secondly, Framson and Bornstein (1993) have identified a NF-Y 
binding site in the human thrombospondin 1 (TSP-1) promoter 
which closely resembles the G/CBE in the human a2(I) 
procollagen promoter (figure 4.26). The TSP-1 NF-Y binding 
site contains an upstream inverted GGAGG-like box with a 
single base mismatch, an inverted CCAAT box and a downstream 
GGAGG box. The functionally important single cytosine spacer 
between the upstream GGAGG and CCAAT motifs is conserved in 
both promoters. These observations strongly suggest that 
G/CBF is identical or related to CBF (figure 4.16) and NF-Y 
and is therefore a member of the hetero-multimeric family of 
CCAAT box binding proteins (section 1.4.3). 
AACATTTTTCTGATTGGTTAAAAGTT Ea 
11 11 111111 I I 
AGCCCCAGCCCTCCCATTGGT-GGAGGCCC a2(I) Procollagen 
11 11 11111111 11111 
GCCCGGCCGCCGCCCATTGGCCGGAGGAAT Thrombospondin 1 
Fig 4.26 Comparison of the G/CBE with NF-Y sites. 
The G/CBE of the human a2(I) procollagen promoter was 
aligned with the NF-Y sites of the thrombospondin 1 
promoter (Framson and Bornstein, 1993) and the Ea 
promoter (MHC class II gene) (Dorn et. al., 1987) . 
The inverted CCAAT boxes are in bold, the GGAGG boxes 
are underlined, while the GGAGG-like box is doubly 
underlined. 
CBF (Karsenty .et. al., 1988) and NF-Y (Dorn et. al.~ 1987), 
however, bind to their respective cis-elements only if they 
contain an intact CCAAT motif. Since mutation of the CCAAT 
box in the G/CBE did not totally abolish G/CBF binding to 
this element, it is possible that G/CBF is not identical to 
CBF and NF-Y as suggested from their respective recognition 
elements. Since it was not possible to accurately determine 
the relationship of G/CBF with other CCAAT box binding 
factors from these experiments, 
(chapter 5) and eventual purification 
throw some light on this matter. 
the characterisation 
of this factor will 
The methylation interference patterns showed that complex II 
and III proteins bound to the same 12 bp cis-element between 
-78 and -67 (the CME). The CME ( 51 GGAGGCCCTTTT31 ) contains 
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the downstream GGAGG box, which loosely forms part of the 
G/CBE, and 3'-flanking sequences. Mutations of the GGAGG box 
and the cytosine dinucleotide at positions -72 and -73 
resulted in a drastic reduction or abolition of complex II 
and III formation. A reverse NF-kB-like consensus sequence, 
5 'GDRRADYccc3 ', (Lenardo and Baltimore, 1989) containing a 
single base mismatch is located between nucleotides -80 and 
-71. The core sequence of the CME is also located in this 
region of the promoter, suggesting that the CME could be a 
NF-kB-like recognition element. 
Another possibility is that 
complex II was SV40-large T 
Jarvis (1986) have shown that 
the protein component of 
antigen. Firstly, Butel and 
SV40 large T antigen is located 
in the nucleus of SV40-transformed cells, and secondly, the 
CME overlaps a large T antigen-like recognition sequence 
present in the a2 (I) procollagen promoter (Ghosh et. al., 
1981). Smith (1989) has shown that large T antigen is not 
responsible for complex II formation by competition gel shift 
analysis and by supershifting using an anti-large T antibody. 
The relationship between complexes II and III proteins and 
other DNA-binding proteins, like NF-kB, will be discussed in 
chapter 5. 
The reconstitution assays demonstrated that complex I, II and 
III proteins bound to their respective sites in a mutually 
exclusive manner. A possible mechanism for the repression of 
a2(I) procollagen gene expression by complex II proteins 
could be via competition with complex III proteins for 
binding to the CME. Binding of complex II to the CME also 
prevented G/CBF from binding to its recognition element. 
Barberis et. al. (1987) have identified a candidate 
repressor, designated the CCAAT displacement factor (CDF), 
which does not bind simultaneously with the CCAAT binding 
factor to their respective overlapping elements in the sea 
urchin histone H2B-1 promoter. CBF inhibits the binding of 
inhibitory factor 2 (IF2) to its recognition sequence in the 
mouse al(I) · procollagen promoter (Karsenty and 
de Chrombrugghe, 1989). Recently, Liu et. al. (1993) have 
demonstrated that the chicken ovalbumin transcription factor 
(COUP-TF) acts as a competitive repressor of the mouse 
lactoferrin gene. This gene, which is activated in response 
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to oestrogen stimulation, contains an overlapping COUP-TF and 
oestrogen receptor binding elements in its promoter. 
These results also indicate that different trans-acting 
factors are involved in the regulation of the human and mouse 
a2(I) procollagen gene. The CME is not present in the mouse 
promoter (figure 4.16) and it is also not clear if the mouse 
CBF is related to G/CBF. It is therefore possible that there 
are different species-dependent mechanisms responsible for 
regulating the expression of this gene. Certain recognition 
elements in the human, hamster and chicken TK promoters are 
not present in the mouse promoter (Arcot et. al., 1989; 
Lieberman et. al., 1988). The chicken and human a2(VI) 
collagen promoters are also structurally different (Koller 
et. al., 1991; Saitta et. al., 1992), suggesting that 
species-dependent mechanisms may be operative in the 
regulation of this gene. 
In summary, two distinct overlapping regulatory elements, the 
GGAGG/CCAAT box element (G/CBE) and collagen modulating 
element (CME), have been identified in the -so bp region of 
the human a2 (I) procollagen promoter. Collagen producing 
cell lines contain only one type of CME binding complex, 
whereas SVWI-38 cells contain two. Evidence indicates that 
the second SVWI-38 complex acts as a repressor of collagen 
synthesis (V. Leaner, unpublished data). 
5.1 INTRODUCTION 
CHAPTER 5 
CHARACTERIZATION OF THE 
PROMOTER BINDING PROTEINS 
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Based on their structure, sequence-specific DNA-binding 
proteins can be divided into two broad categories. The first 
category includes transcription factors comprising a single 
polypeptide containing both DNA-binding and regulatory 
domains. Factors such as Spl (Kadonaga et. al., 1987), Octl 
(Sturm et. al., 1988) and oct2 (Clerc et. al., 1988) can bind 
to their recognition sequences as monomers and/or 
homomultimers. Alternatively, two or more distinct 
polypeptides may interact with each other to produce a 
functionally active factor, making up the second category of 
transcription factors. The fos-jun heterodimer, which binds 
to the AP-1 consensus sequence is a well known example of 
this hetero-multimeric category of transcription factors 
(Chiu et. al., 1988). 
Before attempting to purify a candidate novel sequence-
specific transcription factor or clone its gene~ it is 
advisable to first determine if it is homologous or related 
to previously characterised factors. This is essential 
because; (1) a large number of transcription factors have 
been purified and characterised to date; (2) structurally 
different factors have been shown to bind to the same or 
related promoter elements (section 1.4) and (3) the same 
protein can bind to apparently unrelated elements (Pfeifer 
et. al., 1987a). A variety of techniques, including 
analytical gel filtration (Siegel and Monty, 1966), density 
gradient centrifugation (Martin and Ames, 1961) , uv-
crosslinking (Chodosh et. al., 1986), Southwestern blotting 
(Bowen et. al., 1980) and protein-mediated Southwestern 
blotting (Matsuno et. al., 1989), have been developed and 
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used extensively to characterise DNA-binding proteins in 
crude extracts. 
Physico-chemical characteristics include Stokes radii and 
sedimentation coefficients using gel filtration and sucrose 
or glycerol gradient centrifugation respectively. An 
accurate determination of both the molecular weight and 
frictional ratio can be calculated from these parameters if 
the partial specific volume of the protein can be reasonably 
estimated. This approach has been used to determine the 
native molecular mass of a murine CCAAT box binding factor, 
a-CPl (Kim et. al., 1988 and Kim and Sheffery, 1990). 
The characterisation of trans-acting factors which bind to 
the GGAGG/CCAAT box (G/CBE) and collagen modulating (CME) 
elements is described in this chapter. The techniques 
described above were used to determine the molecular weights 
and structural complexities of these proteins in crude or 
partially purified SVWI-38 or CT-1 nuclear extracts. The 
results were compared with published data on the 
transcription factors in order to determine whether the G/CBE 




5.2.1 NATIVE MOLECULAR WEIGHT DETERMINATION 
Analytical gel filtration (Siegel and Monty, 1966) on 
Sephacryl S-3 oo and glycerol gradient sedimentation (Martin 
and Ames, 1961) were used to determine the Stokes radii and 
sedimentation coefficients of complex I, II and III proteins 
in crude nuclear extracts under non-denaturing conditions. 
5.2.1.1 ANALYTICAL GEL FILTRATION 
Sephacryl S-300 gel filtration columns were packed and 
calibrated and used for nuclear extract fractionation as 
described in Materials and Methods (7.6.1). The 
electrophoretic mobility shift assay (EMSA) was used to 
identify DNA-binding activity in the various fractions using 
fragment E (see section 2.2.4) as a probe (7.4.2). 
In the absence of a detergent such as nonident P-40 (NP-40), 
no separation of the complex I, II and III proteins was 
achieved (figure 5.1). This was probably due to aggregation 
of proteins, since the inclusion of 0.1% NP-40 to the samples 
resulted in good separation of the complexes (compare figure 
5.1 with figures 5.2a and 5.3b). It was not necessary to add 
detergent to the elution buff er, addition to the samples 




the larger complex I proteins eluted first 
complex II proteins and finally the protein 
of complex III (figure 5.3). Identical elution 
volumes were obtained for the proteins involved in the common 
SVWI-38 and CT-1 complexes (figures 5.2 and 5.3). The trace 
amounts of complex II proteins, which were present in some 
batches of CT-1 extracts also eluted from the column with 
elution volumes similar to SVWI-38 complex II proteins. 
The Kav of each complex was calculated from the elution (Ve), 
void (Vo) and total (Vt) volumes as summarised in table 5.1. 
The Stokes radii were determined using a semi-logarithmic 
plot of Stokes radius versus Kav (figure 5.8a). Under non-
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FRACTION NUMBER 




Fig 5 .1 Fractionation of nuclear extracts by 
Sephacryl S-300 gel filtration. crude SVWI-38 nuclear 
extracts were fractionated on a 1.6 cm X 100 cm column 
of Sephacryl S-300 in buffer CB containing 30% glycerol 
and 0.1 M KCl (section 7.6.1). The DNA-binding 
activity in 10 ul of every 5th fraction was assayed 
using 1 ng ( 104 cpm) of end-labelled fragment E as a 
probe (7.4.2). The samples were electrophoresed on 5% 
non-denaturing polyacrylamide gels at 40 c using 
0.5 X TBE. The dried gels were exposed to X-ray film 
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Fig 5.3 Analytical gel filtration of SVWI-38 extracts 
on Sephacryl S-300 in the presence of NP-40. (A) Crude 
nuclear extracts were applied to the column in 
buffer CB containing 0.1 M KCl, 30% glycerol and 0.1% 
NP-40 and processed as described in the legend to 
figure 5.1. (B) Histograms of the relative DNA 
activities in the collected fractions. The 
autoradiograms were scanned and the results for 
complexes I, II and III expressed as % relative 
intensity of each fraction. 
TABLE s.1 Analytical gel filtration of 
SVWI-38 and CT-1 extracts. A Sephacryl S-300 
column was packed and calibrated as described 
in section 7. 6 .1. The Stokes radii (Rs) , 
molecular weights (MW), elution volumes (Ve), 
calculated Kq.V and the standard deviations 
of n determinations are tabulated for the 
protein standards. The void (V 0 ) and total (Vt) volumes were determined using blue 
dextran 2000 and thymidine respectively. 
crude nuclear extracts were fractionated as 
described in section 7.6.1. The 
electrophoretic mobility shift assay was used 
to quantitate the DNA-binding activity in 
each fraction using fragment E (nucleotides 
-110 to -46). The Kav of each complex was 
calculated from their Ve, the V0 and Vt and the Stokes radii determined from the semi-
logarithmic plot of Stokes radius versus Kav· 
STANDARDS/SAMPLES Ve "av Rs MW n 
(ml) (nm> (ICDa) 
STANDARDS 
Thyroglobin 76.8 t D.5 0.113 t 0.004 8.5 669 2 
Ferritin 87.5 t 1.5 0.211 t 0.014 6.1 440 3 
Catalase 99.4 t 1.0 0.320 t 0.009 5.22 232 3 
Aldolase 103.4 t 0.3 0.357 t 0.003 4.81 158 3 
BSA 113.7 t 1.3 0.451 t 0.012 3.55 68 2 
Ovalbunin 123.0 t 0.1 0.537 t 0.001 3.05 43 2 
Blue Dextran (Vo) 64.5 t 0.8 10 
Thymidine (Vt) 173.5 t 0.2 2 
SAMPLES 
C~lex I 99.5 t 0.3 0.321 t 0.003 5.22 t 0.04 232 4 
C~lex II 108.6 t 0.3 0.405 t 0.003 4.12 t 0.03 107 3 
C~lex Ill 120.7 t 0.1 0.516 t 0.001 3.15 t 0.01 50 2 
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denaturing conditions, complex I and III proteins from 
SVWI-38 and CT-1 extracts eluted from the column with Stokes 
radii of 5.22 ± 0.04 nm and 3.15 ± 0.01 nm respectively, 
while the SVWI-38 complex II factor had a Stokes radius of 
4.12 ± 0.03 nm. The Stokes radii of complexes I, II and III 
were comparable to spherical proteins of 232, 107 and 50 KDa 
respectively. The protein distribution of selected SVWI-38 
fractions involved in either complex I, II or III formation 
(labelled pools I, II or III respectively in figure 5.4) were 
checked on 10% SDS-polyacrylamide gels after they had been 
concentrated by acetone precipitation as described in section 
7.5. As shown in figure 5.4 these fractions still contained 
large amounts of contaminating polypeptides. 
5.2.1.2 GLYCEROL GRADIENT SEDIMENTATION 
The sedimentation coefficients (s20 ,w) of the three complexes 
were determined on linear 15 to 40% glycerol gradients as 
described in section 7.6.2. The linearity of the gradients 
were checked by adding 100 ul O. 4% phenol red to the 40% 
glycerol solution before pouring the gradient. After 
centrifugation, fractions were collected (section 7.6.2) and 
the relative concentration of phenol red in the fractions was 
measured at 400 nm (Siegel and Monty, 1966). As shown in 
figure 5.5 the phenol red and therefore the glycerol 
concentration was found to be linear. 
About half a milligram of crude nuclear extracts were 
centrifuged through the gradients using 0.5 mg ovalbumin as 
an internal standard as described in Materials and Methods 
(7.6.2). The DNA-binding activity in the collected fractions 
were quantitively measured by EMSA with fragment E as a probe 
( 7 . 4. 2) . The percentage glycerol in the fractions where 
complex I, II and III activities peaked was calculated for 
both CT-1 (figure 5.6) and SVWI-38 (figure 5.7) extracts and 
are tabulated (table 5. 2) . Sedimentation coefficients of 
4. 9 ± o. 4, 3. 9 ± o .1 and 3 .1 ± o. 3 were calculated for the 
protein components of complexes I, II and III respectively 
(figure 5.8b). 
The following equation was used to estimate the molecular 
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Fig s. s Linearity of the glycerol gradients. One hundred ul of O. 4% phenol red was added to the 40% glycerol solution prior to preparing gradients . . After centrifugation , the fractions were collected as described in section 7.6.2 and the intensity of phenol red in the fractions measured at 400 nm. The plot of fraction number versus absorbance was linear, indicating the linearity of the gradients. 
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Fig 5.6 Glycerol gradient sedimentation of CT-1 nuclear extracts. (A) Half a milligram of crude nuclear extract and 0.5 mg ovalbumin (internal standard) in a final volume of 100 ul was layered onto 15 to 40% linear glycerol ~adients and centrifuged for 16 hrs at 53 000 rpm and 4 Cina Beckman SW65 rotor. Three-drop fractions were collected from the bottom of each centrifuge tube and the DNA-binding activity in 10 ul of each fraction was quantitated by the EMSA as described in section 7 . 4. 2. The positions of complexes I and III are indicated. (B) Histograms of the relative DNA-binding activities in each fraction. The autoradiograms were scanned and the relative intensity of each fraction was plotted. The percentage glycerol in the fractions where complex I and III DNA-binding activities peaked was calculated as described in section 7.6.2. 
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Fig 5.7 Glycerol gradient sedimentation of SVWI-38 nuclear extracts. (A) Half a milligram of crude nuclear extract and 0.5 mg ovalbumin (internal standard) in a final volume of 100 ul was layered onto the gradients, centrifuged, fractions collected and assayed as described in the legend to figure 5.6. 
(B) Histograms of the relative DNA-binding activities in each fraction. The autoradiograms were scanned and the relative intensity of each fraction was plotted. The percentage glycerol in the fractions where the DNA-binding activity of the three complexes peaked was calculated as described in section 7.6.2. 
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Fig s.s stokes radii and sedimentation coefficient determination. Sephacryl S-300 gel filtration columns and 15 to 40% linear glycerol gradients were calibrated and used for fractionation of nuclear extracts as described in Materials and Methods ( 7 • 6. 1 and 7 . 6. 2) . (A) The gel filtration column was calibrated using protein standards and the log of the Stokes radius (thyroglobin, 8.50 nm; ferritin, 6.10 nm; catalase, 5.22 nm; aldolase, 4.81 nm; BSA, 3.55 nm and ovalbumin, 3.05 nm) versus kav for each protein was plotted, where kav=(Ve-Vo)/(Vt-Vo). The Stokes radii of complexes I, II and III were determined from the curve. (B) Glycerol gradient calibration curve was prepared by plotting the percent glycerol ( see section 7. 6. 2) in the fractions where the standard proteins sedimented versus sedimentation coefficient (catalase, 11.3 s; BSA, 4.4 s; ovalbumin, 3.7 s; carbonic anhydrase, 3.2 s and lysozyme, 1. 9 S). The sedimentation coefficients of the three complexes were deteri_nined from the curve. 
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alone (Martin and Ames, 1961): 
(Equation 1) 
where MWsample and MWstd are the molecular weights of the 
samples and protein standards and ssample and Sstd are their 
respective sedimentation coefficients. When BSA was used as 
the standard, complex I, II and III proteins had native 
molecular weights of 80, 57 and 40 KDa respectively. 
5.2.1.3 CALCULATION OF NATIVE MOLECULAR WEIGHTS 
Since there was a discrepancy when the molecular weights of 
the protein components in the three complexes were calculated 
separately from the gel filtration and sedimentation results, 
the native molecular weights and the frictional ratios of the 
proteins were determined from the Stokes radii and 
sedimentation coefficients using the following equations 





0 = a/(3vM/4nN) 1/ 3 
is the molecular weight, f If 0 






(1.0 X 10-3 
kg/m/s) (Resnick et. al., 1993), N is Avogadro's number 
(6.022 X 1023 mol-1), a is the calculated Stokes radius, sis 
the calculated sedimentation coefficient (1 Svedberg unit 
(S) = 10-13 sec), vis the partial specific volume and p is 
the density of H2o at 20° C (0.998 g/ml) (Resnick et. al., 
1993). If the partial specific volume is assumed to be 0.725 
cm3 /g (Kim and Sheffery, 1990), then the native molecular 
weights of complexes I, II and III under non-denaturing 
conditions would be 105, 66 and 40 KDa respectively. The 
frictional ratios of complexes I, II and III were calculated 
to be 1. 68, 1. 54 and 1. 40 respectively. The ratio of the 
long to the short axes (axial ratio) of the factors would 
therefore be approximately 15, 10 and 8 if they were 
ellipsoid (Freifelder, 1982). 
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5.2.2 POLYPEPTIDE COMPOSITION OF THE COMPLEXES 
In order to determine whether the factors which bound to the 
G/CBE and CME boxes were monomers, homo- or heteromultimers, 
uv-crosslinking experiments (Chodosh et. al., 1986), 
analytical gel filtration under denaturing conditions and 
Southwestern blotting (Bowen et. al., 1980) methodologies 
were employed to assay crude or partially purified SVWI-38 or 
CT-1 nuclear extracts. 
5.2.2.1 UV-CROSSLINKING 
UV-crosslinking data were used to determine the molecular 
weights of the polypeptide components which are in close 
contact with the DNA. Double-stranded, 37-mer 
oligonucleotide A (see figure 4.2), containing the G/CBE and 
5'-portion of the CME, was substituted with bromodeoxyuridine 
and 32P-deoxycytidine and used as a probe in electrophoretic 
mobility shift assays as described in Materials and Methods 
(7.6.3). As shown in figure 5.9, the replacement of 
thymidine with bromodeoxyuridine did not affect the ability 
of the oligonucleotide to form complex I, II or III proteins. 
DNA-Protein complexes on the bromodeoxyuridine substituted 
DNA were resolved on non-denaturing polyacrylamide gels, UV-
crosslinked in situ (Wu, C. et. al., 1987), visualised by 
autoradiography, the bands excised, the DNA-protein complexes 
eluted and resolved on 10% SDS-polyacrylamide gels as 
described in sections 7.6.3.2 and 7.6.3.5. Complex I 
comprised proteins with a molecular weight of 120 KDa in both 
SVWI-38 and CT-1 (figure 5. lOa). Occasionally two faint 
bands of 240 and 50 KDa were present (figure 5.lOb). 
Proteins of 78 and 69 KDa were crosslinked in complex II, 
while identical protein smears of 30 to 46 KDa were 
identified in both SVWI-38 and CT-1 complex III. 
Since it was not possible to accurately determine the 
apparent molecular weights of labelled complex III proteins 
using the above method, Sephacryl S-300 fractions, containing 
only complex III DNA-binding activity, were UV-crosslinked to 
Bromodeoxyuridine and 32P-deoxycytidine labelled 
oligonucleotide F and resolved on SDS-polyacrylamide gels. 




Fig 5.9 DNA-protein complex formation with bromodeoxyuridine substituted DNA. 40 ug of crude SVWI-38 and CT-1 nuclear extracts were incubated with 10 ug of poly didC, and 10 ng (105 cpm) of Br-dUTP and 32P-dCTP labelled oligonucleotide A (nucleotides -107 to -71) as described in section 7.6.3. Duplicate samples were electrophoresed on 5% non-denaturing polyacrylamide gels at 40 C in 0.5X TBE. The wet gels were exposed to X-ray film at 40 C between 2 to 16 hours. The position of complexes I, II and III are indicated. 
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Fig s.10 Polypeptide composition of DNA-protein 
complexes. (A) SVWI-38 and CT-1 nuclear extracts were 
incubated with Br-dUTP and 32P-dCTP labelled probe and resolved on 5% non-denaturing polyacrylamide gels as described in the legend of figure 5.9. The DNA-protein 
complexes were UV-cross linked in situ, visualised by autoradiography, the bands excised, the DNA-protein complexes eluted and resolved on 10% SDS-polyacrylamide gels as described in section 7. 6. 3. 2. The molecular weight markers and crosslinked products are indicated in KDa. The lane labelled FP is the free probe. (B) 
UV-crosslinked SVWI-38 (SV) and CT-1 {CT} complex I proteins resolved on a 10% SDS-polyacrylamide gel. 
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The 47-mer oligonucleotide F, extending from nucleotides -107 
to -61, was chosen for these experiments because it contained 
all the recognition sequences, the complete CME, 5 ' - and 
3'-flanking sequences. Sephacryl S-300 fractions containing 
only complex I or II DNA-binding activities were also assayed 
with this oligonucleotide to confirm the previous results. 
In order to determine the optimal time required for UV-
irradiation, binding reactions were irradiated for increasing 
lengths of time (O to 60 min) as described in section 
7. 6. 3 . 3 . The amounts of incorporated label increased when 
SVWI-38 complex I was irradiated for longer time intervals 
(figure 5. lla). As expected, no crosslinked polypeptides 
were generated when UV-irradiation was omitted. The number 
and relative intensities of the four labelled species of 234, 
145, 89 and 79 KDa did not change with the different 
irradiation times tested. It was decided to irradiate the 
binding reactions for 15 min prior to SDS-polyacrylamide gel 
electrophoresis. The 145 KDa band was always the strongest, 
while the 234 KDa band was very faint or sometimes not even 
present. Occasionally an extra band which migrated faster 
than the 145 KDa complex was detected in both SVWI-38 and 
CT-1 extracts (figure 5.12a). 
On average the bands generated by cross linking 
oligonucleotide F to G/CBF were 25 KDa larger than those 
crosslinked to the shorter oligonucleotide A probe (145 
versus 120 KDa and 79 versus 50 KDa). The decrease in the 
mobility of crosslinked G/CBF-oligo F complex bands was 
therefore probably due to the additional DNA. In an attempt 
to minimise this effect the samples were digested with 
nucleases prior to electrophoresis as described in section 
7. 6. 3. 4. Unfortunately, as shown in figure 5. llb, all the 
bands were abolished when the samples were treated with 
nucleases. 
Since the native molecular weight of G/CBF was calculated to 
be 105 KDa (section 5.2.1.3), the predominant 120 and 145 KDa 
bands, produced when partially purified complex I proteins 
were cross linked to oligonucleotides A and F respectively, 
probably contained a single G/CBF. As explained previously, 
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Fig s.11 optimisation for uv-crosslinking. (A) 
Partially purified SVWI-38 complex I proteins 
(Sephacryl S-300 fractions) were crosslinked (UVCL) to 
oligonucleotide F (nucleotides -107 to -61) as 
described in section 7. 6. 3. 3. Briefly the binding 
reactions were irradiated for increasing lengths of 
time (0 to 60 min), resolved on 8% SDS-polyacrylamide 
gels, dried and exposed to X-ray film. The molecular 
weight markers (left) and crosslinked products (right) 
are indicated in KDa. (B) Selected UV-cross linked 
(UVCL} samples (30 min) were treated with nucleases 
(DNase and/or MNase) prior to SOS-PAGE (7.6.3.3). Y 
and N represent treated and untreated samples 
respectively. The molecular weight markers and 
crosslinked products are indicated in KDa. 
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Fig s.12 uv-crosslinking analysis of complex I, II and 
III proteins. Partially purified SVWI-38 and CT-1 
complex I, II and III proteins (Sephacryl S-300 
fractions) were uv-crosslinked to oligonucleotide F 
(nucleotides -107 to -61) as described in section 
7.6.3.3, resolved on SDS-polyacrylamide gels, dried and 
exposed to X-ray film. The molecular weight markers 
(left) and crosslinked products (right) are indicated 
in KDa. (A) UV-crosslinked complex I proteins resolved 
on an 8% gel, (B) UV-cross linked complex II proteins 
resolved on a 10% gel and (C) complex III proteins 
resolved on a 12% gel. 
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bands were most likely degradation products of G / CBF. The 
extra 89 KDa species identified when this factor was 
crosslinked to oligonucleotide F could either be a 
degradation product or a species where only some of the 
components of G/CBF were crosslinked to the probe. The 
presence of the weak 200 and 234 bands coupled to 
oligonucleotides A and F respectively, implied that the 
stoichiomet~y of the various protein components in complex I 
could be complex. It is tempting to speculate that there are 
at least two forms of complex I where the 109 KDa G/CBF 
( section 5. 2. 1. 3) can bind to its DNA-element either as a 
monomer or homodimer to produce protein complexes of about 
120 and 230 KDa respectively. 
Occasionally, an extra complex which migrated slightly faster 
than complex I, was present when nuclear extracts were 
assayed by electrophoretic mobility shift assays using 
oligonucleotide F (figures 4.19, 4.24 and 4.25). Figure 4.19 
also shows that this extra complex was always present and 
much stronger when an oligonucleotide containing a mutated 
CCAAT box, MUT-CCAAT, was used in the binding studies. When 
this extra complex was crosslinked to oligonucleotide A and 
resolved on 10% SDS-polyacrylamide gels, two bands with 
molecular weights of 120 and 50 KDa were identified (figure 
5 .13). The 200 KDa band was not detected, suggesting that 
this complex was structurally a less complex form of 
complex I. This result supports the hypothesis that the 
stoichiometry of G/CBF varies to produce at least two forms 
of the complex I. 
Three predominant bands of 105, 85 and 34 KDa were identified 
when partially purified Sephacryl S-300 fractions containing 
only complex II DNA-binding activity were crosslinked to 
oligonucleotide F and resolved on 10% SDS-polyacrylamide gels 
(figure 5 .12b). Minor bands ranging between 46 and 72 KDa 
where also identified. The 72 and a 56 KDa species were 
always the sharpest in this region of the gel. Occasionally, 
an extra band which migrated slightly faster than the 56 KDa 
species was also present. Assuming the extra 10 bp of 
oligonucleotide F contributed about 25 KDa to the apparent 
molecular weights of the bands (in the form of conformation 











Fig 5.13 Polypeptide composition of complex I and 
"minor" complex I proteins. Crude SVWI-38 nuclear 
extracts were uv-crosslinked to oligonucleotide A as 
described in the legend to figures 5.9 and 5.10. 
complex I (lane 1) and a slightly faster migrating 
complex ("minor" complex I) (lane 2), were excised, the 
DNA-protein complexes eluted and resolved on 10% SDS-
polyacrylamide gels as described in section 7. 6. 3. 2. 
The molecular weight markers (left) and crosslinked 
products (right) are indicated in KDa. 
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to the 78 and 69 KDa bands generated when the shorter 
oligonucleotide A was used in the assay. Since only two 
bands were identified when crude SVWI-38 extracts were 
assayed with oligonucleotide A, the minor bands within the 46 
to 72 KDa range were probably due to degradation of 
complex II proteins during gel filtration chromatography. 
Since both the 78 and 69 KDa bands (figure 5.10a) are 
slightly larger than the native molecular weight of 66 KDa 
for complex II protein(s) as determined from the Stokes 
radius and sedimentation coefficients (section 5. 2 .1), this 
protein could be a monomer, where the smaller band is a 
degradation product. Alternatively, the presence of smaller 
bands could be an indication that the factor is a hetero-
multimer where the protein components of the 34 and 85 KDa 
bands could dimerise to form the 105 KDa crosslinked product. 
When oligonucleotide F was crosslinked to partially purified 
complex III proteins, two products with apparent molecular 
weights of 56 and 44 KDa where identified in both cell lines 
(figure 5.12c). Both these bands are slightly larger than 
the native molecular mass of 40 KDa for the protein component 
of complex III (section 5.2.1). This factor could also be a 
monomer or a mul timer where all the l)Olypeptide components 
are in direct contact with and probably crosslinked to the 
DNA. Alternate splicing of a single gene product or 
degradation during purification could explain the presence of 
the two bands. 
5.2.2.2 DENATURING GEL FILTRATION 
Since it wasn't clear from the UV-crosslinking experiments 
whether complex I, II or III proteins were mul timers or 
monomers, analytical gel filtration experiments were repeated 
under denaturing conditions to obtain more insight into the 
structural complexity of these factors. crude SVWI-38 
extracts were fractionated in the presence of 0.8 M KCl in an 
attempt to disrupt all protein-protein interactions so that 
each protein component would elute independently (Kim 
et. al. , 1988) . 
One to 2 mg of crude SVWI-38 extract containing 0.8 M KCl and 
O. 25% NP-40 in a final volume of 400 ul was loaded onto a 
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Sephadex G-200 column and fractionated with buffer CB 
containing 0.8 M KCl and 0.02% sodium azide as described in 
section 7.6.1. The bulk of the loaded protein eluted in the 
void volume (figure 5.14a). Five ug BSA was added to every 
200 ul fraction collected to minimise protein loss during 
dialysis. Every 5th fraction was dialysed overnight against 
buff er CB ( section 7. 7) containing O .1 M KCl to remove the 
salt and restore DNA-binding activity. The inset in 
figure 5.14a shows that complex II DNA-binding activity 
eluted first, followed by complex I and finally complex III 
activities. 
The Stokes radius of each complex was calculated as described 
previously (section 5.2.1.1) and shown in table 5.3 and 
figure 5.14b. Under denaturing conditions, SVWI-38 complex 
I, II and III proteins had Stokes radii of about 3.68, 4.24 
and 3.17 nm respectively. The Stokes radii of complex II and 
III proteins did not change significantly after fractionation 
in the higher salt concentration, suggesting that these 
factors are monomers. An alternative explanation is that 
their non-covalent protein-protein interactions were not 
disrupted under these conditions as have been shown for the 
protein-protein interaction between the a and B subunits of 
a-CPl (Kim and Sheffery, 1990). The decrease in the Stokes 
radius of G/CBF (complex I) from 5.22 nm to 3.67 nm confirmed 
that the factor is multimeric. Under these conditions the 
various components of the factor sedimented independently and 
G/CBF activity is detected in those fractions where the 
components co-elute. 
5.2.2.3 SOUTHWESTERN BLOTTING 
Both the UV-crosslinking and denaturing gel filtration data 
suggested that the protein components of complexes II and III 
could be monomeric. In order to verify this, Southwestern 
blotting experiments were done as described in Materials and 
Methods (section 7.6.4). 
Crude SVWI-38 and CT-1 nuclear extracts were resolved on 12% 
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Fig 5.14 Gel filtration of SVWI-38 nuclear extracts on Sephadex G-200 in the presence of o.a M KCl. (A) One to two mg crude nuclear extracts in a final volume of -400 ul buffer CB containing 0.8 M KCl and 0.25% NP-40 were applied to a 1 cm X 60 cm column and fractionated with CB containing o. 8 M KCl and O. 02% sodium azide at a flow rate of 3 ml/cm2/h. Two hundred ul fractions were collected and every 5th fraction dialysed against CB containing 0.1 M KCl. The DNA-binding activity in each dialysed fraction was determined by EMSA using fragment E (nucleotides -110 to -46) as a probe (inset). The positions of complexes I, II and III are indicated. (B) The gel filtration column was calibrated using protein standards and the log of the Stokes radius (table 5. 3) versus kav of each standard protein was plotted. The Stokes radii of complexes I, II and III under denaturing conditions were determined from the curve. 
TABLE 5.3 Denaturing analytical gel 
filtration of SVWI-38 nuclear extracts. 
Proteins were fractionated on Sephadex G-200 
columns as described in section 7. 6. 1. The 
Stokes radii (Rs), molecular weights (MW), 
elution volumes (Ve), calculated Kav and the 
standard deviations of n determinations are 
tabulated. The void (V0 ) and total (Vt) volumes were determined using blue dextran 
2000 and thymidine respectively. Crude 
nuclear extracts were fractionated in the 
presence of 0.8 M KCl as described in section 
7.6.1. Every 5th fraction was dialysed 
against buff er CB containing O .1 M KCl to 
restore DNA-binding activity. The DNA-
binding activity in these fractions was 
quantitated by EMSA using fragment E as a 
probe. The K v of each complex was 
calculated from tteir Ve, the V0 and Vt and the Stokes radii determined from the semi-
logarithmic plot of Stokes radius versus Kav 
of the standard proteins. 
STANDARDS/SAMPLES Ve "av Rs MW n 
(ml) (nm) (ICDa) 
STANDARDS 
Catalase 18.76 :t 0.09 0.237 :t 0.003 5.22 232 3 
Aldolase 19.60 :t 0.42 0.271 :t 0.018 4.81 158 2 
BSA 23.50 :t 0.77 0.432 :t 0.032 3.55 68 4 
Ovalb\.min 26.80 :t 0.70 0.568 :t 0.029 3.05 43 3 
Blue Dextran (Vo) 13.02 :t 0.16 7 
Thymidine (Vt) 37.27 :t 0.48 6 . 
SAMPLES 
C~lex I 23.60 0.436 3.68 76 2 
C~lex II 21.53 0.351 4.24 117 1 
C~lex III 25.77 0.527 3.17 49 2 
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nitrocellulose membranes. The membranes were blocked in 
buffer containing either BSA (1% or 5%) or Carnation nonfat 
milk powder ( o. 5% or 1%) to determine the optimal blocking 
conditions. The blocked membranes were probed with 
32P-labelled fragment E (figure 2.8) in buffer containing 
0.25% of either BSA or Carnation nonfat milk powder. Three 
bands of molecular weights 120, 46 and 42 KDa were identified 
when the membranes were blocked with 1 or 5% BSA 
(figure 5.15), whereas only the 120 KDa polypeptide was 
obtained when blocking with 0.5% Carnation nonfat milk 
powder. Filters blocked with buffer containing 1% Carnation 
nonfat milk powder failed to bind any probe due to the 
coating of all the sites and possibly introducing steric 
hindrance. If membranes blocked with 0.5% Carnation nonfat 
milk powder were washed less stringently and exposed to X-ray 
film for longer periods of time four polypeptides with 
molecular weights of 120, 46, 42 and 34 KDa were observed 
(figure 5.16b). 
Membranes were stained with amido black as described in 
section 7.6.4 to check for the efficiency of protein 
transfer. As shown in figure 5.16c, transfer occurred evenly 
across the membranes. Only trace amounts of the large 
molecular weight polypeptides remained in the gels after 
electroblotting (data not shown). 
Since the 46, 42 and 34 KDa bands were present in both 
SVWI-38 and CT-1 nuclear extracts and since they ar~ in the 
size range for complex III proteins, they could be the 
protein component of this complex. The difference in the 
molecular weights of the 46 and 34 KDa bands (12 KDa) and the 
two bands produced in the UV-crosslinking experiments 
(figure 5.12c) were identical (56 KDa to 44 KDa). These data 
therefore suggests that complex III proteins are monomers and 
that the smaller species are probably degradation products 
which still retain DNA-binding activity or modified forms. 
The data also suggested that the SVWI-38 specific complex II 
proteins are hetero-multimers because no SVWI-38 specific 
bands were identified in these experiments. Alternatively, 
if complex II binds as a monomer, then the proteins did not 
renature after electrophoresis. The presence of the very 












Fig 5.15 Optimising conditions for the Southwestern 
blotting experiments. Crude SVWI-38 and CT-1 nuclear 
extracts were resolved on 12% SDS-polyacrylamide gels, 
the gels renatured and the proteins transferred to 
nitrocellulose membranes as described in section ·7. 6. 4. 
The filters were incubated in 50 ml of blocking buffer 
(section 7.7) containing either 1% or 5% BSA or 0.5% or 
1% Carnation nonfat milk powder (NFMP) for at least 2 
hours at room temperature with gentle shaking. The 
blocked membranes were probed with 32P-labelled fragment 
E (nucleotides -110 to -46) in buffer containing either 
0.25% of either BSA or NFMP, washed (section 7.6.4) and 
exposed to X-ray film for between 16 hrs and 3 days. The 
molecular weight markers ( left) and bands (right) are 
indicated in KDa. 
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Fig s .16 southwestern blotting analysis of SVWI-38 and 
CT-1 nuclear extracts. (A) Crude nuclear extracts were 
resolved on 12% SDS-polyacrylamide gels, the gels 
renatured, the proteins transferred to nitrocellulose 
membranes and used in binding assays using fragment E as 
a probe as described in Materials and Methods 
(section 7. 6). (B) Filters processed as above but were 
washed less stringently (shorter period of time) and 
exposed for longer periods of time. (C) After the crude 
nuclear extracts were resolved on 12% SDS-polyacrylamide 
gels and transferred to nitrocellulose membranes, the 
membranes were stained with 0.3% amido black in 20% 
ethanol and 7% acetic acid for 15 min with gentle shaking and destained in warm (50o C} 10% acetic acid. 
-
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not be explained and these results should therefore be 
interpreted with caution (see section 5.3). 
5.2.3 Protein-protein interactions are not DNA-dependent. 
The denaturing gel filtration data showed that the 109 KDa 
G/CBF was a multimer. A 120 KDa and a 145 KDa band was 
observed when this factor was UV-cross linked to 
oligonucleotides A and F respectively. These bands were 
probably generated when a single 109 KDa G/CBF protein-
complex was uv-crosslinked to the respective 
oligonucleotides. Occasionally extra weak bands of 200 and 
2 3 4 KDa were observed when oligonucleotides A and F 
respectively were used in the assays. These results 
suggested that they could be multiple combinations of factors 
in the G/CBF-DNA complex (different forms of the complex). 
To test whether DNA could mediate the multimerisation of 
complex I, II or III proteins, DNA-protein complexes were 
assayed by gel filtration on Sephacryl S-300 column. 
About 40 ug of SVWI-38 or CT-1 nuclear extracts were bound 
with 20 ng (2 X 105 cpm) 32P-labelled oligonucleotide Fin a 
final volume of 80 ul containing 20 ug poly didC.poly didC as 
described in section 7.4.2. The amount of probe chosen for 
these experiments was such that all the probe would be bound 
to proteins. Half a ml of buffer CB containing 30% glycerol 
and O • 1 % NP-4 O was added to the binding reactions, layered 
onto a calibrated Sephacryl S-300 column and fractionated as 
described in Materials and Methods (section 7.6.1). Figure 
5.17, shows that two overlapping DNA-protein peaks (a and b) 
eluted from the column with identical elution volumes when 
comparing SVWI-38- and CT-1-0ligo F complexes. The Kav of 
each peak (table 5.4) was calculated as described previously 








have Stokes radii 
Kav 
of 
5.89 ± 0.09 and 4.09 ± 0.08 nm which are comparable to 
spherical proteins of 295 and 107 KDa respectively. The 
Stokes radius of oligonucleotide F was determined by 
processing 2 X 105 cpm free oligonucleotide over the column 
{peak c in figure 5. 17) . The Stokes radius of peak c was 
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TABLE 5.4 Analytical gel filtration of 
SVWI-38 and CT-1 DNA-protein complexes. A 
Sephacryl S-300 column (100 cm X 1. 6 cm) 
was packed and calibrated as described in 
section 7. 6 .1. The Stokes radii (Rs) , 
molecular weights (MW), elution volumes 
(Ve), calculated Kav and standard 
deviations for n determinations are 
tabulated. The Vo and Vt were determined 
using blue dextran 2000 and thymidine 
respectively. The elution ·profiles of 
SVWI-38- and CT-1-protein-oligo F 
complexes and free oligonucleotide F were 
determined as described in the legend to 
figure 5.17. The Kav of peaks a, band c 
was calculated from their Ve, the Vo and 
Vt and the Stokes radii determined from 
the semi-logarithmic plot of Stokes radius 
versus Kav. 
STANDARDS/SAMPLES Ve Kav Rs MW 
(ml) (nm) (KDa) 
STANDARDS 
Thyroglobin 85.1 ± 0.2 0.095 ± 0.002 8.5 669 
Ferritin 96.9 ± 1.0 0.209 ± 0.010 6.1 440 
Catalase 109.0 0.326 5.22 232 
Aldolase 112.6 0.361 4.81 158 
BSA 119.9 ± 1.3 0.431 ± 0.013 3.55 68 
Blue Dextran (Vo) 75.2 ± 0.6 









Peak A (Complex I) 101.1 ± 0.6 0.250 ± 0.006 5.89 ± 0.09 295 7 
Peak B (Complex III) 116.5 ± 0.6 0.398 ± 0.006 4.09 ± 0.08 107 5 
Peak C (Oligo F) 3.69 ± 0.01 75 120.7 ± 0.1 0.439 ± 0.001 2 
150 
151 
protein of 75 KDa. 
G/CBF eluted from the gel filtration column as a 232 KDa 
protein in the absence of DNA (section 5. 2 .1.1), while the 
protein component of peak a contributed about 220 KDa 
(295 KDa minus 75 KDa) to the DNA-protein complex. Complex 
III proteins, on the other hand, eluted from the gel 
filtration column as a 50 KDa protein in the absence of DNA 
(section 5.2.1.1), while the protein component of peak a 
contributed about 32 KDa {107 KDa minus 75 KDa) to the DNA-
protein complex. Peaks a and b are therefore probably 
complexes I and III respectively. These results therefore 
suggested that the DNA does not mediate multimerisation of 
complex I or III proteins. The complex II peak was masked by 
peaks a and bin the SVWI-38 experiment. 
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5.3 DISCUSSION 
The biochemical and binding properties of complex I, II and 
III proteins in crude and partially purified SVWI-38 and CT-1 
nuclear extracts have been investigated in this and a 
previous study {Smith, 1989). These properties were used in 
comparative studies to determine whether these factors were 
related to previously characterised DNA-binding proteins. In 
this study, analytical gel filtration, glycerol gradient 
sedimentation, UV-crosslinking and Southwestern blotting 
studies were used to determine the native molecular weights, 
Stokes radii, sedimentation coefficients and structural 
complexity of the these transcription factors. 
Under non-denaturing conditions, G/CBF had a Stokes radius 
and sedimentation coefficient of 5. 2 2 ± O. 04 nm ( comparable 
to a spherical protein of 232 KDa) and 4. 9 ± o. 4 s 
respectively, a calculated native molecular weight of 105 KDa 
and a frictional ratio of 1.66. The Stokes radius of 
5. 89 ± O. 09 nm for the G/CBF-oligo F complex on the other 
hand was comparable to a spherical protein of 299 KDa. The 
CCAAT box factor, a-CPl, purified from murine erythroleukemia 
(MEL) cells, has a native molecular weight of 101 KDa, 
sedimentation coefficient of 4.3 S, stokes radius of 5.7 nm 
and frictional ratio of 1.78 (Kim and Sheffery, 1990). The 
ubiquitous CCAAT box binding factor, NF-Y, also has a similar 
sedimentation coefficient on glycerol gradients and the 
estimated molecular weight of the NF-Y /Ea oligo complex is 
250-300 KDa {Hooft van Huijsduijnen et. al., 1987). 
The gel filtration data also showed that G/CBF is a 
multicomponent CCAAT box binding factor because the various 
protein components of the factor eluted independently on 
Sephadex G-200 in the present of 0.8 M NaCl and as an intact 
complex in the absence of salt on Sephacryl S-300. The gel 
filtration data also suggested that the various components of 
the factor interacted with each another in the absence of 
DNA. The proposed heteromeric structure of G/CBF is 
consistent with a number of studies which suggest that the 
related CP-1 {Chodosh et. al., 1988a), a-CPl (Kim and 
Sheffery, 1990) and CBF (Hatamochi et. al., 1988) CCAAT box 
binding factors are heteromers in solution. 
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Three bands of approximately 200, 120 and 50 KDa were 
identified in complex I by UV-crosslinking to a 37-mer 
oligonucleotide A, while four bands of 234, 145, 89 and 
79 KDa by UV-cross linking to the 4 7-mer oligonucleotide F. 
Since G/CBF has a calculated molecular mass of 109 KDa, the 
predominant 120 and 145 KDa bands were probably produced when 
a single heterotypic complex was UV-cross linked to 
oligonucleotides A and F respectively. The 50, 89 and 79 KDa 
bands were probably degradation products, a finding supported 
by the data of Hooft van Huijsduijnen· et. al. (1987). The 
weak 200 and 234 KDa bands suggested that the stoichiometry 
of G/CBF in the DNA-protein complex maybe more complex. 
G/CBF might bind with the oligonucleotides as a dimer to 
produce the larger complexes. This result is consistent with 
that of the heterotrimeric factor, CBF, where three 
polypeptides associate with one another in the absence of DNA 
to form a functional factor with an apparent molecular mass 
of about 113 KDa (Maity et. al., 1992). Glutaraldehyde 
crosslinking with purified CBF, on the other hand, produced 
three bands with apparent molecular weights of 170, 100 and 
80 KDa, suggesting that the structure of CBF may also be more 
complex (Maity and de Crombrugghe, 1992). 
These similarities strongly suggested that G/CBF belongs to 
the family of the previously identified heteromeric CCAAT box 
binding factors, NF-Y, CP-1, a-CPl and CBF. Other studies on 
the effects of heat, ionic strength and various metal ion 
chelators on NF-Y (Hoof van Huijsduijnen, 1987) and G/CBF 
(Smith, 1989) DNA-binding activities supports this 
hypothesis. 
The CME binding proteins (complexes II and III) had Stokes 
radii of 4.12 and 3.15 nm, sedimentation coefficients of 3.9 
and 3.2, native molecular weights of 66 and 41 KDa and 
frictional ratios of 1. 54 and 1. 38 respectively, which did 
not differ when fractionation was performed in the presence 
or absence of KCl. 
Since several bands were identified when complex II proteins 
were UV-crosslinked to oligonucleotides, it was not clear if 
this factor was homo- or hetero-multimeric. The Southwestern 
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blotting data strongly suggested that this factor is hetero-
multimeric since no SVWI-38 specific bands were identified. 
However this observation should be interpreted with caution 
since it is possible that the protein did not renature 
correctly after electrophoresis. The denaturing gel 
filtration results, on the other hand showed that the factor 
is either monomeric or that the protein-protein interactions 
between the various components are stable in 0.8 M KCl. 
The identification of two crosslinked bands with molecular 
weights of 56 and 44 KDa and three bands of 46, 42 and 34 KDa 
when both CT-1 and SVWI-38 nuclear extracts were assayed by 
the UV-crosslinking and Southwestern blotting experiments 
respectively, suggested that complex III proteins were 
monomers. The sizes of the larger bands were similar to the 
native molecular weight of the protein and the smaller bands 
could be degradation products or modified forms. Although 
these results and the denaturing gel filtration data strongly 
suggested that complex III proteins are monomers, the smaller 
bands could be a indication that the factor is hetro-
multimeric, but it is highly unlikely. Additional 
experiments would need to do be done to confirm this 
hypothesis. 
It was not clear from the data how complex II and III 
proteins were related. It is possible that complex III 
proteins are a specific degradation product of complex II 
proteins. Alternatively complex II and III format~on could 
be the result of different post-translational modifications 
of the same factor. They could also contain a common DNA-
binding subunit(s) or they maybe two distinct transcription 
factors which bind to the same cis-element on the collagen 
promoter. On example of the latter is the transcriptional 
activator, interferon regulatory factor-1 (IRF-1), and 
repressor (IRF-2) which bind to the same cis-elements in the 
type I interferon (IFN) and IFN-inducible genes (Harada 
et. al. , 1989) . 
Comparison 
biochemical 
of the recognition sequence 





previously characterised transcription activators NF-Y, 
CBF, CP-1 and a-CPl strongly suggested that G/CBF belongs to 
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a family of heteromeric CCAAT box binding factors. 
Competition experiments with oligonucleotides containing 
consensus sequences for these factors and assays using 
specific antibodies, such as anti-CBF-A (Maity and 
de Crombrugghe, 1992), are in progress and will elucidate 
this relationship. If G/CBF is identical to these previously 
characterised factors, then this factor is probably a 
transcriptional activator of the human a2(I) procollagen 
gene. It isn't clear from the data if the SVWI-38 specific 
complex II proteins is a homo-multimer, a hetero-multimer or 
a monomer. Previous studies have suggested that it is a 
hetero-multimeric factor (Smith, 1989). Although not 
conclusive, the data strongly implied that complex III 
proteins consists of a monomer. Since the CME binding 
proteins are not to our knowledge related to any previously 
characterised DNA-binding factor, they are probably novel 




Previous studies have suggested that a trans-acting factor(s) 
which binds to the proximal promoter of the human a2 (I) 
procollagen gene maybe responsible for the inactivation of 
this gene in a simian virus 40 transformed embryonic lung 
fibroblast cell line (SVWI-38) (Parker et. al., 1989, 1992). 
These fibroblasts secrete a homotrimer of type I collagen 
consisting of three overmodified al(I) chains. No detectable 
amounts of a2(I) protein or mRNA are produced by these cells. 
In this study, the SVWI-38 proximal promoter, which has 
previously been shown to have decreased activity in promoter-
CAT constructs (Parker et. al., 1992) , was sequenced and 
shown to be completely normal, thereby ruling out any 
possibility that mutations within this region of the gene was 
responsible for its inactivation. 
DNA-protein complexes between the proximal promoter and 
nuclear extracts prepared from SVWI-38 fibroblasts and a 
type I collagen producing human embryonic lung fibroblast 
cell line transformed by 1-radiation (CT-1) were investigated 
using the electrophoretic mobility shift assay. Similar DNA-
protein complexes were observed in the -351 to -108 bp region 
in both cell lines. Nuclear extracts from CT-1 fibroblasts 
or the parental WI-38 cell line formed two complexes 
designated complexes I and III with the -110 to +58 promoter 
fragment. Both these complexes also formed with a smaller 
promoter fragment extending from nucleotides -110 to -46. An 
additional complex, complex II, was identified when SVWI-38 
nuclear extracts were assayed, as well as much lower levels 
of complex III when compared with CT-1 cells. Only complexes 
I and II were identified in a non-collagen producing 
transformed macrophage cell line, P388D1 . Since complex II 
is present 
that this 
in non-collagen producing cells, it is possible 
factor is a transcriptional repressor. Parker 
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et. al. (1992) have shown that a small fragment of the 
proximal promoter (-107 to +58) was able to titrate out an 
inhibitory effect on a2 (I) procollagen gene expression in 
SVWI-38 fibroblasts, suggesting that a transcriptional . 
repressor binds to this region of the promoter. Also, cells 
that do not synthesise a2{I) procollagen chains appeared to 
have no detectable amounts (macrophages) or lower levels 
{SVWI-38) of complex III than collagen producing cells. 
These observations suggested that the relative ratios of 
complex II and III, and not merely the absence or presence of 
complex II, may be important in determining whether the a2{I) 
procollagen gene is expressed or not. Interestingly, trace 
amounts of complex II were detected on longer exposures of 
CT-1 and WI-38 autoradiograms, suggesting that low levels of 
this complex was present in type I collagen producing cell 
lines. 
Competition, electrophoretic mobility shift assays and 
methylation interference assays identified two distinct but 
overlapping DNA-recognition elements within the -110 to -46 
region of the a2(I) procollagen promoter. Complex I 
proteins, called the GGAGG/CCAAT binding factor {G/CBF), 
binds to a 21 bp element, 51 GCCCTCCCATTGGTGGAGGcc3 ', between 
nucleotides -92 and -72. This element has been called a 
GGAGG/CCAAT box element (G/CBE) because it contains an 
inverted CCAAT box surrounded by an upstream inverted GGAGG 
box and downstream GGAGG box. The second cis-element, 
5 'GGAGGCCCTTTT3 ', extends from nucleotides -78 to . -67 and 
contains the G/CBE downstream GGAGG box and 3'-flanking 
sequences. CT-1 nuclear extracts formed one complex with 
this element (complex III), whereas SVWI-38 extracts formed 
two complexes (complexes II and III) involving the same 
element. Since complex II protein(s), a candidate 
transcriptional repressor, bound to this novel 12 bp element, 
the element has been named the collagen modulating element 
{CME). 
Further characterisation of the G/CBE using DNA-binding 
assays, methylation interference assays and mutation 
analysis, suggested the CCAAT box and the inverted upstream 
GGAGG box were very important motifs for G/CBF binding. 
Deletion of a single cytosine, which separates these two 
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motifs, abolished or drastically reduced the formation of 
complex I. These assays also suggested that the downstream 
GGAGG box is involved in weak non-specific DNA-protein 
contacts and that it very loosely forms part of the G/CBE. 
In fact, replacement of this element with random sequences 
did not abolish complex I formation. The G/CBE is highly 
homologous with the CBF element in the mouse a2 (I) 
procollagen promoter (Hatamochi et. al., 1986; Maity et. al., 
1988) and the NF-Y site within the thrombospondin 1 promoter 
(Framson and Bornstein, 1993). The thrombospondin 1 NF-Y 
site contains the downstream GGAGG box. while the mouse a2(I) 
procollagen and human thrombospondin promoters contain an 
upstream inverted GGAGG and GGAGG-like boxes respectively. 
The crucial cytosine residue which separates the upstream 
GGAGG and CCAAT boxes is conserved in both these promoters. 
These observations suggested that G/CBF may be related or 
identical to NF-Y and CBF. Physico-chemical analysis, such 
as gel filtration, glycerol gradient sedimentation and uv-
crosslinking experiments, of G/CBF also suggested that this 
factor belongs to the family of previously characterised 
hetero-multimeric CCAAT box binding factors, NF-Y (Hooft van 
Huijsduijnen et. al., 1987), a-CPl (Kim and Sheffery, 1990) 
and others. UV-crosslinking and denaturing gel filtration 
data suggested that this factor, like the other hetero-
multimeric CCAAT box binding factors, is a multicomponent 
CCAAT box binding protein. In contrast to CBF (Karsenty 
et. al., 1988) and NF-Y (Dorn et. al., 1987), which bind to 
their respective cis-elements only if they contain ~n intact 
CCAAT motif, mutation of the CCAAT box in the G/CBE did not 
totally abolish G/CBF binding. The physico-chemical and 
binding data, however, strongly suggested that G/CBF is 
related to the transcriptional activators NF-Y, a-CPl, CBF 
and others. Other studies on the effects of heat, ionic 
strength and various metal ion chelators on the ubiquitous 
NF-Y (Hooft van Huijsduijnen, 1987) and G/CBF (Smith, 1989) 
DNA-binding activities supports this hypothesis. 
Mutations of the downstream GGAGG box and the cytosine 
dinucleotides at positions -72 and -73 (motifs within the 
CME) resulted in a drastic reduction or abolition of complex 
II and III formation. Methylation interference and mutation 
analysis data suggested that the upstream GGAGG and CCAAT 
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boxes were also involved in weak DNA-protein contacts with 
complex II and III proteins. Since the CME bears some 
resemblance to the NF-kB consensus sequence (Lenardo and 
Baltimore, 1989), the CME could be a NF-kB-like recognition 
element. The CME also overlaps a large T antigen-like 
recognition sequence present in the human a2(I) procollagen 
promoter (Ghosh et. al., 1981). Smith (1989) has shown that 
large T antigen is not responsible for complex formation with 
the CME. Al though not conclusive, the UV-cross linking and 
Southwestern blotting data suggested that complex II 
protein(s) are multimeric. Since the ·Stokes radius of this 
factor did not change during fractionation on a denaturing 
gel filtration column, the protein-protein interaction 
between the various subunits of this factor are very stable 
assuming a multimeric factor. Smith (1989) has postulated 
that complex II proteins consist of at least two subunits. 
UV-crosslinking, Southwestern blotting and denaturing gel 
filtration data suggested that complex III is a monomer. 
Additional experiments would need to be done to confirm the 
polypeptide composition of complexes II and III and their 
relationship to previously identified proteins. 
It was not clear from the data how complex II and III 
proteins are related to one another. It is possible that 
complex III proteins are a specific degradation product of 
complex II proteins. Although unlikely, different post-
translational modification of the same factor could result in 
complex II and III formation. Alternatively, complex II and 
III proteins could contain a common DNA-binding subunit (s) 
or, more likely, they may be two distinct transcription 
factors which bind to the same cis-element within the 
collagen promoter. 
Methylation interference and binding assays demonstrated that 
complex I, II and III proteins bound to their respective 
elements in a mutually exclusive manner. It can be 
postulated that the candidate transcription activators, G/CBF 
and complex III proteins, together with the candidate 
transcriptional repressor, complex II proteins, tightly 
regulate the expression of the human a2(I) procollagen gene 
in type I collagen producing (CT-1 and WI-38) and non-
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producing (SVWI-38) cells. Numerous examples have been 
characterised where a transcriptional repressor and activator 
binds to distinct overlapping (Barberis et. al., 1987) or the 
same (Harada et. al., 1989) recognition element in a mutually 
exclusive manner to regulate gene expression. Kim et. al. 
(1990) and Lim et. al. (1992) have identified a strong 
monomeric activator, cx-CP2, which is present in limiting 
amounts and competes with cx-CPl, a weaker but more abundant 
transcriptional activator, for binding to distinct 
overlapping recognition sites in a mutually exclusive manner 
to regulate the ex-glob in gene. Similarly, in the type I 
collagen producing CT-1 cell line, complex III proteins may 
strongly activate transcription when it binds to the CME. 
The abundant G/CBF may compete with complex III proteins for 
binding to the G/CBE in a mutually exclusive manner to weakly 
activate transcription of the cx2(I) collagen gene. 
Conversely, complex II proteins may compete with complex I 
and III proteins in similar manner to inhibit the expression 
of this gene in SVWI-38 fibroblasts. The results of this 
study will make it possible to further examine the functions 
of these transcription factors and their interaction with one 
another in the regulation of the human cx2 (I) procollagen 
gene. 
Finally, since the CME is not present in the mouse cx2 (I) 
procollagen promoter, this study also suggested that 
different mechanisms may be operational in different species 




MATERIALS AND METHODS 
7.1 SUBCLONING AND PLASMID DNA ISOLATION 
7.1.1 PREPARATION OF DNA FRAGMENTS 
Plasmids were digested with the required restriction enzymes, 
the fragments were resolved on either non-denaturing 
polyacrylamide or agarose gels and the band of interest 
eluted from the gels using one of the following methods. 
7.1.1.1 CRUSH SOAK METHOD 
The DNA fragments were resolved on polyacrylamide gels and 
stained with ethidium bromide. The band of interest was 
excised, the gel and sliced into small pieces and transferred 
to microfuge tubes, to which 1 volume ~f DNA elution buffer 
(section 7.7) was added. The tube was incubated overnight at 
37° c with gentle rotation, the buffer removed with a drawn-
out pasteur pipette and transferred to a fresh microfuge 
tube. The gel slices were washed with 0.5 volumes of DNA 
elution buffer, added to the above and the DNA precipitated 
overnight at -20° C by the addition of 2.5 volumes 96% 
ethanol. The DNA was pelleted, washed with 70% ethanol, 
dried under vacuum and resuspended in a small volume of 
lX TE. The recovered DNA fragments were used in ligation 
reactions ( section 7. 1. 2) or in DNA-protein binding assays 
(section 7.4). 
7.1.1.2 ELECTRO-ELUTION 
The DNA fragments were resolved on agarose gels containing 
ethidium bromide using lX TBE as the tank buffer. The DNA 
band was excised from the gel and placed in a dialysis tube 
containing 0.5 ml 0.2X TBE. The sealed dialysis tube 
containing the gel slice was placed in lX TBE and the DNA 
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fragment was electro-eluted from the gel slice at 25 rnA for 
2 hrs. The efficiency of elution was checked under UV light. 
At the end, the polarity was reversed at 100 rnA for 1 min to 
remove the DNA fragments from the walls of the dialysis tube. 
The buffer in the dialysis tube was removed and the DNA was 
precipitated overnight at -20° C by the addition of 
2.5 volumes 96% ethanol. The DNA pellet was washed with 70% 
ethanol, dried under vacuum and resuspended in a small volume 
of lX TE. The recovered DNA fragments were used in ligations 
as described in section 7.1.2. 
7.1.1.3 ELECTROPHORESIS INTO WHATMAN 3MM PAPER 
The DNA fragments were resolved on a 1% agarose gel 
containing ethidium bromide using lX TAE as the tank buffer. 
A slit was made in front of the band to be eluted and a strip 
of sterile Whatman 3MM paper about the same width as the band 
was inserted into the slit so that it protruded a few 
millimeters from the gel {Errington, 1990). The DNA was then 
electrophoresed into the paper, the paper removed, trimmed 
and placed into a 500 ul microfuge tube with a small hole in 
the bottom. The microfuge tube was place inside a 1. 5 ml 
Eppendorf tube, 10 ul lX TAE was added to the Whatman 3MM 
paper and the tubes centrifuged for 20 sec to recover the 
DNA. The recovered DNA fragments were used in ligations as 
described in section 7.1.2. 
7.1.1.4 QIAEX EXTRACTION PROTOCOL 
The QIAEX gel extraction kit (Diagen GmbH, Dusseldorf, 
Germany) was used to extract DNA fragments from low-melting 
agarose gels. DNA fragments were extracted from the gels as 
described by the manufactures and used in ligation reactions 
(section 7 .1. 2). 
7.1.2 BLUNT-END LIGATION 
7.1.2.1 FILLING OF RECESSED 3 1 -ENDS 
The Klenow fragment of E. Coli DNA polymerase was used to 
fill recessed 3 1 -ends of double stranded DNA (Sambrook 
et. al., 1989). 1 unit of the Klenow fragment was added per 
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microgram of DNA in lX Klenow buffer (section 7.7) in a final 
volume of 20 ul, containing 0.5 mM each of dATP, dTTP, dCTP 
and dGTP. The reaction mixture was incubated at room 
temperature for 30 min, phenol/chloroform extracted, and 
ethanol precipitated to recover the DNA. 
7.1.2.2 BLUNT ENDING WITH T4 DNA POLYMERASE 
In order to blunt end DNA molecules with 3 '-overlaps, the 
3'-5' exonuclease activity of T4 DNA polymerase was used 
(Sambrook et. al., 1989). One unit of· T4 DNA polymerase per 
microgram of DNA w~s added to 20 ul of lX T4 DNA polymerase 
buffer containing 0.5 mM each of dATP, dTTP, dCTP and dGTP. 
The reaction mixture was incubated at 370 C for 1 hour, 
phenol/chloroform extracted and ethanol precipitated to 
recover the DNA. 
7.1.2.3 LIGATION 
Ligations were performed in a final volume of 10 ul as 
recommended by the manufactures. A DNA insert to vector 
ratio of 5:1 was usually used in the ligation reactions. 
7.1.3 PREPARATION AND TRANSFORMATION OF COMPETENT E.coli 
CELLS 
Competent DK-1 cells, an E. Coli K12 strain, were prepared as 
follows: 10 ml of L-Broth was inoculated with 50 ui of DK-1 
from a glycerol stock and grown overnight at 370 c with 
shaking. One-ml of the overnight culture was used to 
inoculate 300 ml of L-Broth in a 1000 ml flask. The bacteria 
were grown with vigorous shaking until the OD650 was between 
0.2-0.4. The cells were pelleted by centrifugation at 
5000 rpm (4o C) for 10 min in a Beckman JA 10 rotor, gently 
resuspended in 40 ml of ice cold 60 mM CaC12 , 10 mM Pipes, 
pH 7.2, left on ice for 20 min and re-centrifuged at 5000 rpm 
and 40 C for 10 min. The cells were resuspended in 4 ml of 
60 mM cacl2 , 10 mM Pipes, pH 7. 2 containing 15% glycerol, 
frozen in 200 ul aliquots in a dry ice-ethanol bath and 
stored at -10° C. 
The transformation efficiency was checked 




108 colonies per 
Aliquots of competent cells were thawed on ice. 100 ul of 
the cells were transferred to 10 ml plastic tubes, 5 ul of 
ligation mixture was added to the cells, incubated on ice for 
30 min and heat shocked at 42° C for 2 min. One-ml of 
prewarmed (37° C} L-Broth was added to the cells and 
incubated at 370 c for 1 hour without shaking. 20, 50, 100 
or 200 ul aliquots were plated out onto ampicillin plates and 
incubated overnight at 37° c. 
7.1.4 SCREENING OF BACTERIAL COLONIES 
The alkaline lysis procedure (Birnboim and Doly, 1979; 
Birnboim, 1983) was used to prepare plasmid DNA for rapid 
analysis. Seven-ml of L-Broth containing O .1 mg/ml 
ampicillin in a 12 ml sterile tube was inoculated with a 
single bacterial colony and grown overnight at 370 C with 
shaking. Cells were harvested at 2000 rpm for 10 min in a 
Beckman TJ-6 centrifuge at 40 c. The pellet resuspended in 
200 ul of "RAPS" solution 1, transferred to a 1. 5 ml 
microfuge tube and incubated for 5 min at room temperature. 
The bacteria were lysed with 400 ul of "RAPS" solution 2 on 
ice for 5 min. Three-hundred ul of "RAPS" solution 3 was 
added to the lysed cells and incubated for 5 to 10 min on 
ice. The precipitated chromosomal DNA and bacterial .proteins 
were removed by centrifugation in a microfuge for 5 min at 
4 ° C. The supernatants were transferred to a fresh tube, 
centrifuged again as above and the supernatants transferred 
to another fresh tube. Six hundred ul (0.8 volume) of 
isoproponal was added to the supernatants and the nucleic 
acids allowed to precipitate at -20° C for 30 min. The 
plasmid DNA and RNA was recovered by centrifugation, washed 
with 70% ethanol, dried under vacuum and resuspended in 70 ul 
TE. 
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7.1.5 LARGE-SCALE PLASMID DNA ISOLATION 
Large-scale plasmid preparation was either by CsCl-ethidium 
bromide centrifugation (Radloff et. al., 1967) or QIAGEN 
columns. 
7.1.5.1 cscl-ETHIDIUM BROMIDE CENTRIFUGATION 
Two hundred ml of 
5000 rpm for 5 min 
overnight cultures were harvested 
in a Beckman JA 10 rotor at 40 c. 
at 
The 
pelleted cells were resuspended in 2. 5 ml of 
solution (section 7.7) and incubated on ice 
Sucrose/Tris 
for 5 min. 
One ml of Sucrose/Tris solution containing 5 mg/ml lysozyme 
was added to the resuspended cells and incubated for a 
further 5 min on ice before the addition of 2 ml of 250 mM 
EDTA (pH 8. 0) . After 5 min on ice the cells were lysed by 
the addition of 4.5 ml of TTE and incubated on ice for 20 min 
with gentle mixing at 5 min intervals. The lysate was 
centrifuged at 20 ooo rpm for 30 min in a Beckman JA 20 rotor 
at 40 C to pellet the chromosomal DNA and cellular debris. 
The supernatant was carefully decanted into a measuring 
cylinder, CsCl was added to a final concentration of 1 mg/ml 
and dissolved by gentle shaking before the addition of 80 ul 
of 10 mg/ml ethidium bromide to every ml of lysate. The 
lysates were transferred to a 5 ml Beckman Quick-Seal 
ultracentrifuge tubes, centrifuged at 55 000 rpm for 20 hrs 
in a Ti70.1 rotor at 20° C. 
The plasmid bands were removed from the ultracentrifuge tubes 
using 20-G needles, transferred to a Corex tubes and 
extracted with an equal volume of 1-butanol saturated with 
water to remove the ethidium bromide. The extractions were 
repeated until all the ethidium bromide was removed from the 
aqueous phase. The aqueous phase was dialysed against a vast 
excess O. lX TE to remove the CsCl, ethanol precipitated, 
washed twice with 70% ethanol and dried under vacuum. The 
plasmid DNA was resuspended in about 0.5 ml TE and the purity 
and concentration of the DNA measured by absorbance at 260 
and 280 nm. 
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Alternatively, 2 volumes of water and 3 volumes (original} of 
isopropanol were added after butanol extractions and the 
plasmid DNA was precipitated on ice for 10 min. Chilling to 
below -20° c was avoided to prevent the CsCl from 
precipitating out. The plasmid pellet was washed, dried and 
resuspended in TE. 
7.1.5.2 QIAGEN COLUMNS 
QIAGEN columns (Diagen GmbH, Dusseldorf, Germany} were used 
to prepare plasmid DNA from 500 ml overnight cultures as 
described by the manufactures. 
7.1.6 DNA SEQUENCING 
DNA sequencing was performed using the Sanger dideoxy chain 
termination method {Sanger et. al., 1977} as described by the 
manufactures Sequenace™ (United States Biochemical 
Corporation, Cleveland, Ohio}. 
Briefly, the double-stranded plasmids were denatured in 0.2 M 
NaOH, 0.2 mM EDTA for 5 minutes at room temperature followed 
by the addition of o .1 volume of 2 M NH3Ac {pH 4. 6} and 
3. 5 volumes of ethanol. After leaving at -10° C for 10 
minutes, DNA was pelleted, washed with 70% ethanol and dried 
under vacuum. The DNA was redissolved in 7 ul of distilled 
water to which 1 ul of primer and 2 ul of Sequenase reaction 
buffer was added. The reaction mixture was heated at 65° c 
for 10 minutes, 370 c for 30 minutes and allowed to cool to 
room temperature for at least 2 hours. 
The DNA sequencing reaction was carried out essentially as 
described by the suppliers and the samples were analysed on 
6% denaturing-polyacrylamide sequencing gels. 
7.2 CELL CULTURE 
Human fibroblasts were grown and maintained in Eagle's Basal 
Medium (BME), supplemented with 10% heat-inactivated foetal 
calf serum, 100 ug/ml penicillin and 100 ug/ml streptomycin 
at 370 c. At confluence, the cells were washed with PBS and 
harvested with 0.05% trypsin in PBS containing 10 mM EDTA at 
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370 C for 5 min. The cells were washed in BME, resuspended 
in BME and split at a ratio of either 1:2 
(SVWI-38 and CT-1). 
(WI-38) or 1:3 
Mouse macrophage cells were grown in suspension in RPMI-1640 
medium, supplemented with 10% heat-inactivated foetal calf 
serum, 100 IU/ml penicillin, 100 ug/ml streptomycin and 
0.25 ug/ml fungizone (Flow Laboratories, Irvine, Ayrshire, 
Scotland). 
The cell lines used were: 
1) WI-38: a human embryonic lung fibroblast line, obtained 
from the American Type Culture Collection (ATCC CCL-75). 
2) CT-1: WI-38 fibroblasts transformed by gamma-radiation, a 
gift from Dr M. Namba, University of Tokyo (Namba et. al., 
1980). 
3) SVWI-38: WI-38 fibroblasts transformed with simian 
virus-40 (de Haan et. al., 1986). 
4) P388D1 , a mouse tumour macrophage cell line, which were a 
gift from Dr L. Thilo, University of Cape Town (Koren 
et. al., 1975). 
7.3 PREPARATION AND FRACTIONATION OF CRUDE NUCLEAR EXTRACTS 
The method of Dignam et. al. (1983) was used for the 
preparation of crude nuclear extracts from cultured cells. 
For small-scale preparations of nuclear extracts, the method 
of Lee and Green (1990) was used. 
7.3.1 PREPARATION OF DIGNAM NUCLEAR EXTRACTS 
The monolayers were harvested with a rubber policeman in ice 
cold PBS, pelleted at 2000 rpm and 40 C for 3 min in a 
Beckman Model TJ-6 centrifuge, washed in 5 packed cell 
volumes (PCV) of ice cold PBS and resuspended in 5 PCV off 
buffer A. For suspension cultures, the medium was 
centrifuged for 5 min to pellet the cells, washed and 
resuspended in buffer A as above. The cells were allowed to 
swell for 10 min on ice, pelleted and resuspended in 2 PCV 
(original PCV) of buffer A. The resuspended cells were lysed 
with 10-15 strokes of a Dounce Homogeniser and checked 
microscopically for cell lysis. The nuclei were pelleted, 
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the supernatant discarded and centrifuged again at 13 000 rpm 
and 40 c for further 20 min in a Beckman JA 20 rotor to 
remove all trace amounts of cytoplasmic material. The nuclei 
were resuspended in 3 ml of buffer C per 109 cells and 
homogenised with 10-15 strokes of a Dounce Homogeniser. The 
homogenate was transferred to a 50 ml tube, stirred gently 
for 30 min on ice to extract the 0.42 M salt soluble proteins 
and pelleted at 13 ooo rpm and 40 Cina Beckman JA 20 rotor 
for 30 min to remove the nuclear debri. The supernatant was 
dialysed against 50 volumes of buffer D for 5 hrs at 4 O C, 
the dialysate centrifuged at 13 000 rpm and 40 C for 20 min 
in a JA 20 rotor and the supernatant stored in 20 to 100 ul 
aliquots at -10° c. 
7.3.2 SMALL-SCALE NUCLEAR EXTRACT PREPARATION 
The monolayer and macrophage cultures were harvested as 
described above, washed in 3 O PCV of ice cold PBS, 
resuspended in 1 PCV of buffer A and allowed to swell on ice 
for 5 min. The cell suspension was lysed by 5 cycles of slow 
aspiration and rapid ejection using a 1 ml syringe with a 26-
gauge needle. The syringe was rinsed with buffer A prior to 
use to prevent excess air accumulation in the cell 
suspension. Cell lysis was checked microscopically and the 
homogenate was centrifuged for 20 sec at 40 c in a microfuge. 
The nuclei were resuspended in two-thirds PCV of buff er C, 
stirred on ice for 30 min and centrifuged for 5 min at full 
spead in a microfuge to pellet the nuclear debris. The 
supernatant was dialysed for 2 hours against buffer D at 
40 c. The dialysate was divided into small aliquots, frozen 
in liquid nitrogen and stored at -10° c. 
7.3.3 DIFFERENTIAL SALT EXTRACTION 
Nuclei were prepared as described above (section 7.3.1), 
resuspended in 3 ml buff er C containing o. 1 M NaCl, 
homogenised with 15 strokes of a dounce homogeniser and 
stirred gently on ice for 20 min. The nuclei were pelleted 
at 13 000 rpm and in a Beckman JA 20 rotor at 40 c and the 
supernatant transferred to a fresh tube. The nuclei were 
re-extracted stepwise with buffer C containing o. 2 M, o. 3 M 
or 0.4 M NaCl as described above. The 0.1 M, 0.2 M, 0.3 M 
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and o. 4 M NaCl supernatants were dialysed against buffer D 
for 5 hours and the dialysates centrifuged at 13 ooo rpm for 
20 min in a JA 20 rotor to remove any debris. The 
supernatants were divided into small aliquots, quick frozen 
in liquid nitrogen and stored at -10° C. 
7.3.4 HEPARIN-AGAROSE CHROMATOGRAPHY 
One ml of de-aerated heparin-agarose (Sigma) was packed into 
a siliconised pasteur pipette plugged with glasswool. The 
column was equilibrated with 5 to· 10 ml of buffer CB 
(section 7.7) containing 0.1 M KCl and a flow rate of 
6 ml/hour. All manipulations were performed at 40 C. 
Columns were stored in buffer CB containing O .1 M KCl and 
0.02% sodium azide and washed with 5 to 10 ml of 0.1 M CB to 
remove the sodium azide prior to use. 
Six to 12 mg of crude nuclear extract was applied to the 
column and allowed to flow under gravity. The column was 
washed with about 7 ml of buffer CB containing 0.1 M KCl and 
eluted stepwise with 5 ml buffer CB containing 0.2 Mor 0.4 M 
KCl at a flow rate of 6 ml/hour. The columns were 
regenerated with buffer CB containing 1.0 M KCl to remove any 
trace amounts of bound protein and re-equilibrated with 
buffer containing 0.1 M KCl. 
The elution of protein from the column was moni tared by 
absorbance at 280 nm (LKB 2158 Uvicord). The fractions were 
concentrated using Centricon 10 microconcentrators (Amicon 
corporation, Massachusetts, USA} and the salt concentration 
adjusted to o .1 M KCl. The protein concentration of each 
fraction was determined by the Bradford (1976) method. The 
electrophoretic mobility shift assay was used to test for 
DNA-binding activity in each fraction. 
7.4 DNA-PROTEIN INTERACTIONS 
7.4.1 END-LABELLING OF DNA 
DNA fragments were end-labelled using either the Klenow end-
labelling method or by kinasing 5'-ends. The Klenow fragment 
of E. Coli DNA polymerse was used to end-label 3 '-recessed 
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ends of double-stranded DNA as previously described (Sambrook 
et. al., 1989). One-unit of the Klenow DNA polymerase was 
added to 0.5 ug of DNA in klenow buffer in a final volume of 
20 ul. The reaction mixture was incubated at room 
temperature for 1 to 2 min before 3 ul of dNTP mix containing 
3 . 3 mM each of dATP, dTTP and dGTP and 2 ul ( 2 o uci) of 
(a-32PJ-dCTP were added. The reactions were incubated for a 






end-labelled using T4 
polynucleotide kinase (Ausubel et. al., 1987). One unit of 
T4 polynucleotide kinase was added per 0.5 ug of 
dephosphorylated DNA in polynucleotide kinase buffer 
containing (gamma- 32PJ-ATP with a final volume of 25 ul and 
incubated at 370 C for 60 min. 
The labelling reactions were stopped by extraction with an 
equal volume of 24: 1 (v/v) chloroform: isoamylalcohol. The 
unincorporated nucleotides in the aqueous phase was separated 
from the labeled DNA by chromatography on Sephadex G-50. 
When necessary, 1 unit of calf intestine alkalinal 
phosphatase (CIAP) (Boehringer) was added to DNA and 
incubated for 30 min at 370 c. At the conclusion of the 
incubation 1/10 volume of 500 mM EGTA was added and incubated 
for 45 min at 65° C to inactivate the CIAP. The samples were 
extracted twice with an equal volume of TE-saturat~d phenol 
and once with 1 volume 24:1 (v/v) chloroform isoamylalcohol. 
The DNA was ethanol precipitated from the aqueous phase, 
washed, dried under vacuum and resuspended in TE to give a 
final concentration of 1 ug/ul. 
7.4.2 ELECTROPHORETIC MOBILITY SHIFT ASSAYS (EMSA) 
Three to 4 ug of crude nuclear extract or partially purified 
protein fractions were incubated in incubation buffer (IB) 
containing 4 ug poly didC.poly didC in a final volume of 
20 ul for 10 min at room temperature. One-ng ( 104 cpm) 
32P-labelled probe was added and the incubation continued for 
another 30 minutes at 40 C (Fried and Crothers, 1981). After 
adding 2 ul of 0.25% bromophenol blue in 35% glycerol, the 
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DNA-protein complexes were immediately resolved on 5% non-
denaturing polyacrylamide gels at 140 V for about 2 hrs at 
40 c using 0.5X TBE. After drying, the gels were exposed to 
X-ray film for 8 to 20 hours. 
In competition 
et. al., 1986) 
experiments 
a 25- to 
{Garthew 
200-fold 
et. al., 1985; Singh 
molar excess of the 
appropriate double stranded oligonucleotide was incubated 
with nuclear extract for 10 min prior to the addition of 
probe. 
Autoradiograms were scanned using a CliniScan densitometer or 
a Beckman DU 650 spectrophotometer with gel scanning 
accessory to determine the relative intensities of the 
retarded bands. In these instances, the gels were exposed to 
X-ray film so that the image was within the linear range of 
the film. 
7.4.3 MUTUALLY EXCLUSIVE BINDING ASSAYS 
Five, 10, 15 and/or 20 ug of partially purified protein 
fractions were incubated in IB containing an equivalent 
amount of poly didC.poly didC (i.e. 5, 10, 15 or 20 ug) in a 
final volume of 37 ul for 10 min at room temperature. One-ng 
{104 cpm) 32P-labeled DNA was added and the incubation 
continued for another 20 minutes at 40 c so that DNA-protein 
complexes could form. Three-ul of partially purified 
fractions containing different DNA-binding proteins was added 
and incubated for a further 20 minutes at 40 c. After adding 
2 ul 0.25% bromophenol blue in 35% glycerol, the DNA-protein 
complexes were immediately resolved on 5% non-denaturing 
polyacrylamide gels at 40 C using O. 5X TBE, the gels dried 
and exposed to X-ray film for 8 to 20 hours 
7.4.4 METHYLATION INTERFERENCE ASSAY 
The method of Ausubel et. al. (1987) was modified as 
described below. About 5 ug of plasmid pNJ-59 was linearised 
with either Hind III or Eco Rl, dephosphorylated and end-
labelled as described in section 7.4.1. The phosphorylated 
plasmid was digested with either Eco Rl or Hind III to 
produce a probe labelled at one end. The digests were 
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resolved on 7% polyacrylamide gels and the appropriate band 
was eluted as described in section 7.1.1.1. To methylate the 
DNA probe, 1 ul of OMS was added to 106 cpm kinased probe in 
a final volume of 30 ul IB and incubated at room temperature 
for 10 min. Forty-ul of OMS stop buffer (section 7.7), 1 ul 
of 10 ug/ul tRNA, 130 ul o. 3 M sodium acetate and lmM EDTA 
and 600 ul absolute ethanol was added and the DNA 
precipitated in a dry ice/ethanol bath for 15 min. The DNA 
pellet was resuspended in 220 ul 0.3 M sodium acetate, 1 mM 
EDTA and re-precipitated by the addition of 750 ul absolute 
ethanol as above. The precipitation was repeated for a third 
time, washed with 70% ethanol, dried under vacuum and 
resuspended in TE to give a final concentration of 2 X 104 
cpm/ul. 
About 80 ug of crude nuclear extract and 20 ug 
poly didC. poly didC was incubated at room temperatue in a 
final volume of 80 ul IB. After 10 min, 2-5 X 105 cpm of 
methylated probe was added and the incubation continued for 
another 30 min at 40 C. After the addition of 4 ul of 0.25% 
bromophenol blue in 35% glycerol, the DNA-protein complexes 
were immediately resolved on 5% non-denaturing polyacrylamide 
gels at 40 c using 0.5X TBE. The resolved complexes and free 
probe were electrophoretically transferred from the gel onto 
DEAE membranes at 500 mA for 1 hour at room temperature in 
lX TBE. The DEAE membranes were sealed in a plastic bag and 
the complexes visualised by autoradiography (1 hr at 40 C). 
The complexes and free probe bands were excised, Rlaced in 
Eppendorf tubes followed by the addition of 200 ul DEAE 
elution buffer, 2 ul of 10% sos, and incubated for 60 min at 
65° C. The supernatants were transferred to a separate 
tubes, the membranes washed with an equal volume of TE and 
the supernatants pooled. The residual debris were removed by 
centrifugation and the supernatants 
tube. After adding 1 ul of 10 ug/ul 
precipitated by the addition of 
ethanol, left at -10° c for 30 min, 
and dried under vacuum. 
transferred to a fresh 
tRNA, the eluted DNA was 
3 volumes of absolute 
washed with 70% ethanol 
The dried pellets were resuspended in 1 M piperidine and 
heated for 30 min at 90° C to cleave at the modified sites. 
The cleaved DNA was transferred to a fresh tube, 1. 2 ml 
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1-butanol added and the samples vortexed vigorously until a 
single phase was obtained. After centrifugation for 5 min, 
the DNA pellet was resuspended in 150 ul 1% sos, extracted 
with 1.2 ml 1-butanol as before, washed with 80% ethanol, 
dried under vacuum and resuspended in 0.5X formamide loading 
buffer. Equal counts of the samples were resolved on 12% 
polyacrylamide/urea sequencing gels, dried and exposed to 
X-ray film without intensifying screens for at least 16 hrs. 
7.4.5 OLIGONUCLEOTIDES SYNTHESIS AND ANNEALING 
Al 51 GGGCCCCCAGCCCCAGCCCTCCCATTGGTGGAGGCcc3 ' 
A2 51 GGGCCTCCACCAATGGGAGGGCTGGGGCTGGGGGccc3 ' 
Bl 51 GGGCCCCCAGCCCCAGCCCTCCCATTGG3 ' 
B2 5 'ccAATGGGAGGGCTGGGGCTGGGGGCCc3 ' 
Cl 51 GGGCCCCCAGCCCCAGCCCTccc3 ' 
C2 51 GGGAGGGCTGGGGCTGGGGGccc3 ' 
Dl 51 GGAGGCCCTTTTGGAGGCACCCTAGGGCCAGG31 
D2 5 'ccTGGCCCTAGGGTGCCTCCAAAAGGGCCTcc3 ' 
El 51 CAGCCCTCCCATTGGTGGAGG31 
E2 5 'ccTCCACCAATGGGAGGGCTG3 ' 
F2 51 GCCTCCAAAAGGGCCTCCACCAATGGGAGGGCTGGGGCTGGGGGCcc3 ' 





51 GCCTCCAAAAGGGAATAAACCAATGGGAGGGCTGGGGCTGGGGGCcc3 ' 
51 GCCTCCAAAAGTTCCTCCACCAATGGGAGGGCTGGGGCTGGGGGCCC31 
51 GCCTCCAAAAGGGCCTCCACCAATGTTATTGCTGGGGCTGGGGGCcc3 ' 
51 GGGCCCCCAGCCCCAGCAATAACATTGGTGGAGGCCCTTTT,GGAGGC31 
MUT-dUS-1 51 CAGCCCTCCATTGGTGGAGG31 
MUT-dUS-2 5 'ccTCCACCAATGGAGGGCTG31 
Sense and complementary antisense oligonucleotides 
corresponding to regions of the 59 bp Sma 1 - Bst Nl fragment 
of the human a 2 {I} procollagen promoter were synthesised on a 
Beckman system 200 A DNA synthesizer. To produce double-
stranded oligonucleotides A, B, c, D, MUT-US and MUT-dUS 
{figures 4.7, 4.18 and 4.20) the complimentary single 
stranded oligonucleotides Al and A2, Bl and B2, Cl and C2, Dl 
and D2, El and E2, MUT-US-1 and MUT-US-2 or MUT-dUS-1 and 
MUT-dUS-2 were denatured at 90° C for 5 min and allowed to 
anneal at 370 C for 60 min prior to cooling to room 
temperature. 
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The 47-mer double-stranded oligonucleotides F, MUT-CCAAT, 
MUT-CME and MUT-CME2 (figures 4.7 and 4.19) were produced by 
annealing single-stranded oligonucleotides Al to F2, 
MUT-CCAAT, MUT-CME and MUT-CME2 as described above. The 
Klenow fragment of E. Coli DNA polymerase was used to produce 
double-stranded oligonucleotides as described previously in 
section 7 .1. 2 .1. 
7.5 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS 
Protein extracts were analysed on 10 cm long 5 to 12% sos-
polyacrylamide gels (Laemmli, 1970). 
Separating gel: 
5 to 7.5 ml 40% Acrylamide Stock Solution (38:2) 
6.25 ml 1. 5 M Tris-Cl (pH 8.8) 
1.25 ml 100 mM EDTA 
0.25 ml 10% sos 
to 25 ml H20 
250 ul 10% Ammonium Persulphate 
25 ul TEMED 
The separating gel was poured, a layer of water was pipetted 
over the gel surface and left to polymerise for at least 
1 hr. 
The stacking gel (Smith, I et. al• I 1988) : 
1 ml 40% Acrylamide Stock Solution (38:2) 
2.5 ml 0.5 M Tris-Cl (pH 6.8) 
0.5 ml 100 mM EDTA 
0.1 ml 10% sos 
0.1 ml 0.4% Phenol Red 
5.7 ml H20 
100 ul 10% Ammonium Persulphate 
10 ul TEMED 
An equal volume of 2X treatment buffer and 2 ul of DNA stop 
buffer was added to between 20 and 50 ug of protein. The 
samples were heated at 90° c for 3 min, loaded onto the gel 
and electrophoresed at 20 mA until the samples had run into 
the separating gel and thereafter at 25 mA in lX SOS-PAGE 
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tank buffer. The gels were stained for 4 hrs in Coomassie 
blue stain and destained for 1 hour in solution 1 and at 
least 6 hrs with 2 changes of solution 2. 
When necessary, dilute protein samples were concentrated 
acetone precipitated according to Hager and Burgess, 1980. 
Briefly, 5 volumes of cold acetone (-20° C) was added to each 
sample and incubated on ice for 30 min. After centrifugation 
the pellet was washed with absolute ethanol, dried under 
vacuum and resuspended in 20 ul treatment buffer. 
7.6 PHYSICO-CHEMICAL ANALYSIS OF DNA-BINDING PROTEINS 
Analytical gel filtration chromatography and density gradient 
centrifugation (Siegel and Monty, 1966), UV crosslinking 
(Chodosh et. al., 1986) and south-western blotting (Bowen 
et. al., 1980) were employed to determine the molecular 
weights of the trans-acting factors in crude or partially 
purified nuclear extracts. 
7.6.1 ANALYTICAL GEL FILTRATION CHROMATOGRAPHY 
A de-aerated 80% slurry of Sephacryl S-300 (Pharmacia) in 
buffer CB containing o .1 M KCl was packed into a Pharmacia 
column (1.6 cm X 100 cm) at a flow rate of 1 ml/min at 40 c. 
The column was equilibrated with CB containing 0.1 M KCl at a 
flow rate of 6 ml/h (3 ml/cm2/h). 
Sephadex G-200 columns were prepared as a 80% slurry (Fine 
grade, Pharmacia) in CB containing 0.8 M KCl as recommended 
by the manufactures. The slurry was de-aerated and packed 
into a 1 cm X 60 cm column at a flow rate of 1 ml/min at 
40 c. The column was equilibrated with CB containing 0.8 M 
KCl and 0.02% sodium azide at a flow rate of 1.8 ml/h (2.3 
ml/cm2/h). 
To calibrate the Sephacryl S-300 column, protein standards 
were prepared as follows: 2 mg thyroglobin, 2 mg ferritin, 
4 mg catalase, 2 mg aldolase (Pharmacia), 4 mg BSA (Bayer-
Miles) and/or 7 mg ovalbumin (Sigma) were dissolved in 0.5 to 
1 ml of CB containing o .1 M KCl and 30% glycerol, layered 
onto the column and eluted at a flow rate of 6 ml/h. Two mg 
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each of catalase, aldolase or BSA or 4 mg each of ovalbumin 
or carbonic anhydrase dissolved in 0.5 ml CB containing 0.8 M 
KCl were used to calibrate the Sephadex G-200 column at a 
flow rate of 1.8 ml/h. 
The elution volumes (Ve) of the protein standards were 
monitored by spectrophoretic absorbance at 280 nm (LKB 2158 
Uvicord SD UV-monitor). The void (Vo) and the total (Vt) 
volumes of the columns were determined using o. 2 mg blue 
dextran 2000 (Pharmacia) and 2 mg thymidine (Sigma) 
respectively (Kim and Sheffery, 1990) .· A calibration curve 
was prepared by plotting the log of the Stokes radius 
(thyroglobin, 8.50 nm; ferritin, 6.10 nm; catalase, 5.22 nm; 
aldolase, 4.81 nm; BSA, 3.55 nm and ovalbumin, 3.05 nm) 
versus kav' where kav=(Ve-Vo)/(Vt-Vo) (Siegel and Monty, 
1966) . 
Between 5 and 18 mg of crude nuclear extract in a final 
volume of approximately 2 ml of CB containing 0.1 M KCl, 30% 
glycerol and o .1% Nonidet P-40 were applied to the 
Sephacryl S-300 column and eluted with CB containing o .1 M 
KCl (without NP-40) at . a flow rate of 6 ml/h. The samples 
were eluted, 1 ml fractions collected, frozen in liquid 
nitrogen and stored at -10° C until further use. Between 5 
and 14 ul of each fraction was used in electrophoretic 
mobility shift assays containing 2 ug poly didC.poly didC per 
reaction, as previously described (section 7.4.2). 
The elution volumes of DNA-protein complexes were analysed by 
binding about 40 ug of crude nuclear extract with 20 ng 
(2 X 105 cpm) of 32P-labeled oligonucleotide F in a final 
volume of 80 ul, as described in section 7.4.2. Half-a-ml of 
CB containing 0.1 M KCl, 30% glycerol and 0.1% NP-40 was 
added to the binding reaction, layered onto the column and 
eluted as described above. One-ml fractions were collected 
from the column and the amount of radioacti vety in each 
fraction was determined. 
One to 2 mg of crude extract in a final volume of 400 ul 
containing o. 8 M KCl and o. 25% NP-40 was layered on top of 
the Sephadex G-200 column. Once the sample had run into the 
column, buffer CB containing 0.8 M KCl and 0.02% sodium azide 
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was gently layered onto the column and the samples eluted 
with this buffer. The elution of protein from the column was 
monitored and 200 ul fractions were collected as described 
above. The fractions were frozen in liquid nitrogen and 
stored at -10° c. 
7.6.2 GLYCEROL GRADIENT SEDIMENTATION 
Linear 15 to 40% glycerol gradients in SB (section 7.7) were 
prepared at 40 c as described by Martin and Ames (1961). In 
order to calibrate the gradients, 0.5 to o. 75 mg each of 
catalase, BSA, ovalbumin, carbonic anhydrase and/or lysozyme 
in a final volume of 100 ul was layered onto the glycerol 
gradients. The samples were centrifuged for 16 hrs at 
53 000 rpm and 40 C in a Beckman SW65Ti rotor with slow 
deceleration. A hole was punched at the bottom of the tubes 
and about 36 fractions of 3 drops each were collected. The 
protein concentration in each fraction was determined by the 
Bradford (1976) method. Fifteen-ul of each fraction was also 
resolved on 6 or 10% SDS-polyacrylamide gels as described in 
section 7. 5. A calibration curve was prepared by plotting 
% glycerol in the fractions were the standard proteins 
sedimented versus sedimentation coefficient (catalase, 11.3; 
BSA, 4.4; ovalbumin, 3.7; carbonic anhydrase, 3.2 and 
lysozyme, 1.9). The percent glycerol in each fractions was 
calculated as follows: 
% glycerol= 40% - (FN X 25% / TF} 
where FN was the fraction number and TF was the tot~l number 
of fractions collected. 
Approximately O. 5 mg of crude nuclear extract and o. 5 mg 
ovalbumin in a final volume of 100 ul was layered onto the 
gradients and centrifuged as described above. Three drop 
fractions were collected from the bottom of each centrifuge 
tube, frozen in liquid N2 and stored at -10° c. The protein 
concentration and the SOS-PAGE analysis of each fraction was 
determined as decribed above. The DNA-binding activities in 
10 ul of each fractions was quantitated by the 




The method of Chodosh et. al. (1986) was used to UV crosslink 
DNA-binding proteins to radioactively labelled DNA probes. 
7.6.3.1 PREPARATION OF Br-dU SUBSTITUTED PROBES 
Complementary oligonucleotides Cl and A2 or Cl and F2 were 
annealed as previously described (section 7.4.5). 
Bromodeoxyuridine (Br-dU) and 32P-deoxycytosine ( 32P-dC) were 
incorporated into 0.5 ug of the annealed oligonucleotides in 
a final reaction volume of 20 ul containing 10 units Klenow 
fragment of E. Coli DNA polymerase, 32P-dCTP and 100 uM each 
of dATP, dGTP and Br-dUTP. The reaction mixtures were 
incubated at room temperature for 15 min, after which 1 ul of 
10 mM dCTP was added and the incubation continued for a 
further 30 minutes to produce double-stranded Br-dU and 
32P-dC substituted double-stranded oligonucleotides. After 
organic extractions, the free nucleotides were removed by 
Sephadex G50 gel filtration. 
7.6.3.2 IN-SITU DNA-PROTEIN CROSSLINKING 
Forty ug of crude nuclear extract was pre-incubated with 
10 ug Poly didC.Poly didC in a final volume of 40 ul IB for 
10 minutes at room temperature. Ten-ng (10 5 cpm) of 32P-dC 
and Br-dU substituted probe was added and incubation 
continued for another 30 minutes on ice (Fried and ~rothers, 
1981). After adding 2 ul of 0.25% bromophenol blue in 
35% glycerol, the DNA-protein complexes were immediately 
resolved on 5% non-denaturing polyacrylamide gels at 40 C 
using 0.5% TBE as the tank buffer. The wet gels were sealed 
in plastic bags and irradiated for 30 min with a UV 
transilluminator at 305 nm and intensity 7000 uW/cm2 
(Fotodyne) (Wu, C et. al., 1987). The UV crosslinked 
complexes were visualised by autoradiography of wet gels for 
2 to 16 hours. 
The complexes were excised from the gels, chopped into slices 
and eluted with 1 volume of protein elution buffer at room 
temperature for 3 hours with gentle shaking. The 
supernatants were transferred to fresh tubes, the gel slices 
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washed with 100 ul protein elution buffer, the supernatants 
pooled and centrifuged to remove any debris. Carrier BSA was 
added to the combined supernatants to a final concentration 
of 0.1 ug/ul, followed by 5 volumes of cold (-20° C) acetone 
and the proteins were precipitated on ice for 3 O minutes. 
The protein pellets were washed with 100% EtOH, dried under 
vacuum for 5 minutes and resuspended in treatment buffer 
(Hager and Burgess, 1980). The samples were analysed by SOS-
PAGE as described in section 7.5. 
7.6.3.3 DNA-PROTEIN CROSSLINKING PRIOR TO ELECTROPHORESIS 
Ten to 15 ul of partially purified nuclear extracts were 
incubated with the DNA probes as described in section 
7. 6. 3 . 2 . The binding reaction mixtures were pipetted as 
drops onto parafilm, covered with inverted Eppendorf tubes, 
irradiated for 30 min at 305 nm and intensity 7000 uW/cm2 
(Fotodyne transilluminator) and transferred to Eppendorf 
tubes. 
On occasions, 1 ul of O. 4 M CaC12 , 1 unit of micrococcal 
nuclease and 4 ug DNase 1 were added to each UV irradiated 
sample and incubated at 370 C for 30 min. For proteinase K 
treatment, 4 ug of the proteinase K was added to the reaction 
mixtures and incubated for 60 min at 550 c. 
After one volume of 2X treatment buffer was added, the 
samples were analysed by SOS-PAGE on 8, 10 or i2% gels 
(section 7.5). 
7.6.4 SOUTHWESTERN BLOTTING 
Thirty to 50 ug crude nuclear extract were resolved on 6 or 
8% SDS-polyacrylamide gels as described in section 7.5, 
except that the boiling step prior to loading was omitted. 
The gel was incubated for 20 min in 200 ml of electroblotting 
buffer with gentle shaking and the proteins 
electrophoretically transferred from the gel to Amersham 
Hybond-C nitrocellulose membranes overnight at 10 V followed 
by 40 V for a further 30 min at 40 C in electroblotting 
buffer (Towbin et. al., 1979). 
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The filters were incubated in 50 ml blocking buffer for at 
least 2 hours at room temperature with gentle shaking. The 
blocked filters were incubated for a further 2 hours at room 
temperature in Seal-a-Meal freezer bags containing 2 to 10 ml 
binding buffer and 5 X 105 cpm/ml (50 ng/ml) of klenow 
labelled DNA probe {Matsuno et. al., 1989). The filters were 
washed at room temperature with 3 X 50 ml changes of washing 
buffer for 10 min each with gentle shaking. The washed 
filters were sealed in plastic bags and exposed to X-ray 
film. 
On occasions filters were stained im 0.3% amide black in 20% 
ethanol and 7% acetic acid for 15 min with gentle shaking and 
destained in warm (5o° C) 10% acetic acid. 
7.7 BUFFERS AND SOLUTIONS 
DNA Elution Buffer 
0.5 M Ammonium Acetate 
10 mM Magesium Acetate 
1 mM EDTA 
lX TE Buffer 
10 mM Tris-Cl {pH 8.0) 
1 mM EDTA 
lX TBE Electrophoresis Buffer 
90 mM Tris-borate (pH 8.0) 
90 mM Boric Acid 
2.5 mM EDTA 
lX TAE Electrophoresis Buffer 
40 mM Tris-acetate 
5 mM Sodium Acetate 
1 mM EDTA 
lOX Klenow Buffer 
0.1 M Tris-Cl {pH 7.5) 
0.1 M MgC1 2 
0.5 M NaCl 
10 mM DTE 
lOX T4 DNA Polymerase Buffer 
0.33 M Tris-acetate {pH 7.9) 
0.66 M Potassium acetate 
0.1 M Magnesium acetate 
5 mM OTT 
1 mg/ml BSA 
L-Broth 
10 g/1 Tryptone 
5 g/1 Yeast Extract 
5 g/1 NaCl 
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"RAPS" Solution 1 
25 mM Tris-Cl (pH 8.0) 
10 mM EOTA 
50 mM Glucose 
"RAPS" Solution 2 
200 mM NaOH 
1% sos 
"RAPS" Solution 3 
3M Potassium Acetate (pH 4.8) 
sucrose/Tris Solution 
50 mM Tris-Cl (pH 8.0) 
25% Sucrose 
TTE 
50 mM Tris-Cl (pH 8. 0) 
0.5% Triton x-100 
6.25 mM EOTA 
PBS (pH 7.3) 
137 mM NaCl 
2.7 mM KCl 
4.3 mM Na 2HP04 .7H20 
1.4 mM KH 2Po4 
Dignam Buffer A 
10 mM Hepes (pH 7.9) 
1. 5 mM MgC1 2 
10 mM KCl 
0.5 mM OTT 
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Dignam Buffer c 
20 mM Hepes {pH 7.9) 
25% glycerol 
0.42 M NaCl 
1. 5 mM MgC1 2 
0.2 mM EOTA 
0.5 mM OTT 
0.5 mM PMSF 
1 ug/ml leupeptin 
1 ug/ml pepstatin A 
Dignam Buffer D 
20 mM Hepes {pH 7.9) 
20% glycerol 
0.1 M KCl 
0.2 mM EOTA 
0.5 mM OTT 
0.5 mM PMSF 
1 ug/ml leupeptin 
1 ug/ml pepstatin A 
lOX Polynucleotide Kinase Buffer 
500 mM Tris-Cl {pH 7.5) 
100 mM MgC1 2 
50 mM OTT 
0.5 mg/ml BSA 
SX IB 
100 mM Hepes {pH 7.9) 
250 mM KCl 
2.5 mM OTT 
1. 0 mM EOTA 
5 mM MgC1 2 
20% Ficoll 400 
DMS Stop Buffer 
1.5 M Sodium Acetate {pH 7.0) 
1 M B-mercaptoethanol 
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DEAE Elution Buffer 
10 mM Tris-Cl (pH 8.0) 
1 mM EDTA 
1 M NaCl 
Formamide Loading Buffer 
95% formamide 
20 mM EDTA 
0.05% bromophenol blue 
0.05% xylene cyanol 
CB Buffer 
50 mM Tris-Cl (pH 7.9) 
0.1 mM EDTA 
0.5 mM OTT 
20% Glycerol 
0.5 mM PMSF 
1 ug/ml leupeptin 
1 ug/ml pepstatin A 
40% Acrylamide stock Solution (38:2) 
38% Acrylamide 
2% BIS 
2% Ion exchanger V 
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The solution was mixed on a roller for 16 hrs at 40 c, 
filtered and stored at 40 C. 
2X Treatment Buffer 
0.125 M Tris-Cl {pH 6.8) 
4% sos 
20% Glycerol 
5 mM EDTA 
10% 2-Mercaptoethanol 
DNA Stop Buffer 
0.05% Bromophenol Blue 
0.5% sos 
1 mM EOTA 
50% Glycerol 
sx SOS-PAGE Tank Buffer 
0.25 M Tris-Cl (pH 8.3) 
1.92 M Glycine 
0.5% sos 
coomassie Blue Stain 
0.125% Coomassie Blue R-250 
50% Methanol 
10% Acetic Acid 
Destain Solution 1 
50% Methanol 
10% Acetic Acid 
Destain Solution 2 
7% Methanol 
5% Acetic Acid 
SB Buffer 
20 mM Hepes (pH 7.9) 
0.1 M KCl 
0.2 mM EOTA 
0.5 mM PMSF 
0.5 mM OTT 
1 ug/ml leupeptin 
1 ug/ml peps ta tin A 
Protein Elution Buffer 
50 mM Tris-Cl (pH 8.0) 
0.1 mM EOTA 
150 mM NaCl 
0.1% sos 
5 mM OTT 
0.5 mM PMSF 
1 ug/ml leupeptin 
1 ug/ml pepstatin A 
Electroblotting Buffer 
0.05 M Tris 
0.19 M Glycine 
20% Methanol 
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Southwestern Blocking Buffer 
10 mM Hepes (pH 7.9) 
0.5% Carnation low fat milk powder 
Southwestern Binding Buffer 
10 mM Hepes (pH 7.9) 
50 mM NaCl 
10 mM Mgcl2 
0.1 mM EDTA 
1 mM DTT 
0.25% Carnation low fat milk powder 
Southwestern Washing Buffer 
10 mM Hepes (pH 7.9) 
50 mM NaCl 
10 mM MgC1 2 
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APPENDIX A 
CANDIDATE TRANSCRIPTION FACTORS AND THEIR RECOGNITION 
SEQUENCES 
207 
DNA sequences recognised by sequence-specific transcription 
factors in the proximal a2(I) procollagen promoter (-351 to 
-1) were identified by searching a database of transcription 
factors, TFD SITES (release 4.3), maintained by 
Dr D. Ghosh ( 1990) at the National Center for Biotechnology 
Information, National Library of Medicine, National 
Institutes of Health. The following table contains a list of 
recognition sequences (SEQUENCE) found in this region of the 
promoter, the candidate transcription factors (TRANS FACTOR), 
the position of the 5' end of the sequence (POS), the name of 
the sequence (NAME) and the reference. The abbreviations CS 
and RS mean consensus 
sequence respectively. 
sequence and reverse (inverted) 
POS SEQUENCE NAME TRANS FACTOR REFERENCE 
-33 TATAAA TATA BOX.2 TFIID Bucher and Trifonov (1986) 
-33 TATAAAT TATA BOX (CS) TFI ID Breathnach and Chabon (1981) 
-33 TATAAA His3-Tr-TATA TFIID Chen and Struhl (1988) 
-33 TATAAA Ad2MLP US.3 TFIID Sawadogo and Roeder (1985) 
-33 TATAAATAG TFIID/TBP (H2B-1 gene) TFI ID/TBF Barberis et. al. (1987) 
-33 TATAAA TFI ID/TBF?·RS TFI ID/TBF Yu, C. et. al. (1987) 
-33 TATAAATA B-FACTOR-HSP70 B-factor Parker and Topel (198~) 
-49 AGGGAAAC Nodulin consensus A (RS) Unknown Mauro et. al. (1985) 
-82 TGGTGG HC3 (RS) Unknown Augereau and Chambon (1986) 
·84 ATTGG CCAAT Box (RS) CBF Maity et. al. (1988) 
-104 CCCCCAGCCC AP-2 (CS 4) AP-2 Imagawa et. al. (1987) 
-115 GGCTGCCC AP-2 (CS) AP-2 Mitchell et. al. (1987) 
-122 CAGCTGT GT-11Ba-SV (RS) GT· I !Ba Xiao et. al. (1987) 
-122 CAGCTGT GT-I!Bb-SV (RS) GT-IIBb Xiao et. al. (1987) 
-122 CAGCTGTGG GT-Ilb/Pvu Box AP-4 Jones et. al. (1988) 
-122 CAGCTGTGG AP-4 (RS) AP-4 Jones et. al. (1988) 
-123 CCAGCTGTGG AP-4 (CS) AP-4 Mermod et. al. (1988) 
-128 TCCTCC malT-malPp Unknown Raibaud et. al. (1985) 
-128 TCCTCC malT (CS, RS) malT Raibaud et. al. (1985) 
-129 CTCCTCCC JCV repeated sequence (RS) Unknown Martin et. al. (1985) 
-136 CCGCAGGC AP-2 (CS 3) AP-2 Mitchell et. al. (1987) 
-143 TGCGCCC MRE (CS 2) Unknown Culotta and Hamer (1989) 
-160 CCATTC H2A conserved US Unknown Yells (1986) 
-187 GCCAGCCC AP-2 (CS) AP-2 Mitchell et. al. (1987) 
-201 AACCAAT CAAT.1 CP1 Chodosh et. al. (1988a) 
-229 AAAGTGT CAP/CRP-lac (RS) CAP/CRP Taniguchi et. al. (1979) 
-257 GAGTCA GCN4-ILV1. 1 GCN4 Arndt and Fink (1986) 
-257 GAGTCA GCRE (RS) GCN4 Hope and Struhl (1985) 
-257 GAGTCA GCN4-HIS3.2 GCN4 Arndt and Fink (1986) 
-257 GAGTCA GCN4-HIS (RS) GCN4 Arndt and Fink (1986) 
-257 GAGTCA GCN4-HIS3.5 (RS) GCN4 Hope and Struhl (1985) 
-257 GAGTCA GCN4-HIS4.1 (RS) GCN4 Arndt and Fink (1986) 
-257 GAGTCA GCN4-HIS4.2 (RS) GCN4 Arndt and Fink (1986) 
-258 CGAGTCAG AP1·Histone H3.2 (RS) AP-1 Sharma et. al. (1986) 
208 
Candidate Transcription Factors and their Recognition Sequences (cont) 
POS SEQUENCE NAME TRANS FACTOR REFERENCE 
-258 CGAGTCAG TRE-Egr-1.1 (RS) AP-1 Tsai-Morris et. al. (1988) 
-269 TATGCA EFII-RSV EFII Sealey and Chalkley (1987) 
-278 GGGCGG BGP1 (RS) BGP1 Cereghini et. al. (1988) 
-278 GGGCGG Sp1 (CS 2) Sp1 Briggs et. al. (1986) 
-278 GGGCGG Sp1-IE-3. 1 (RS) Sp1 Jones and Tjian (1985) 
-278 GGGCGG Sp1-IE-3.2 Sp1 Jones and Tjian (1985) 
-278 GGGCGG Sp1-IE-3.4 (RS) Sp1 Jones and Tjian (1985) 
-278 GGGCGG Sp1-IE-3.5 (RS) Sp1 Jones and Tjian (1985) 
-278 GGGCGG Sp1-IE-4/5.2 (RS) Sp1 Jones and Tjian (1985) 
-278 GGGCGG LSF-SV40 (RS) LSF Kim et. al. (1987) 
-278 GGGCGG Sp1-SV40.4 Sp1 Gidoni et. al. (1984) 
-278 GGGCGG Sp1?-U2snR.1 (Sp1) Janson et. al. (1987) 
-278 GGGCGG Sp1?-U2snR.3 (Sp1) Janson et. al. (1987) 
-278 GGGCGG Sp1 (CS 3) Sp1 Gidoni et. al. (1984) 
-278 GGGCGGAG JCV repeated sequence Unknown Martin et. al. ( 1985) 
-278 GGGCGGAG Sp1-SV40.2 Sp1 Gidoni et. al. ( 1985) 
-278 GGGCGGAG Sp1-SV40.3 Sp1 Gidoni et. al. (1984) 
-278 GGGCGGAG Early-Seq1 (RS) Unknown Fromm and Berg (1982) 
-282 CGGAGGGCGG AP-2 (CS 4, RS) AP-2 lmagawa et. al. (1987) 
-290 GGAGGA malT (CS) malT Raibaud et. al. (1985) 
-290 GGAGGA malT-malPp (RS) Unknown Raibaud et. al. (1985) 
-294 GGCGGG Sp1-hsp70 Sp1 Greene et. al. (1987) 
-294 GGCGGG hsp70.2 Unknown Wu, c. et. al. (1987) 
-294 GGCGGG Sp1-IE-3.3 (RS) Sp1 Jones and Tjian (1985) 
-294 GGCGGG Sp1-IE-4/5 (RS) Sp1 Jones and Tjian (1985) 
-295 GGGCGG Sp1 (CS 2) Sp1 Briggs et. al. (1986) 
-295 GGGCGG BGP1 (RS) BGP1 Cereghini et. al. (1988) 
-295 GGGCGG Sp1-IE-3.1 (RS) Sp1 Jones and Tjian (1985) 
-295 GGGCGG Sp1-IE-3.2 Sp1 Jones and Tjian (1985) 
-295 GGGCGG Sp1-IE-3.4 (RS) Sp1 Jones and Tjian (1985) 
-295 GGGCGG Sp1-IE-3.5 (RS) Sp1 Jones and Tjian (1985) 
-295 GGGCGG Sp1-IE-4/5.2 (RS) Sp1 Jones and Tjian (1985) 
-295 GGGCGG LSF-SV40 (RS) LSF Kim et. al. (1987) 
-295 GGGCGG Sp1-SV40.4 Sp1 Gidoni et. al. (1984) 
-304 GGCGGG Sp1-IE-4/5 (RS) Sp1 Jones and Tjian (1985) 
-305 GGGCGGGGGA AP-2 (CS 4, RS) AP-2 lmagawa et. al. (1987) 
-305 GGGCGG BGP1 (RS) BGP1 Cereghini et. al. (1988) 
-305 GGGCGG Sp1-IE-3.1 (RS) Sp1 Jones and Tjian (1985) 
-305 GGGCGG Sp1-IE-3.2 Sp1 Jones and Tjian (1985) 
-305 GGGCGG Sp1-IE-3.4 (RS) Sp1 Jones and Tjian (1985) 
-305 GGGCGG Sp1-IE-3.5 (RS) Sp1 Jones and Tjian (1985) 
-305 GGGCGG Sp1-IE-4/5.2 (RS) Sp1 Jones and Tjian (1985) 
-305 GGGCGG Sp1 (CS 2) Sp1 Briggs et. al. (1986) 
-305 GGGCGG LSF-SV40 (RS) LSF Kim et. al. (1987) 
-305 GGGCGG Sp1-SV40.4 Sp1 Gidoni et. al. (1984) 
-305 GGGCGG Sp1?-USsnR.1 (Sp1) Janson et. al. (1987) 
-305 GGGCGG Sp1?-USsnR.2 (Sp1) Jansom et. al. (1987) 
-295 GGGCGG Sp1?-U2snR.1 (Sp1) Janson et. al. (1987) 
-295 GGGCGG Sp1?-U2snR.3 (Sp1) Janson et. al. (1987) 
-295 GGGCGGGA Early-Seq1 (RS) Unknown Fromm and Berg (1982) 
-295 GGGCGG Sp1 (CS 3) Sp1 Gidoni et. al. (1984) . 
-295 GGGCGGGA JCV repeated sequence Unknown Martin et. al. (1985) 
-304 GGCGGG Sp1-hsp70 Sp1 Greene et. al. (1987) 
-304 GGCGGG hsp70.2 Unknown Wu, c. et. al. (1987) 
-304 GGCGGG Sp1-IE-3.3 (RS) Sp1 Jones and Tjian (1985) 
-305 GGGCGGGG Early-Seq1 (RS) Unknown Fromm and Berg (1982) 
-305 GGGCGG Sp1 (CS 3) Sp1 Gidoni et. al. (1984) 
-305 GGGCGGGG (Sp1 )-TK.1 (RS) (Sp1) Mc Knight and Kingsbury (1982) 
-305 GGGCGGGG JCV repeated sequence Unknown Martin et. al. (1985) 
-310 GGAAAG IE1.2 (RS) Unknown Ghazal et. al. (1984) 
-311 TGGAAAG SV40.6 Unknown Pfeifer et. al. (1987a) 
-311 TGGAAAG SV40.16 Unknown Pfeifer et. al. (1987a) 
-311 TGGAAAG SV40.13 Unknown Pfeifer et. al. (1987a) 
-314 ACTTGG WAP US6 Unknown Lubon and Henninghausen (1987) 
-344 GCACTC MT- 1.1 Unknown Andersen et. al. (1987) 
